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Normal haemopoiesis derives from a bone marrow pool of pluripotent stem 
cells capable of self renewal and multilineage differentiation. Further developments 
in autografting and gene therapy will rely on a clearer definition and 
understanding of these primitive cells and an ability to manipulate them effectively. 
Phenotypic and functional differences between bone marrow and peripheral blood 
stem cells have been identified and exploited. Techniques for the mobilisation and 
harvesting of stem cells are established in clinical practice but consensus is lacking 
on the optimum approach for different diseases. In malignancy, there is great 
interest in removing contaminating tumour cells from harvests in the hope of 
reducing relapse rates. Stem cell selection using the CD34 antigen has been 
commonly used for such purging strategies. The concentration of stem cells 
produced by CD34 selection provides an ideal product for further manipulation by 
cell expansion and /or genetic modification. These techniques should facilitate the 
future engineering of more specific therapeutic cell products. 
I have examined three specific aspects of the manipulation of haemopoietic stem 
cells with the aim of generating clinically useful therapeutic products. These were: 
a disease -specific mobilisation regimen in CML, clinical scale CD34 selection and 
transplantation in myeloma and genetic modification of stem cells to alter their 
function using PNH as a model disease. 
A disease -specific mobilisation procedure was studied in patients with CML in an 
attempt to collect mainly normal progenitors for subsequent transplantation. This 
in vivo purging strategy relies on the differential mobilisation of Ph +ve/Ph -ve stem 
cells following myelosuppression. The Hydroxyurea /G-CSF regimen used was 
markedly less toxic than existing methods and the results compared favourably, 
with 28% of the harvests entirely Ph -ve and 56% showing a major response. 
Cytogenetic responses have been demonstrated post transplant in some patients. 
Clinical scale ex vivo tumour purging was performed in myeloma patients by CD34 
selection using an immunoaffinity column (CeprateTM). This procedure can effect a 
3 -4 log tumour reduction and also yields cells suitable for further laboratory 
manipulation. I wished to confirm that the method was clinically acceptable. All but 
one patient achieved an adequate CD34 +ve cell dose for transplant post selection 
and engraftment was normal, confirming the safety and efficacy of the approach. 
Genetic modification of peripheral blood stem cells was achieved using a retroviral 
construct (CD59 -TM) capable of ameliorating the complement sensitivity in FNn. 
This was used successfully to transduce CFU -GM and BFU-E in peripheral blood 
and stem cell harvests from patients with haematological malignancy. Transduction 
efficiency was maximised by multiple cycles of infection in the presence of 113, 116 
and SCF. A technique was developed for the simultaneous assessment of cell 
complement lysis and surface phenotype by flow cytometry to detect the presence 
and function of the novel construct. In FMI, the most primitive peripheral blood 
stem cells are of normal phenotype which has prompted suggestions from some 
authors that they might be collected and used for autologous transplantation. I have 
shown however, that G-CSF mobilises mainly cells of PM phenotype in these 
patients. This, combined with the observation that the overall progenitor numbers 
in these hypoplastic patients are low suggests that the prospects for autografting or 
gene therapy are poor in this disease. 
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1.1 The Haemopoietic Stem Cell 
Marrow production of mature blood cells throughout life is accomplished by 
the activity of a small pool of haemopoietic stem cells (HSC) which are defined by 
their ability to self renew or differentiate into any of the lymphohaemopoietic 
lineages (Gordon & Blackett, 1994; Scott & Gordon, 1995; Leitman & Read, 1996) 
(Figure 1.1). There has been intense debate regarding the nature of the HSC and in 
recent years other developments such as the increasing diversity of bone marrow 
transplantation strategies and research into gene therapy have quickened the pace of 
stem cell research owing to their dependence on an accurate understanding of the 
behaviour of these elusive but important cells. (Apperley & Williams, 1990a). 
History 
It had long been suggested that there were specialised cells capable of maintaining 
haemopoiesis but evidence for this did not begin to accrue until the late 1940s when 
it was shown that lead shielding of the spleen could save rodents exposed to lethal 
radiation (Jacobson et al 1949). This implied that protected HSCs in the spleen 
migrated to blood and marrow and repopulated the haemopoietic system. Further 
animal work supporting this theory was published over the next few years including 
cross -circulation experiments between irradiated and non -irradiated rats and 
demonstration of the radioprotective effects of marrow infusion in mice and guinea 
pigs (Ford et al 1956; Lorenz et al 1951). 
Figure 1.1 
Diagram showing a scheme for the development of mature, terminally differentiated 
cells of all lineages from a single putative pluripotent stem cell. This cell can renew 
itself by division or differentiate down any of the pathways shown. 
Heemopoietic Stem and Progenitor Cells 
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In the 1960s, Till and co- workers used the spleen colony forming assay (CFU -S) in 
mice to elucidate these observations (Till & McCulloch, 1961; Till et al 1964). They 
showed that marrow infusions after lethal irradiation led to the formation of 
heterogeneous haemopoietic colonies in the spleens of these animals which could be 
harvested and re- tfansplanted into second hosts where more colonies would be 
formed (Siminovitch et al 1963). Analysis of these secondary colonies showed that 
all lymphoid and myeloid cell types were represented. (Wu et al 1967; Wu et al 
1968). This work implied that the marrow contained cells capable of both 
multilineage differentiation and of self renewal and a model of the HSC and its 
behaviour was put forward which is still valid, if contentious (Till et al 1964). Over 
the last three decades since this work was first published, increasingly sophisticated 
methodology has been employed to further delineate, investigate and purify the 
putative HSC. 
General features of the HSC 
There is as yet no single accepted test by which the pluripotent HSC can be defined. 
The search for this elusive sub -population has involved a large number of techniques 
including: cell separation using physical properties such as density centrifugation and 
filtration (Goodman, 1960; Morrison, 1967), in -vivo radioprotection assays 
(Ploemacher & Brons, 1988), in -vivo colony formation (CFU- S)(Till & McCulloch, 
1961), a variety of in vitro culture assays (see below), exposure to cell cycle specific 
cytotoxic agents (Harrison & Lerner, 1991; Hodgson & Bradley, 1979; Smith et al 
1991) and immunophenotypic analysis (Terstappen et al 1991; Sutherland et al 
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1993; Baum et al 1992; Lansdorp et al 1990). These approaches have all helped to 
shed light on the biology and behaviour of HSCs but they may define different cell 
types and/or stages of maturation and no consensus has been reached as to the 
precise relevance of each assay or the stage of cell development that it concerns. 
Results from these areas of work have led to a generally agreed view that the early, 
pluripotent HSC resembles a small lymphocyte morphologically and is relatively 
quiescent in steady state haemopoiesis, the majority being in Go phase of the cell 
cycle at any one time (Lajtha, 1979; Gordon & Blackett, 1994; Morrison & 
Weissman, 1994). They can self renew or differentiate into any blood cell type and 
can protect animals from otherwise lethal doses of radiation by effecting long term 
marrow repopulation (Ford et al 1956; Lorenz et al 1951). They are resistant to the 
effects of cell cycle specific cytotoxic agents such as 5-Fluorouracil or 4- 
Hydroxyperoxycyclophosphamide (Harrison & Lerner, 1991; Hodgson & Bradley, 
1979; Smith et al 1991) and to retroviral infection (Williams et al 1984a) and are 
capable of initiating long term marrow cultures in vitro (Dexter et al 1977; Gartner 
& Kaplan, 1980). By flow cytometry their surface phenotype can be shown to 
include: CD34 +vebnght (Sutherland et al 1993), CD38 -ve (Terstappen et al 1991), 
Thy -1 +ve (Baum et al 1992), rhodamine -123áa (Lansdorp et al 1990), and 
CD45RO +ve (Lansdorp et al 1990) and to lack the expression of specific antigens 
associated with commitment to any of the haemopoietic lineages. 
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Stem cell kinetics 
The HSC is capable of maintaining blood cell production throughout life in a healthy 
individual and also of repopulating the marrow following injury such as cytotoxic 
chemotherapy or radiation. There have been many theories concerning the 
behaviour of these cells and there is as yet no agreement. The controlling factors 
determining the cell's decision to renew, differentiate or proliferate have been 
envisaged as being stochastic (random), intrinsic, cell age related or extrinsic from 
cytokines or the marrow microenvironment. There is a wealth of evidence for all of 
these models and more than one may be important. 
The first models of HSC kinetics were based on the concept of a biologically 
homogeneous population of HSC in which the decision to renew or differentiate was 
a stochastic event for each cell (Till et al 1964; Ogawa et al 1983; Gordon & 
Blackett, 1994) . This theory was supported by the results of murine CFU -S work 
(Till et al 1964) and was able to offer an explanation for the observed heterogeneity 
of spleen colonies by invoking a mechanism whereby HSCs would randomly 
undergo variable numbers of renewal divisions before differentiating. Some 
colonies would therefore be expected to contain many re- platable CFU -S from HSCs 
which had continued to self renew and others more differentiated progeny of varying 
lineages (Siminovitch et al 1963). Stochastic models allow for biologically identical 
HSCs to achieve short and long term haemopoiesis depending on the number of self - 
renewal divisions they undergo before differentiating (Gordon & Blackett, 1994; 
Gordon & Amos, 1994). Gordon et al have argued for this interpretation and have 
demonstrated just such in vitro heterogeneity in the maturity of progenitors derived 
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from single, primitive plastic adherent cells (Gordon, 1994; Gordon et al 1995; 
Gordon et al 1996). Kay suggested that the self renewal capacity of HSCs might be 
time related, diminishing with successive cell divisions and proposed the theory of 
clonal succession in which haemopoiesis is sustained largely by one lineage of HSC 
and its progeny until their proliferative capacity is exhausted (Kay, 1965). Others 
have suggested that multiple lineages sustain haemopoiesis and each cell's capacity 
for self renewal is an intrinsic, not stochastic feature (Metcalf & Moore, 1971; 
Rosendaal et al 1979). Models have been put forward where there is an envisaged 
continuum of renewal potentials intrinsic to each cell and dependant on the age of 
that cell (Helman et al 1978). Others have suggested a number of discreet 
maturation stages or subpopulations of HSCs with within each, a relatively 
consistent and pre -determined potential for renewal (Micklem & Ogden, 1976; 
Morrison & Weissman, 1994). Morrison and Weissman have proposed such a model 
in which the HSC pool is subdivided into three phenotypically distinct 
subpopulations each with a different potential for self renewal and differentiation. In 
this deterministic model, the decision whereby a cell renews or differentiates is an 
intrinsic feature and not random or due to external influence. Here, there would only 
be a finite number of renewal divisions in each subpopulation and this is backed 
experimentally by the ability to predict the self renewal potential of HSCs by their 
phenotypic differences (Morrison & Weissman, 1994). The haemopoietic 
microenvironment and an increasing number of cytokines and their interaction with 
HSCs has been suggested to influence stem cell behaviour (Metcalf, 1989), while 
some argue that these factors only influence committed cells, the decision to self 
renew being intrinsic (Ogawa, 1993). 
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At present then, there are two major distinctions between workers in the field of 
stem cell biology. Firstly there is dispute as to whether the stem cell pool is 
homogeneous (Gordon & Blackett, 1994) or is separated into biologically distinct 
subpopulations (Morrison & Weissman, 1994; Morrison et al 1995) and secondly 
there is the debate over the mechanisms controlling HSC behaviour, be they 
stochastic (Ogawa et al 1983), intrinsic (deterministic) (Morrison et al 1995), age 
related (Micklem & Ogden, 1976) or external (VanZant & Goldwasser, 1979). It is 
of course entirely possible that a combination of these and other factors may act in 
consort either throughout stem cell life or at specific stages of haemopoiesis. 
Gene marking studies in marrow reinfused after myeloablative treatment have 
provided insights into stem cell behaviour during and after haemopoietic 
reconstitution. It has been shown that in the early post transplant stages, 
haemopoiesis is characterised by rapid and erratic fluctuations in many stem cell 
clones whereas a small number of more stable lineages come to dominate in the long 
term. (Capel el al 1989; Capel et al 1990; Jordan & Lemischka, 1990). Stochastic 
models would suggest that this phenomenon is due to progressive clonal extinction 
as HSCs randomly differentiate or terminally mature. Deterministic or intrinsic 
theories would see this as a pre -programmed fate of cells belonging to different sub - 
populations responsible for long and short term haemopoiesis. 
The experimental evidence underlying these various hypotheses is substantial but 
tends in the main to rely on work from three areas: Animal models (mainly mouse), 
non -physiological in vitro culture assays where the complex effects of growth factors 
and the interactions with the haemopoietic microenvironment cannot be reproduced 
and finally, extremes of human physiology in the setting of reconstitution following 
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bone marrow transplantation. All data from such studies must be cautiously 
interpreted. In view of this, it is perhaps not surprising that there are many models 
which have fundamental differences and for which there are equally vociferous 
proponents. The behaviour of the HSC is likely to remain even more contentious 
than its definition and description for some time to come. Despite these difficulties, 
the consideration of kinetic models is important as it has major implications for the 
outcome of transplantation strategies such as purging (Champlin, 1996; Johnson et al 
1996b), stem cell expansion (Haylock et al 1992b; Brugger et al 1993) and the 
survival of therapeutic genetic material introduced into these cells (Apperley & 
Williams, 1990a; Brenner, 1996). 
Haemopoietic stem cell assays 
Following the demonstration of colonies in the spleen of the mouse and the 
protection of animals from the otherwise lethal effects of radiation by marrow 
infusion (Lorenz et al 1951; Ford et al 1956; Till & McCulloch, 1961) assay systems 
have been devised based on in vitro growth of cells under a range of different culture 
conditions. More recently, work on the surface immunophenotype of HSCs has 
allowed these cells to be identified and sorted. It has been possible to combine 
phenotyping and culture experiments in an attempt to more accurately define stages 
of stem cell development (Terstappen et al 1991). 
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In -vitro culture assays 
It is relatively easy to create conditions in which colonies of committed progenitor 
cells will grow from samples of human blood or marrow. Such assay systems exist 
for erythroid (BFU -E), granulocyte- macrophage (CFU -GM) and megakaryocytic 
(CFU -Mk) progenitors. In addition to this there are a number of techniques for the 
growth of cell types that have some or most of the features of HSCs. These more 
primitive cell assays fall into two main types depending whether the system 
measures the cells directly or by the secondary production of more mature daughter 
cells (Gordon, 1993). Direct clonogenic assays of primitive stem cells include the 
CFU -GEMM (which gives rise to granulocytic, erythroid, monocytic or 
megakaryocytic lines and may have a limited in -vitro capacity for self renewal) 
(Gordon, 1993), blast colony forming cell assay (Bl -CFC) (Nakahata & Ogawa, 
1982), cobblestone area forming cell assay (CAFC) (Breems et al 1994) and the high 
proliferative potential colony forming cell assay (HPP -CFC) (Bradley & Hodgson, 
1979). The Bl -CFC described by Ogawa shows both secondary replating ability and 
multilineage differentiation. These cells are almost all out of cycle and together these 
features suggest that it is a measure of a very primitive cell. Similar blast colonies 
can be seen if human marrow cells are seeded onto pre -formed stromal layers and 
are probably similar to the cobblestone area forming cell (CAFC) described in this 
setting in mice (Breems et al 1994). Subsets of these stromal adherent Bl- 
CFC /CAFC have been described which develop rapidly (5 days) or more slowly (21 
days), the latter having more primitive features (Tucker et al 1993). The HPP -CFC 
were originally described in murine culture where they are characterised by the 
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ability to form large colonies of macrophages, their resistance to 5 -FU, multilineage 
potential and haemopoietic reconstitution in vivo (Bradley & Hodgson, 1979). 
Human counterparts for this cell type have been described (McNiece et al 1989). 
Phenotypic studies and replating experiments suggest that the CAFC and Bl -CFC are 
probably ancestral to HPP -CFC and CFU -GEMM but they all show primitive 
features and probably represent overlapping populations of closely related cells. All 
such assays share an important limitation as there is no technique that can reproduce 
the degree of self renewal that occurs in vivo. This could imply that these assays are 
failing to detect the most primitive HSCs or simply that physiological cell behaviour 
cannot be seen in these artificial conditions. 
Assays that rely on measurements of daughter cells (secondary clonogenic potential) 
include long term bone marrow culture (LTBMC) (Dexter et al 1977; Gartner & 
Kaplan, 1980), the long term culture initiating cell assay (LTCIC) (Eaves et al 1992) 
and delta assays, in which subsets of primitive cells are selected by adherence 
properties (Dowding & Gordon, 1992; Gordon, 1994) or 4 -HC treatment (Smith et al 
1991) and then cultured, following which their production of CFU -GM can be 
assessed. LTBMC consists of the maintenance of haemopoiesis by primitive cells 
within or adherent to a layer of stroma. This is done either by innoculating marrow 
onto tissue culture plastic where a stromal layer will form or by a two stage process 
where the stromal layer is pre -formed and irradiated after which cells of interest can 
be added. The LTCIC assay is a quantitative version of this principle in which the 
supernatant CFU -GM numbers are measured at 5 weeks of culture. The 5 week delay 
ensures the death of CFU -GM and more committed HSCs that might have been 
present in the innoculum at the beginning of the culture. LTCICs have been 
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estimated at 1 -2 per 10,000 marrow cells or 1 -2% of CD34 +ve cells (Sutherland et al 
1990). Their numbers have been shown to correlate significantly with CAFCs 
(Reading et al 1994). 
Delta assays of adherent cells also delineate cell types with features of HSCs. For 
these assays, the cells of interest are pre -selected by adherence to stroma or plastic, 
washed to remove non -adherent committed progenitors and then cultured for a week 
after which the production of CFU -GM in the supernatant is measured (Dowding & 
Gordon, 1992; Gordon, 1994). An alternative to adherence is to treat the cell source 
with 4 -HC and culture as above (Smith et al 1991). Cells capable of giving rise to 
CFU -GM in these systems have been shown to have features of very primitive HSCs 
and probably overlap with the LTCIC and CAFCB1 -CFC (Gordon, 1993; Gordon, 
1994; Gordon et al 1996). 
Assays based on surface immunophenotype 
The CD34 antigen is widely used to identify stem cells. It was discovered using 
strategies to identify surface markers for primitive cells representing minor MNC 
subsets present in marrow but scarce in peripheral blood (Civin et al 1984). Cells 
bearing this antigen can be rapidly quantitated by flow cytometry after staining with 
appropriate MABs and this has been adopted as the simplest and quickest technique 
for stem cell assay in blood or marrow, particularly for clinical use (Trischmann et al 
1993; Siena et al 1993) (see chapter 2, sections 216 and 2.28 for methodology). 
CD34 is a heavily glycosylated transmembrane glycophosphoprotein belonging to 
the sialomucin family of surface molecules. It is expressed on around 1.5% of 
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marrow MNCs but on less than 0.5% of peripheral blood cells (Civin et al 1984; 
Krause et al 1996b). Expression on other tissues is debated but it is certainly present 
on small vessel endothelial cells and embryonic fibroblasts (Fina et al 1990). Its 
predicted structure shows no strong overall homology to other proteins. The 
cytoplasmic region of the molecule shows a very high degree of conservation 
between human, canine and murine CD34 suggestive of an important functional role 
(Krause et al 1996b). There are no enzymatic motifs in the structure but parts of the 
extracellular portion show similarity to molecules with known functions in cell 
adhesion. Interestingly, early data from CD34 knock out mice shows that they 
survive normally and have normal blood counts and differentials (Krause et al 
1996b). Such animals can respond appropriately to radiation induced marrow 
suppression but show reduced colony formation in vitro. At present then, the exact 
function of CD34 remains uncertain. Two possible functional roles have been 
suggested, namely cell -cell adhesion and inhibition of stem cell differentiation. It is 
hypothesised that stem cells may bind to marrow stroma by a mechanism involving 
an L- selectin like molecule and CD34 and that such interactions could be critical to 
their localisation within the haemopoietic microenvironment and thus have 
functional significance (Baumheter et al 1993; Baumhueter et al 1994). There is also 
evidence that terminal differentiation of myeloid cells requires downregulation of 
CD34 and it may thus have a role in the differentiation process both in normal and 
leukaemic stem cells (Fackler et al 1995). 
CD34 selected cells are of blast or small lymphocyte morphology (Figure 4.1) and 
are enriched for colony forming cells of all types including the primitive LTCIC and 
BI-CFCs (Srour et al 1991; Terstappen et al 1991; Gordon et al 1996). By contrast, 
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in culture, the CD34 -ve fraction is depleted for these cells. The CD34 +ve cell 
fraction contains precursors capable of short and long term haemopoietic 
reconstitution as evidenced by transplantation experiments in animals and man 
(Berenson et al 1988; Berenson et al 1991). Culture of the CD34 +ve subset yields 
colonies of progenitor cells at different stages of maturation and this antigen seems 
to be expressed on all primitive precursors up to and including more mature 
progenitors such as CFU -GM or BFU -E. In view of this heterogeneity there has been 
much interest in phenotypically subdividing CD34 +ve cells into functionally 
different compartments. It has been shown that the level of expression of CD34 
varies with maturity, the CD34 bright cells being more primitive than the CD34a'n' 
(Andrews et al 1989; Bernstein et al 1991). Other antigens have been used to further 
subdivide the CD34 +ve fraction. The combination of CD38 negativity and Thy -1 
positivity with lack of lineage specific antigens such as CD13 and CD33 is seen on 
the most primitive precursors. (Srour et al 1991; Terstappen et al 1991; Morrison & 
Weissman, 1994). 
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1.2 Autologous Stem Cells in Haematological Malignancy 
Rationale for autologous transplantation 
During this century, the treatment of haematological malignancy with 
cytotoxic agents has progressed from relatively non -toxic single agent approaches 
through increasingly complex and myelosuppressive combination chemotherapy 
regimens (De et al 1972) to myeloablative therapy with marrow rescue from 
allogeneic or autologous stem cell sources (Perry & Linch, 1996). The considerable 
increases in toxicity have been offset at least in part by improvements in supportive 
care and greater understanding of the problems of the neutropenic patient. 
Allogeneic transplantation offers the additional potential benefit of immunological 
tumour kill and is thus not simply a form of dose intensification (Nash & Storb, 
1996; Marmont, 1993). This form of therapy is however only applicable to patients 
of a relatively young age for whom an adequately HLA- matched marrow donor can 
be found. Even where this is available there is a substantial treatment related 
morbidity and mortality and consequently only a small minority of patients at 
presentation will ultimately undergo and survive such a procedure. This has led to 
increasing interest in supporting high dose treatment with autologous stem cells, 
historically from the patients marrow but now increasingly with cells mobilised into 
the peripheral blood following chemotherapy and/or growth factor administration 
(To et al 1997). Stem cell support allows high doses of cytotoxic drugs to be 
administered, achieving increased tumour cell kill in sensitive malignancies, which 
might be expected to translate into improved disease control and long term survival. 
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This theory has been tested in a wide range of haematological malignancies. Initial 
small series are being increasingly supplemented by larger clinical studies. In certain 
areas, the adoption of HDT with stem cell support may confer a true survival 
advantage but despite a large body of publications, definitive evidence for this is 
still sparse in the literature and much work is still in progress. In the malignant 
lymphomas, only the PARMA study (Philip et al 1995) has so far been able to show 
a survival advantage in 109 patients with NHL studied over a 7 year period. In 
myeloma there is emerging evidence for prolonged survival with HDT (Attal et al 
1996). In the acute leukaemias there are many trials of autologous transplantation 
but as yet no consensus as to its advantage and in CML there is no prospective 
randomised data although a recent analysis of the literature has suggested a plateau 
in the survival curve after autologous marrow or stem cell transplantation (McGlave 
et al 1994b). 
The ability to collect autologous stem cells easily from patients has other potential 
applications apart from supporting high dose therapy. Such cells could be 
manipulated in vitro or in vivo with the aims of reducing tumour cell contamination 
before reinfusion (Johnson et al 1996b), expanding the stem cell and/or committed 
progenitor pool to enhance engraftment characteristics (Haylock et al 1992b) or 
introducing therapeutic genetic material into a primitive cell in which it might 
continue to be usefully expressed after transplantation (Brenner, 1996). 
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Sources of stem cells for autologous transplantation 
Stem cells can be obtained directly from the bone marrow cavity by needle puncture 
or via the peripheral blood using an apheresis machine. Both sources have been used 
extensively and there is clear data to show that they achieve rapid and sustained 
haematopoietic reconstitution following myeloablative treatment (To et al 1997). 
Despite this, there are important quantitative and qualitative differences between 
marrow and blood stem cells. These differences have been responsible for dramatic 
changes in clinical practice with the percentage of autologous transplants using 
blood rather than marrow cells rising from 15% to 75% in the first four years of the 
1990's according to the European Blood and Marrow Transplant Group (EBMT) 
(Gratwohl et al 1996). The use of PBSCs lagged behind marrow by around 15 
years, only becoming routine in the mid 1980's (To et al 1997). Previously, while it 
had been appreciated that there were small numbers of stem cells in peripheral 
blood, their use for transplantation had not seemed practical. Richman et al first 
demonstrated that their numbers could be transiently increased by chemotherapy 
(Richman et al 1976) suggesting that blood might be an adequate source. This 
process, discussed below, is termed stem cell mobilisation. Mobilised stem cells 
could be collected by apheresis and were subsequently shown to provide both rapid 
and durable engraftment (Mahendra et al 1996; Vesole et al 1996a; To et al 1997). 
PBSC collections have been shown to contain adequate numbers of primitive stem 
cells and greater numbers of more mature progenitors which are considered 
responsible for the shorter period of neutropenia seen following PBSCT (Bender et 
al 1991; Craig et al 1993). It is now accepted that PBSCs provide more rapid 
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engraftment and this has become the most important reason for the decline in the use 
of marrow in such procedures (To et al 1992). Most of the data confirming this has 
been by historical comparison with marrow transplant results although randomised 
trials have been done (Beyer et al 1995). In addition to this benefit, their use is 
generally preferred because patients find it easier to undergo stem cell mobilisation 
rather than a marrow harvest under general anaesthetic and there is evidence that the 
degree of tumour cell contamination may be less than that in the marrow in certain 
diseases, although this may not necessarily translate into improved survival (Sharp et 
al 1995; Henry et al 1996). In some cases there is the advantage of mobilising cells 
in patients who have had pelvic disease or radiotherapy and would be difficult to 
harvest conventionally for practical reasons. 
In summary then, it is possible to use either marrow or blood stem cells to support 
HDT but PBSCs have now largely replaced marrow as the preferred source for 
reasons of convenience, rate of engraftment and perhaps the degree of tumour 
contamination. 
Mobilisation and collection of PBSCs 
In the early 1970's it was appreciated that progenitor cells could be transiently 
mobilised into the peripheral blood following administration of endotoxin or 
adrenocorticotrophin and after strenuous exercise (Barrett et al 1978). By 1980 it had 
been demonstrated that large numbers of CFU -GMs could be collected from the 
peripheral blood by leucapheresis (Korbling et al 1980) and it was then feasible to 
combine these two observations and successfully collect adequate progenitors from 
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the blood for transplantation. The first mobilisation regimens used myelosuppressive 
chemotherapy alone (To et al 1984). Later it was found that the combination of 
growth factors and chemotherapy enhanced the progenitor yield and since then it has 
become standard practice to combine chemotherapy with G -CSF or GM -CSF 
(Schwartzberg et al 1992). GM -CSF was the first growth factor used in this setting 
but is now less common, mainly due to an inferior side effect profile. 
The phenomenon of progenitor cell mobilisation remains poorly understood. It is 
believed that it involves a perturbation of the normal adhesive interactions between 
haemopoietic cells and the marrow stroma which in health localise blood production 
to the marrow cavity (Simmons et al 1994; Turner, 1994). Primitive haemopoietic 
cells express a wide range of cell adhesion molecules (CAMs). The ligands for many 
of these are found on marrow stromal cells (Long, 1992). There is evidence of 
changes in expression and/or function of some of these ligand pairs after exposure to 
a range of factors known to induce mobilisation and also during stem cell 
maturation. Examples include the release of progenitor cells into the circulation after 
functional blocking of the ß -1- integrin VLA -4 (Papayarmopoulou & Nakomoto, 
1993) and the observation that c -kit expression (the SCF receptor) falls during 
maturation of CD34 +ve cells and is very low in mobilised peripheral blood 
CD34 +ve cells compared to their marrow counterparts (Mohle et al 1993). Despite 
this latter observation, it has been shown that G -CSF is far less efficient at 
mobilising stem cells in mice deficient in SCF or its receptor (Steel/WW strains) 
suggesting that mobilisation may involve a number of different interactions (Cynshi 
et al 1991). This concept is supported by observations that in vitro interference with 
adhesion molecule function produces rapid but short lived effects whereas the in 
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vivo kinetics of G -CSF mobilisation in patients shows a time lag, with CD34 +ve 
cells appearing in the peripheral blood after several days. The implication of this is 
that G -CSF administration sets off a chain of events leading to release of stem cells 
from the marrow, the basis of which is as yet unknown. A more complete 
understanding of the mechanism may, in the future, allow more efficient 
mobilisation, perhaps with patients benefiting from reduced apheresis requirements. 
An additional possibility might be the construction of mobilisation regimens which 
specifically release the cells of interest while reducing tumour cell trafficking in 
which CAMs have also been shown to play a part (Dorudi & Hart, 1993). This could 
allow a form of in vivo cell purging at the point of stem cell collection with 
reduction in tumour cell contamination. 
The dosage of G -CSF used in conjunction with chemotherapy is usually in the range 
of 3- 61,1g/kg /day and is generally started the day after chemotherapy although it may 
be possible to delay the growth factor until the fifth or even eighth day post chemo 
with a cost saving (Haynes et al 1995). Chemotherapy alone produces a variable 
increase in progenitors up to 50 fold and this appears to be roughly proportional to 
the degree of myelosuppression (Schwartzberg et al 1992). The addition of growth 
factors was shown in one large series to double the mononuclear cell yield and 
increase the CD34 +ve numbers 4 -6 fold (Schwartzberg, 1993). 
There is a substantial body of literature concerning the optimum form of 
chemotherapy to use in a mobilisation regimen. The most commonly employed is 
cyclophosphamide at doses ranging from 1.5 to 7 grams per square metre. As well as 
its long pedigree as a mobilisation agent, this drug has the advantages of low toxicity 
to non -dividing stem cells, a reasonable side effect profile and activity against a wide 
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range of tumours (To et al 1997). Other agents alone or in combination have been 
used with success and in many clinical 3ettings it is possible to collect stem cells 
following the chemotherapy that is being administered for disease control rather than 
perform a Separate mobilisation proccedure (Craig et al 1992). This latter approach is 
convenient but may suffer from variable progenitor yields from different regimens 
and requires considerable flexibility regarding leucapheresis services. 
Mobilisation using only growth factors (without chemotherapy) is applicable to some 
situations and cells collected by l_eucapheresis following G -CSF alone are capable of 
rapid haemopoietic reconstitution (Sheridan et al 1992) This approach is indicated 
for collecting cells from normal donors for allogeneic stem cell transplantation 
where chemotherapy toxicity would be unacceptable. CT -CSF at a dose of arntmd 
lOpg/kg/day for 4 days is the commonest regiYen and studies have suggested that 
escalation of the dose beyond 16wg/kc! day does not improve yield. The side effect 
profile of Cr -CSF is good with mild to moderate hone nain and flu -like symptoms 
being seen in around 30 of subjects and occasional transient increases in liver 
eny es. Currently available products vary in terms of their glycosylation and some 
suggest that the glyrosylated form may he superior (Hoglund et al 1995), Clinical 
studies have shown both to he effective. 
As well as a or GM -CSF a number of other factors and combinations have been 
investigated including: SCF, SCF±G -CSF, Tr 3, Flt3 ligand and i, -lo,. These have 
all been shown in animals or humans to mobilise to some degree and there is 
continuing interest in combinations of such factors and the use of sequential therapy 
(Andrews et al 1994; Brasel et al 1995). Since the simple use of a -CSF is 
established and adequate for most clinical settings, clinicians are seeking approaches 
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that would improve the mobilisation in those cases where marrow damage from 
heavy pre- treatment has rendered cell yields poor. 
How many stem cells are required ? 
In the clinical setting there are essentially three types of assay that are applied for the 
assessment of harvest quality: MNC counts, semi -solid progenitor colony assays, and 
enumeration of CD34 +ve cells by flow cytometry. As described above, both culture 
and flow cytometry can be used to attempt to separate and quantify the more 
primitive subsets of stem cells which in theory might be most relevant to stable long- 
term marrow reconstitution. Despite much work in this area, these culture assays 
remain more complex, expensive and time consuming and in many instances do not 
yield results in time to be clinically useful (for example the 5 -8 week lag for the 
LTCIC assay). In routine clinical practice, it has not yet been found useful to look 
beyond the relatively simple CFU -GM or CD34 assay for the prediction of good 
engraftment from a harvested product and some workers find the simple MNC count 
adequate. There have been many reports concerning the relationship between MNC, 
CD34 and CFU -GM cell dose reinfused and speed and quality of engraftment 
following high dose treatment. Two thresholds have been established although there 
is some disagreement on the exact levels chosen. The lower threshold seeks to 
define a number of CD34 +ve cells or CFU -GMs below which rapid and sustained 
engraftment may not occur. This level is around 20x104 CFU -GM/kg or 1 -2x106 
CD34 +ve cells /kg patient body weight (Bender et al 1992; Weaver et al 1995). It 
follows that these are minimum rather than desirable results of harvest. With greater 
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numbers there is a steady improvement in rate of engraftment but there appears to be 
an upper threshold beyond which there is no further benefit. This probably lies 
around 50x104 CFU -GM/kg or 5 -8x106 CD34 +ve cells /kg (Weaver et al 1995). 
Similar assays have been used to determine the best time to commence apheresis 
after mobilisation. Regimens using chemotherapy alone used the peripheral white 
count and commenced apheresis when this rose above 1x109 /l. Later approaches 
using combinations of chemotherapy and growth factors usually aimed for a higher 
count of 2- 5x109/1. and more recently this has been improved by the rapid estimation 
of CD34 numbers in the peripheral blood with most centres starting apheresis when 
the CD34 count is above 10- 20 /11. After G -CSF alone it is customary to collect on 
the 5th or 6th day when the white count will often be greater than 30x109 /l. 
In our centre, we have been studying the relationship between engraftment and other 
more `stem cell' specific markers by flow cytometry including Thy -1 and L- selectin 
(CD62L). There does appear to be a correlation with sustained engraftment using 
these markers but whether this will be clinically useful is as yet uncertain (Rawstron 
et al 1998). 
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1.3 Manipulation of Haemopoietic Stem Cells 
Background 
It is clear from a consideration of the uses of stem cells described above that 
different cell products have different properties and it would be logical to collect and 
process them in such a way that the final result best suits the particular clinical need. 
Cells can be manipulated in a variety of ways and it is likely that in the future the 
reinfused products will be better characterised and more specific than is currently 
possible. Methods of cell manipulation of current clinical interest include: selection, 
expansion and genetic modification. These approaches are not mutually exclusive. 
For example, it might be possible to select a particular population, genetically 
modify it and then expand it ex -vivo before putting it to clinical use. At present such 
technology has not advanced sufficiently to produce definite clinical benefit but 
there is promising work in all of these areas. 
Cell selection 
Selection is the process by which the products derived from marrow or mobilised 
peripheral blood are altered either to enhance the content of a desired cell type 
(positive selection) or reduce and if possible eliminate unwanted cells (negative 
selection). There is no reason why these processes should not be combined to 
maximise the purity of a final product. The major applications of these techniques 
are in purging harvests of contaminating tumour cells in malignancy (Shpall et al 
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1994), altering the proportions of immune reactive T cells in allogeneic 
transplantation and treatment of autoimmune disease (Russell et al 1996; Snowden 
et al 1997) and selecting pure populations of repopulating cells for further 
manipulation such as expansion or gene therapy (Alcorn & Holyoake, 1996; Brenner, 
1996). A wide variety of selection methods have been investigated both in vivo and 
in vitro. In vivo, specific mobilisation techniques have been shown to allow 
collection of Ph -ve stem cells in patients with CML (Carella et al 1997) and I 
describe a clinical study of one such novel regimen in chapter 3 (Johnson et al 
1996a). More commonly, cells are selected after collection. Examples of such in 
vitro methods have included: specific culture conditions favouring survival of normal 
cells in CIVIL (Barnett et al 1993), exposure of collections to cytotoxic agents active 
against malignant cells in AML (Rowe & Liesveld, 1996), complement- mediated 
lysis of T -cells induced by the Campath antibody before allogeneic transplantation 
to reduce graft versus host disease (Butturini & Gale, 1988), removal of 
contaminating tumour cells by immune adsorption in lymphoproliferative disorders 
using MABs to lymphoid antigens (Gribben et al 1991) and selecting specifically for 
the stem cell fraction in collections using antibodies to CD34 (Berenson et al 1991). 
Cell selection using the CD34 antigen (which was described in section 1.1) has been 
the most widely studied of all methods as it is present on cells with long term 
repopulating ability and is absent on most solid tumours (Krause et al 1996b). It is 
therefore ideally suited for tumour purging strategies and for producing cell 
products which are starting points for expansion and genetic modification. 
Berenson et al demonstrated in 1988 that CD34 cells selected using MAB 12.8 
could restore full haemopoiesis in lethally irradiated baboons (Berenson et al 1988). 
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Since then, there have been a number of studies demonstrating the clinical 
applicability of the technique and the adequacy of short and long term engraftment 
using CD34 selected products (Berenson et al 1991; Schiller et al 1995). I describe 
one such study in chapter 4 (Johnson et al 1996b) and the methodology of selection 
in chapter 2. A major part of the interest in this method of selection has revolved 
around its ability to achieve a tumour purge in harvested cell products. Outside the 
haemopoietic system, CD34 is expressed only on endothelial cells and some 
fibroblasts (Krause et al 1996b). It is not generally detectable in solid tumours nor in 
most lymphoproliferative disorders. The recent explosion of interest in intensive 
HDT with stem cell reinfusion in these diseases has led to research looking at MRD, 
harvest tumour cell contamination and the origins of relapse after autografting. It 
has been shown that malignant cells frequently contaminate PBSCHs and that in 
some diseases there may even be a specific mobilisation of tumour cells by the 
chemotherapy /growth factor combination (Rill et al 1994; Owen et al 1996; Brugger 
et al 1994). The gene marking studies of Brenner and others has shown that 
malignant cells reinfused in autografts can contribute to relapse in some cases 
(Brenner et al 1994). If tumour cells are present in harvests and can contribute to 
relapse, there is a rationale for the use of CD34 selection. The efficiency of purging 
by this method has been investigated ( Cagnoni & Shpall, 1996). Ideally, one would 
wish to achieve adequate CD34 yields with a high purity correlating with a 
maximum tumour reduction for all patients. In practice, while CD34 yields appear 
clinically adequate from most studies, the purity is inconsistent. Clonal cells are still 
detected in some products after selection and malignant contamination below the 
level of assay detection is possible and may be relevant. Where it has been 
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quantitated, the log reduction in tumour burden has been quoted at between 2.7 and 
4.5 (Schiller et al 1995). It seems unlikely that CD34 selection alone will adequately 
purge products and whether the current technology will impact on disease free 
survival is unknown (To et al 1997; Cagnoni & Shpall, 1996). Studies of HDT in 
breast cancer and lymphoma have suggested that survival is improved in those 
patients who are autografted with successfully purged products (Fields et al 1996; 
Gribben et al 1991) but these may simply represent the patients with low disease 
burden and no randomised trial of autografting with unmanipulated versus CD34 
selected stem cells has yet been reported. Tumour reduction may be improved by 
combining positive CD34 selection with negative tumour depletion steps using 
MABs to tumour -specific antigens. While this may improve the purging efficiency, 
loss of cells occurs at all stages reducing yield and potentially affecting engraftment 
and the procedure becomes more costly and labour intensive. It is too early to say 
whether such strategies will find a place in clinical practice. 
An alternative approach to post harvest stem cell selection has been reported by 
Tricot et al who have used high speed cell sorting to isolate a population of 
CD34 +ve, Thy -1 +ve, lineage marker negative cells which are thought to be 
phenotypically close to the pluripotent stem cell. They have autografted myeloma 
patients using this technology with some initial success but report problems with 
delayed engraftment and increased opportunistic infections (Tricot et al 1995; Siegel 
et al 1997). 
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Cell expansion 
The use of cell culture systems to investigate the complexities of haemopoiesis has 
been discussed in section 1.1. The ongoing refinement of culture systems and the 
elucidation of the actions of a multitude of soluble agents such as growth factors and 
interleukins has opened the door to the possibility of clinical scale ex vivo cell 
expansion (Alcorn & Holyoake, 1996). It is now proving possible to expand cell 
numbers many fold, harvest the result and reinfuse them into patients following 
chemotherapy. The safety and practicality of this approach has been well 
documented (Silver et al 1993; Brugger et al 1995a) but it remains to be seen 
whether long term repopulating cells are expanded (or indeed preserved) by these 
systems (Srour et al 1993). Haemopoietic reconstitution after truly myeloablative 
chemotherapy has not yet been consistently achieved in human subjects using solely 
ex vivo expanded cell products (Holyoake et al 1995). 
Theoretically, there are many applications for this technology (Alcorn & Holyoake, 
1996). Stem cell expansion could shorten harvest procedures and allow useful 
products to be derived from inadequate collections in heavily pre -treated patients. 
The expansion of stem cells from a small PBSC collection might have a tumour 
purging effect as there is evidence that contaminating clonal cells do not grow in 
such systems (Brugger et al 1995b). It might also be possible to enlarge the stem cell 
content of cord blood samples allowing safe adult allo- transplants and to expand 
populations of genetically modified primitive cells as vehicles for gene therapy 
protocols. Large numbers of committed, lineage restricted cells could be produced 
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and infused after autografting to provide short term support pending engraftment and 
so reduce the period of severe neutropenia (Williams et al 1996). 
Initially, studies concentrated on murine marrow and were aimed at delineating the 
factors that were most important for cell growth and differentiation in simple liquid 
culture systems. Combinations of 1L3 and 11,6 were the first to be used successfully 
and these remain important in most systems (Bodine et al 1989). Successive studies 
defined several other important agents, most notably: SCF, G-CSF Or GM-CSF, ILA Ñ 
and erythropoietin. These liquid culture systems yielded large increases in total cell 
numbers and, importantly, cell types associated with long term repopulating potential 
were also increased (Ploemacher et al 1993). Muench et al demonstrated that 
lethally irradiated mice could be rescued with allogeneic marrow cells that had been 
expanded ex vivo and that they retained long term donor derived haemopoiesis 
T R, h 1 99 This + tv that (LVf,iencL, et al L i ). f 1115 ánd other murine studies suggested that ex vivo 
expansion might provide a cell source fitting all the criteria required for human 
transplantation. 
A huge amount of resources have been targeted at clinical scale stem cell expansion 
last It is important to that most li, fi in the SL few years. f 5 fú Ori O note gh 1vr such applications, purified 
CD34 cells have been the preferred cell source at input but that some workers have 
suggested that there may be advantages in using `younger' stem cells derived from 
cord blood or foetal liver tissue (Traycoff et al 1995). These latter two sources may 
yield cells of greater ultimate proliferative capacity as suggested by their increased 
telomeric DNA (Vaziri et al 1994). Two basic approaches have been scaled up to a 
clinically practical level. These are: suspension cultures supplemented with 
cytokines and stromal -based cultures. The former are simply modifications of the 
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original liquid culture methods described above with optimised conditions. Cells 
are generally cultured for between 8 and 21 days in such systems with many fold 
increases in total numbers (Haylock et al 1992a). Progenitor cells also increase 
under these conditions but their numbers tend to fall off approaching 21 days 
presumably as more primitive cells are `exhausted' through differentiation. A vital 
question concerning this approach is whether true repopulating cells are maintained 
or increased during the process. Data is conflicting but CD34 estimations and 
LTCIC assays suggest that this may in fact not occur (Williams et al 1996; Srour et 
al 1993). This is worrying and as yet there is virtually no clinical data available. 
The alternative approach is to use a stromal -based culture system. This is 
conceptually appealing as it seeks to mimic the interactions that occur in the marrow 
microenvironment. Liquid cultures by contrast require a better understanding of the 
soluble factors which stroma releases and cannot supply the potentially important 
cell -cell interactions. The hope is that `physiological' stroma -based methods may 
achieve expansion of the most primitive cells which must be a major goal. The 
systems are, however, considerably more complex and expensive. There is now 
emerging evidence that such stromal cultures, scaled up in bioreactors with constant 
perfusion of medium and the necessary stimulating factors can lead to expansion of 
LTCIC (Koller et al 1995). 
While such products have been successfully transfused with no toxicity into patients 
there is still no firm clinical evidence that current expansion techniques can produce 
adequate long term haemopoietic reconstitution at a clinical scale (Holyoake et al 
1995). 
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The goal of research at present is to elucidate the factors and conditions required to 
reliably expand primitive stem cell numbers in a simple practical system. If this is 
achieved it could have major implications for transplantation and the delivery of 
gene therapy. 
1.4 Cell Modification - Gene Therapy 
Introduction 
Gene therapy may be defined as the introduction of new genetic material 
into a cell in order to change that cell's phenotype. Since recombinant DNA 
technology became available it has been rapidly incorporated into medicine with a 
range of new diagnostic tools and therapeutic products. Although the application of 
the new genetic understanding to gene therapy appeared obvious, it has required a 
concerted and co- ordinated development in diverse areas of scientific and medical 
interest to reach clinical practice and the earliest phase one clinical studies are only 
now being reported (Boucher et al 1994; Grossman et al 1994; Malech et al 1995). 
This difficulty reflects the many pre- requisites of any effective gene therapy protocol 
which include: accurate molecular definition of a disease and choice of the genetic 
target, the construction of novel therapeutic genetic material and associated 
regulatory factors if required, a suitable vector with which to introduce this material 
and a mechanism for targeting this vector to the required tissue in which stable 
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integration and expression of the gene over a useful timescale and at an effective 
level will be required (Dunbar, 1996a; Flotte & Ferkol, 1997). 
Applications 
The range of human disease that could theoretically benefit from such an approach is 
wide and growing (Apperley & Williams, 1990b; Dunbar, 1996a). The first results 
of a clinical gene therapy protocol were reported in 1989. This was a gene marking 
experiment to investigate the fate of modified lymphocytes in malignant melanoma 
(Rosenberg et al 1990). More than 100 clinical trials in human gene transfer have 
been approved in the USA alone since then, some of which are reporting preliminary 
data (Flotte & Ferkol, 1997). The majority of these protocols are in malignant 
disease. These include: gene marking studies, attempts to improve tumour immune 
recognition ( `tumour vaccine') by transducing tumour cells with activating cytokines 
such as IL2, the introduction of suicide genes to cancer cells such as HSV thymidine 
kinase and attempts to alter drug sensitivity by manipulating drug resistance gene 
mechanisms. Outside the field of malignancy, gene therapy can be applied to 
genetic disorders which result in low or absent levels of a protein or enzyme for 
example: Cystic Fibrosis, Chronic Granulomatous Disease, the Haemophilias, 
Gauchers disease, Fanconi's anaemia and SC1D due to adenosine deaminase 
deficiency. Certain other acquired, infectious or multifactorial diseases have also 
been investigated such as AIDS, peripheral vascular disease and rheumatoid arthritis. 
The target tissue and choice of vector will depend on the disease and the chosen 
approach. Examples of such varied approaches include the re- implantation of ex- 
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vivo transduced hepatocytes to correct familial hypercholesterolaemia (Grossman et 
al 1994) and the in vivo transduction of lung epithelial cells by aerosolised vector in 
cystic fibrosis (Boucher et al 1994). 
Haemopoietic stem cells as targets for gene therapy 
Many gene transfer protocols have focused on the haemopoietic stem cell (Dunbar, 
1996a). These are highly desirable targets due to their capacity for self renewal and 
multilineage differentiation. They can be easily collected from blood or marrow, 
genetically manipulated and reinfused into patients where their kinetic properties 
would in theory allow long term maintenance of a constantly proliferating cell source 
containing the new gene. In addition, as has already been discussed above, these 
cells might be purified and/or expanded ex vivo before or after genetic alteration to 
improve transduction efficiency and increase numbers for transplantation (To et al 
1997; Holyoake & Alcorn, 1994; Alcorn & Holyoake, 1996). There has been a 
considerable amount of work on gene transfer to animal and human haematopoietic 
stem cells over the last decade. Some fundamental problems have complicated the 
research including the difficulty of isolating true long term repopulating cells for 
which there is no specific assay and the natural quiescence of these cells which 
renders them resistant to transduction by some vectors (Miller et al 1990). The same 
properties complicate selection and expansion of these cells with the result that the 
most desirable cell target for gene therapy has proved by its very nature the most 
inaccessible. 
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Vectors for gene transfer 
A vector is a means to introduce novel DNA sequences into a target cell. They can 
be broadly divided into viral and non -viral and table 1.1 lists some of the vectors 
used in gene transfer both in vivo and in vitro. Currently, viral vectors remain the 
most efficient vehicles for DNA delivery. Key questions remain to be answered 
concerning the available viral agents. Firstly, do they have the ability to transduce 
the most primitive stem cells? Secondly, what design of vector and which 
conditions are optimal for maximising transduction efficiency? Thirdly, are the 
kinetics of primitive cells likely to be altered by the process of achieving efficient 
transduction such that they will lose some or all of their self -renewal capacity and be 
stimulated to differentiate? Finally, what implications will the answers to these 
questions have for the duration of stable transduction and long term gene expression 
in vivo? An idealised vector for stem cell transduction would be easily produced in 
high titre, free of helper (wild -type) virus, non -pathogenic to man, capable of 
packaging large DNA inserts, efficient and stable at integration, invisible to the host 
immune response and capable of transducing non -dividing cells. None of the 
currently available candidates fulfils all these criteria. 
Retroviral vectors such as those based on the MoMLV have been the most widely 
studied. It is now over 13 years since it was first demonstrated that gene vectors 
based on murine leukaemia viruses were able to successfully incorporate 
specifically designed genetic material into murine haemopoietic stem cells with 
subsequent expression of the new gene in cells of both myeloid and lymphoid 
lineages (Williams et al 1984b). 
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Retroviral vector production based on the MoMLV is depicted in figure 1.2. A 
packaging cell is produced by transfection with a MoMLV whose packaging 
sequence (j) has been deleted such that no intact viral particles can be produced. 
When this cell line is transfected with the engineered retroviral construct, a producer 
cell line is created. The gag, pol and env genes of the modified virus are replaced by 
the DNA insert of choice but the W sequence is intact allowing the virus to utilise the 
gag, pol and env of the packaging cell to create infective viral particles (Miller, 
1990). These are released into culture supernatant and can be collected and used for 
transduction. Details of methodology related to this process are described in chapter 
2. Retroviral vectors enter target cells via specific cell receptors, following which 
their RNA undergoes reverse transcription using the reverse transcriptase enzyme 
from which the virus name is derived (Coffin, 1990). The cDNA so produced enters 
the nucleus upon mitosis and is stably integrated into host DNA. Since the vector 
has no gag, pol or env genes, the resulting replication products cannot form new 
infective viral particles and are thus termed replication defective. The target cell is 
capable of continuing production of the engineered gene without further infective 
risk to other host cells. Recombination events within producer lines could, however, 
lead to the production of wild -type virus and refinements of technique are required to 
safeguard the process (Markowitz et al 1988b). Retroviral vectors have the attractive 
property of stable nuclear integration (Coffin, 1990) and they have been the most 
studied system to date. They are however limited in the insert size they can accept 
(up to 7Kb) and are in general of fairly low titre (105 -107 cfu/ml). 
Figure 1.2 
Diagram depicting the production of a retroviral producer cell line. The packaging 
line is created by transfection with an enfeebled MoMLV from which the `P 
sequence has been deleted. The lack of this sequence means that this cell line 
contains the genes encoding for the retroviral gag, pol and env proteins but cannot 
produce intact particles. A new retroviral construct is then created in which the gag, 
pol and env genes are excised and replaced by the desired DNA insert. This construct 
has a normal Y' sequence. When the packaging cells are transfected with this, they 
are able to supply the gag, pol and env proteins for assembly by the 'P sequence into 
intact, infective viral particles containing the new insert. This is now a producer cell 
line. The particles released can only infect one cell as they will not be able to 
produce their own gag/pol/env for production of new virus. The insert is however 
integrated into the genome and is available for transcription by the infected cell. 
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Target cell specificity can be altered by the use of vectors with different envelope 
glycoproteins, termed retroviral pseudotypes and there is evidence that efficiency of 
transduction is improved with certain strains, for example the gibbon -ape leukaemia 
virus (GALV) (Miller et al 1991). Perhaps most importantly, the physical barrier of 
the nuclear membrane appears an absolute one at present and it seems unlikely that 
truly quiescent cells such as pluripotent haemopoietic cells could be transduced 
using these viruses unless they enter mitosis (Miller et al 1990). 
Other viral vectors of current interest include the adenoviruses (AV) and adeno- 
associated viruses (AAV). AV are DNA viruses responsible for mild upper 
respiratory illness in man and enter cells by receptor mediated endocytosis after 
which they induce lysosomal disruption and are then free to enter the nucleus 
(Horowitz, 1990). Replication defective AV vectors can be produced by deletion of 
viral genes (E la, E 1 b and E3) and replacement with the relevant construct. They 
have the advantage of infecting non -dividing cells with great efficiency and being 
produced in high titre (Jaffe et al 1992). Despite this, there are problems with 
transient expression due to lack of integration, the induction of an inflammatory 
epithelial response in animal studies and the development of a strong immune 
response to repeated exposure. Phase 1 trials in cystic fibrosis where repeated 
aerosols of vector are administered by inhalation have confirmed these unwanted 
effects in human subjects (Boucher et al 1994). 
AAV are non -pathogenic, replication defective, human DNA parvoviruses which 
require co- infection with helper virus such as HSV or AV for productive infection. 
In the absence of these, AAV establishes a latent infection in the host genome 
through site specific integration on chromosome 19 (the AAVS1 site) (Chatterjee et 
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al 1995). This integration is very stable and has been maintained in tissue culture for 
over 100 passages. The promise of a harmless, high titre vector which achieves 
stable site specific integration and can infect non -dividing cells has made this an 
appealing virus for study. Some initial hopes may be unrealistic however as the 
genetically engineered vectors do not appear to share the site specific integration of 
the wild type virus, increasing the possibility of insertional mutagenesis. It has also 
been found that transgene persistence after transduction may not always reflect 
stable integration ( Flotte et al 1994; Russell et al 1994). Despite these doubts, they 
are currently an important area of study. 
Efficiency of gene transfer into stem cells 
The majority of available data concerns retroviral vectors. In animal stem cell 
transduction experiments, it has been possible to achieve expression of transgenes 
for at least 6 -12 months, with the best results in mutine models (Wilson et al 1990; 
Correll et al 1992). The efficiency of transfer has been improved by prior 
concentration of primitive cells using pre -treatment with cycle -specific cytotoxic 
agents and stimulation with cytokines (Bodine et al 1991). Under optimal 
conditions, with selected stem cells, growth factors and co- culture with viral 
producer cell lines, murine LTCICs have been successfully transduced, with up to 
50% of daughter cells containing the marked gene (Fraser et al 1990). Similar 
experiments in larger animals have however been less successful. Although 
multilineage marking can be achieved, the proportions of marked cells are low at 
around 0.1 -1% of marrow cells (Schuening et al 1991). 
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Table 1.1 Vectors for Gene Transfer 
Non -Viral Vectors Viral Vectors 
Calcium phosphate precipitation Murine Leukaemia viruses 
(MLV) 
Electroporation Adenovirus 
DMSO shock Adeno- associated virus 
Microinjection (single cell) Herpes Simplex Virus 
Liposome- mediated MLV pseudotypes 
Receptor- mediated transfer 
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Human in vitro data has followed this work and high transduction efficiencies (often 
>50 %) of CD34 +ve selected cells from marrow, blood or cord blood have been 
achieved using progenitor cell assays as markers of success. Optimal transfer is 
again dependent on the addition of growth factors and/or stromal elements (Nolta & 
Kohn, 1990; Moore et al 1992). The most important question this raises is the extent 
to which we can infer from these assays that true repopulating cells are transduced. 
In addition to these surrogate assays, answers may come from long term gene 
marking studies in vivo. Trials have been reported showing persistence of marker 
genes in patients following marrow transplantation with ex vivo retrovirally 
transduced cells (Brenner, 1996; Dunbar et al 1995). Some patients remain PCR 
positive for the reporter gene in multiple lineages for over 18 months following the 
procedure but again, the proportion of marked cells is generally low. Clinical 
protocols attempting stem cell retroviral transduction and reinfusion using active 
gene constructs are underway, notably in SC1D /ADA deficiency, Fanconi's anaemia 
and chronic granulomatous disease (CGD). There are preliminary reports of 
persistent detection of the therapeutic genes in vivo (Malech et al 1995). 
The study of AAV gene transfer is less advanced than that of retroviruses. Despite 
this, there is evidence that lethally irradiated mice reconstituted with AAV 
transduced cells retain multilineage gene expression for >6 months, implying that 
primitive stem cells can be targeted (Podsakoff et al 1994). In vitro data is available 
for human stem cell transduction and suggests that AAV vectors are highly efficient 
at transferring genes to CD34 +ve cells, cord blood and LTCIC (Zhou et al 1994; 
Goodman et al 1994). These and other vectors may offer considerable future 
promise. 
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In summary, the field of gene therapy is in its clinical infancy with only phase 1 data 
available and many trials underway. Viral vectors remain the most efficient methods 
of gene transfer but much is still unknown concerning the life cycle of these agents 
and their mechanisms of infection, integration, persistence and immunogenicity. 
The goal of long term, stable, controlled gene expression is still elusive but it seems 
increasingly likely that this will ultimately be achieved. 
1.5 PNH: Stem Cells and Gene Therapy 
PNH is caused by an acquired somatic mutation in a haemopoietic stem cell which 
leads to the co- existence of normal and `PNH' haemopoiesis. It is therefore an 
interesting model disease in which to study normal and abnormal stem cell 
behaviour and the possibility of gene replacement as therapy. 
History and clinical features of PNH 
The molecular biology of this rare but fascinating disorder has recently been clarified 
(Miyata et al 1993; Rosse & Ware, 1995) but as a clinical entity it has puzzled 
physicians and scientists for two hundred years. The first probable description of the 
disease in the literature was an "Account of a singular periodic discharge of blood 
from the urethra" written in 1794 by a Scottish surgeon, Charles Stewart (Stewart, 
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1794). Several case reports in the nineteenth century probably describe cases of 
PNH but the first detailed description is credited to Paul Strubing in 1882 (Strubing, 
1882). The rarity of PNH probably accounts, at least in part, for the delay between 
the first reference to a probable case and the recognition of the disorder as a distinct 
clinical entity. Strübing's description was of a 29 year old man with a six year 
history of the passage of brown -black urine intermittently in the mornings, always 
clearing by noon. His conclusions were detailed and astonishingly perceptive, 
suggesting as he did that there was intravascular haemolysis with persistent 
haemosiderinuria and that some of the patient's symptoms were due to thrombosis. 
He even concluded (correctly) that a red cell defect was to blame and that attacks 
were precipitated by sleep. Despite this insight, the work was largely ignored and 
when Marchiafava reported a case in Italy 29 years later it was regarded as a new 
entity (Marchiafava & Nazari, 1911). Marchiafava published a further case in 1928 
and showed that both patients had haemosiderinuria as a clinical feature. He named 
this `new' disease "chronic haemolytic anaemia with perpetual haemosiderinuria" 
(Marchiafava, 1928). Over the next 3 years, Micheli studied these cases and others 
from the literature and published his observations in 1931 in which PNH acquired 
the new title of "splenomegalic haemolytic anaemia with haemoglobinuria and 
haemosiderinuria, Marchiafava -Micheli type" from which the disease retains the 
eponym to this day (Michelli, 1931). The modern term PNH was in fact first coined 
shortly prior to Micheli's paper in a description of a case from the Netherlands by 
Enneking (Enneking, 1928). 
The clinical features of PNH can be considered under two broad headings. Firstly 
there is the strong association with aplasia (first described in 1944 in a patient with 
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Fanconi's anaemia and PNH ( Dacie & Gilpin, 1944)) and the possible link with 
subsequent clonal malignancy in the form of MDS or AML (Tichelli et al 1988) and 
secondly there are the classical features of haemolysis and thrombosis which led to 
the first descriptions of the syndrome described above (Socie et al 1996). Aplasia is 
probably always present to some degree but may range from the dominant clinical 
manifestation with anaemia, infections and haemorrhage to apparent normality of 
cell counts with only laboratory culture evidence of reduced marrow reserve. It is 
clear that PNH can co -exist with, antedate or post -date an episode of hypoplasia 
(Dacie & Lewis, 1961; Dacie & Lewis, 1972) and that the aetiology of the 
hypoplasia (idiopathic, viral or drug induced) is not specific to the development of 
PNH (De Planque et al 1989). Even in cases when there is insufficient evidence to 
diagnose AA, an isolated cytopenia (most commonly thrombocytopenia) is very 
common. Where MDS or AML occur they will usually supervene over any other 
features and frequently lead to the patient's death. It is uncertain whether PNH itself 
is truly pre -leukaemic. Cases of AML and MDS have been reported, some where the 
malignant cells have been of PNH phenotype and some where they were normal 
(Shichishima et al 1993; Stafford et al 1995). In view of this it might be more 
appropriate to take the view that patients with AA may go on to develop PNH or 
AML/MDS rather than to consider PNH as a separate, pre -leukaemic disorder. 
Patients presenting with classical PNH are mostly young adults (median age 35 
years) although cases at both extremes of life have been reported. There may be a 
slightly higher incidence in females. There is no reported racial variation (Sirchia & 
Lewis, 1973; Krautrachue et al 1978). Haemolysis is common and results in the 
classical episodes of haemoglobinuria that first drew attention to the disease. The 
55 
anaemia is related both to the degree of haemolysis and the extent of aplasia and 
ranges from a normal Hb level to severe recurrent anaemia requiring multiple, life- 
long transfusions (Hillmen et al 1995). Thrombosis is the other cardinal clinical 
feature. Panton, in 1924 was the first to describe this association and it has been 
confirmed in many series since (Panton et al 1924; Dacie & Lewis, 1972). Although 
it is largely venous, occasional reports of unusual arterial occlusions in patients of 
young age without vascular risk factors suggest that this is not exclusive. The 
commonest sites are the hepatic (Budd -Chiari syndrome), portal, intestinal, 
pulmonary and deep peripheral veins but at autopsy there have been studies showing 
thrombosis in many unusual sites such as veins of the pancreas, omentum, seminal 
vesicle and bladder (Dacie & Lewis, 1972; Peytremann et al 1972). Physical signs in 
PNH are non -specific and largely related to complications with the exception of 
modest splenomegaly which can be found in nearly half of patients. There is a 
spectrum of disease from acute haemolysis or thrombosis and little or no evidence of 
aplasia to patients with severe AA or other haematological disorders who are noted 
on investigation to have detectable PNH clones by laboratory testing only. 
Hillmen et al have examined the records of 80 consecutive PNH patients registered 
at the Hammersmith hospital in London between 1940 and 1970 giving an insight 
into the long term clinical course of the disease ( Hillmen et al 1995). In this paper, 
the median age at diagnosis was 42 years, with 84% of patients having episodes of 
frank haemoglobinuria as a chief symptom at some stage of their illness. A diagnosis 
of aplasia was made prior to the diagnosis of PNH in 29% and 5 of the patients who 
presented with frank haemolytic PNH subsequently developed aplasia. The median 
survival from diagnosis was 10 years which was substantially less than that of age 
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and sex matched controls. 58% of the 60 deaths to date in this cohort were directly 
attributable to PNH, with thrombosis being the commonest cause and Budd -Chiari 
syndrome the commonest fatal thrombotic event. In total, 39% of all patients 
suffered a thrombosis during follow up. Interestingly, spontaneous remission was 
noted in 12 cases in this series and none of the 80 patients developed MDS or AML. 
Pathophysiology of PNH 
Initial attempts to explain the clinical features understandably concentrated on the 
visible haemolytic component. With modern techniques it is now appreciated that 
individuals can have PNH cells detectable in the absence of typical clinical features 
and that there is a strong relationship with AA. Furthermore it is appreciated that 
normal and `PNH' haemopoiesis co -exist in the marrow, the proportion varying from 
case to case and over time in individuals (Rosse, 1973). The underlying cause of 
PNH is an acquired genetic mutation (Miyata et al 1993). Most workers believe that 
a degree of marrow damage /failure is an essential pre- requisite for PNH to develop 
in the presence of this mutation and that clinical sequelae depend on the nature of 
the initiating insult and the proportion of the patient's haemopoiesis that is PNH 
(Bessler et al 1994b). An understanding of the pathophysiology of the disease 
requires knowledge of this genetic defect, the pressures that lead to the development 
of PNH following mutation, the biochemical consequences of the defect and the 
mechanisms by which this translates into the clinical phenotype. 
Attempts to understand the basis of the haemolysis began in Rotterdam in 1911 
when Hÿmans van den Bergh noted that PNH erythrocytes were sensitive to lysis in 
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vitro when exposed to carbon dioxide (Hymans van den Bergh, 1911). By the 1930s, 
it had been shown that the erythrocyte lysis was caused by complement and was pH 
dependent with optimal lysis in acidified conditions (Dacie et al 1938). Despite a 
substantial body of laboratory work clarifying the haemolytic defect in PNH 
erythrocytes it was not until the late 1980s that a cellular mechanism could be 
hypothesised. Following earlier observations in the 1950s that some membrane 
bound proteins were absent from PNH cells, a diverse range of missing proteins 
was described (Rotoli et al 1993). Some of these (particularly DAF and MIRL) 
were involved in the regulation of complement activity at cell surfaces and it was 
presumed that their absence led to the erythrocyte sensitivity and subsequent 
haemoglobinuria. The initial belief that DAF (CD55) was the important molecule 
was proved incorrect when it was shown that individuals of the so called Inab red 
cell phenotype, who have an inherited DAF deficiency, had no clinical illness or in 
vitro red cell complement sensitivity (Telen & Green, 1989). MERL (CD59) was the 
next candidate. This is an 18kD protein which inhibits formation of the complement 
membrane attack complex. When red cells were treated with blocking antibodies to 
CD59, they were indeed rendered complement sensitive. Further evidence for the 
significance of this molecule came in 1992 when a 22 year old man was described 
who had a homozygous deficiency of CD59 on all haemopoietic cells and suffered 
PNH -like symptoms with haemolysis and a cerebral thrombosis (Yamashina et al 
1990). It seems likely that the haemolytic and thrombotic features of PNH are 
mediated by complement sensitivity and that CD59 deficiency is an important cause 
of this. 
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A major step in appreciating the underlying disease pathology came in 1986 when it 
was shown that all the proteins absent in PNH were attached to the membrane by a 
glycolipid (GPI) anchor (Davitz et al 1986). It was clear from this that the defect in 
PNH cells lay in the GPI structure, the details of which are depicted in Figure 1.3. 
Studies using labelled intermediates have demonstrated that GPI synthesis in PNH 
cells is almost absent due to failure of addition of N- acetylglucosamine to 
phosphatidyl -inositol early in the biosynthetic pathway, although the exact detail is 
as yet unclear (Hillmen et al 1993). 
A gene whose cDNA is able to correct the GPI synthetic defect in all human cell 
lines transfected to date has now been discovered and cloned (Miyata et al 1993). 
This gene is situated on the short arm of the X chromosome, contains 6 exons and 
codes for a protein of 54kD in size which has homology to some plant glycosyl 
transferases. The gene has been named PIG -A, a term derived from its ability to 
restore the GPI synthetic defect in class A murine cell lines which belong to the same 
complementation class as lymphoblastoid cell lines derived from PNH patients 
(Bessler et al 1994a). Since the gene was cloned, several workers have sought 
mutations in PNH patients and it has become clear that this is a consistent finding in 
the disease. A recent report summarised the mutations found to date (Rosse & Ware, 
1995). 84 mutations were found in 72 patients but the list is growing rapidly. The 
commonest are deletions or insertions which between them account for well over 
half. Most are small (often single nucleotide) but 2 large ( >100 nt) deletions have 
been described. A number of patients have been described in whom there is more 
than one mutation in the gene (Rosse & Ware, 1995; Bessler et al 1994b). 
Figure 1.3 
Diagram of the GPI anchor. Proteins anchored through this structure are absent in 
PNH cells. The PNH defect appears to be at an early stage in the synthesis of the 

















Since all the mutations described to date abolish or severely impair GPI synthesis, it 
may be that the development of PNH requires an almost complete lack of GPI - 
linked proteins and that less deleterious PIG -A mutations occur but do not result in 
disease. Thus it is now clear that PNH is an acquired clonal disorder of 
haemopoietic stem cells due to mutations in the PIG -A gene. This results in 
defective GPI- anchor synthesis and absence of a number of proteins (including 
complement defence proteins) from the cell surface. The resulting sensitivity to 
complement and subsequent lysis of erythrocytes leads to the episodes of 
haemoglobinuria that originally defined the disease. The cause of the thrombotic 
tendency in PNH is not as well understood but there is evidence for a unifying 
hypothesis involving increased activity of complement on GPI -deficient platelets 
(Wiedmer et al 1993). 
While the genetic and biochemical events in PNH and their relationship to the 
clinical manifestations of the disease are quite well understood, the precipitating 
factors and relationship to aplasia and malignant transformation are more 
speculative. It was Dacie in 1963 who, putting forward the theory of clonality in 
PNH, suggested "the PNH change, resulting perhaps from somatic mutation, may 
be particularly likely to occur in damaged marrows, perhaps where early or abortive 
attempts at regenerative haemopoiesis are occurring" (Dacie, 1963). This perceptive 
view fits well with the current concept of a clonal disorder arising in damaged 
marrow as an escape phenomenon through an acquired growth advantage (Young, 
1992). 
There is now considerable support for the idea that PNH clones proliferate in the 
presence of external selection pressure which favours expansion of GPI -deficient 
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cells. There are several lines of evidence for this: The strong relationship with 
marrow failure or disruption that has already been discussed is one. PNH 
haemopoiesis is clearly able to thrive in a marrow whose normal stem cell pool is 
severely diminished. Molecular evidence in the presence of more than one 
(sometimes several) independent PIG -A gene mutations in different PNH lines in the 
same patient implies that there is a selection pressure operating for GPI deficient 
cells (Bessler et al 1994b). Culture experiments do not suggest any intrinsic growth 
advantage for GPI deficient cells, indeed there is generally a reduction in the 
numbers of progenitor colonies in PNH blood and marrow (Rotoli & Luzzatto, 
1982). Two `dynamic' experiments are worthy of mention. Firstly, it has been 
shown that mononuclear cells from PNH patients can inhibit the growth of normal 
progenitors in culture but that this inhibition is removed if the normal cells are 
stripped of their GPI -linked proteins by PI -PLC treatment before culture (Rotoli et al 
1995). This is direct evidence that a cell (probably a CD8 +ve T cell) mediated 
suppression of the marrow may be operating in AA/PNH to which GPI deficient cells 
are partly resistant. Secondly, patients treated with the CAMPATH 1H antibody 
have been shown to develop GPI deficient T cell clones. This antibody causes lysis 
of CD52 +ve cells and as this antigen is GPI linked there is a strong selection 
pressure for CD52 -ve cells. The frequency with which this has been observed 
suggests that PIG -A mutations may be common in normal individuals and merely 
require suitable selection pressure for such a clone to be manifest. In our institution, 
we have been able to demonstrate that the PIG -A mutation in one such CAMPATH 
treated patient was present pre- treatment in stored blood by using an allele specific 
PCR (Rawstron et al 1997b). 
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In summary, P14 i is an acquired stem cell disorder due to mutation of the PIG -A 
gene The lack of GPI anchored proteins (particularly CD59) on PNH cells probably 
Accounts for the clinical features of the disease and may well also provide a basis to 
understand the mechanism by which PNN haemopoiesis can develop in damaged or 
hypoplastic marrow. 
Treatment options in PN$ 
Treatment can be directed at the disease process itself or the clinical manifestations. 
The former requires immunosuppression or bone marrow transplantation in a similar 
way that one would approach the treatment of severe AA (De Planque et al 1989). 
The success of this approach is itself supportive evidence for the theory of PNH 
pathogenesis described in the preceding section. As an alternative or additional 
made of treatment, supportive therapy is available for some of the clinical 
manifestations including cytopenias and thrombosis. 
Supportive therapy includes the use of folic acid, blood transfusions and iron 
chelation for the treatment of anaemia, anticoagulation for the prevention of 
thrombosis and perhaps the use of growth factors where cytopenia is severe (Ikeda et 
al 1993; Ninomiya et al 1993). There have been reports of improvements in all cell 
line counts and of the disappearance of PNM clones after administration of G -CSF 
and Erythropoietin but no controlled trials exist to quantitate this effect and 
distinguish it from the natural fluctuations of the disease and occasional spontaneous 
remissions that are seen (Ball_eari et al 1996; Bourantas, 1994). Whether growth 
factors impact on survival in PNH is unknown. 
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Immunosuppression can be effective in the management of PNH associated with 
severe aplasia just as it is in AA without a PNH clone (Stoppa et al 1996; van et al 
1995). Combinations of anti -lymphocyte globulin, steroids and cyclosporin A are 
used. Steroids alone are used in the treatment of PNH by some clinicians but their 
effectiveness is in doubt and has never been proven in a randomised trial. 
Allogeneic bone marrow transplantation is a more radical approach to treatment and 
the usual indication in PNH has been the coexistence of AA. Storb et al performed 
the first reported transplant in 1973. This patient achieved remission with a fully 
functioning marrow graft and no PNH clone (Storb et al 1973). Since then there 
have been a number of further cases of PNH with associated AA which have been 
transplanted (Kawahara et al 1992) but the high mortality and morbidity of the 
procedure makes it generally unsuitable for the treatment of patients with classical 
PNH who lack significant cytopenias. 
Syngeneic transplantation for PNH has been reported by several workers either with 
or without conditioning chemotherapy (Graham et al 1996; Endo et al 1996). To 
date, 8 out of the 9 cases `transplanted' without conditioning have relapsed with 
PNH despite initial responses. Those given chemotherapy appear to sustain their 
remissions. This observation is in keeping with the hypothesis previously stated that 
AA and subsequent PNH is caused by an autoimmune stimulus and that part of the 
successful treatment is to eradicate this either by immune suppression or 
myeloablation. In the unconditioned syngeneic cases the donated normal marrow 
was presumably subject to the same autoimmune destruction and the PNH clone 
again thrived under this selection pressure. 
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Potential targets for gene therapy in PNH 
PNH is due to an abnormality in a single gene and is therefore a disease which could 
lend itself to genetic modification. While it might be thought that the obvious 
approach would be replacement of the mutated PIG -A, the experience with 
syngeneic transplantation in PNH described above suggests that this might not be 
advantageous. Recurrence after infusion of normal syngeneic cells shows that the 
aetiological process is still active and can destroy normal haemopoiesis. If this 
theory is correct then the introduction of genetically normal PIG -A constructs, even 
with conditioning chemotherapy, might simply lead to a situation where the modified 
PNH cells are as suppressed as the remaining marrow and patients would trade PNH 
for AA which is likely to be clinically more deleterious. A more elegant solution 
would be to target the GPI -linked proteins which are responsible for the selective 
growth advantage in PNH and modify the normal stem cells in this way. This would 
allow growth of normal marrow in the face of immune attack and in turn remove the 
advantage from the PNH stem cells which would no longer be competitive. This 
approach would require a precise understanding of the mechanism of selection 
pressure in PNH/AA which we do not as yet have and also presumes that the growth 
advantage and the sensitivity to complement reside in different GPI linked proteins. 
An alternative approach has been investigated by Rother et al where CD59 activity 
alone is restored to PNH cells using a retroviral vector containing a modified CD59 
construct anchored to cell surfaces through a transmembrane domain rather than a 
GPI anchor (CD59 -TM) (Rother et al 1994). Since CD59 is largely responsible for 
erythrocyte lysis and possibly also for the thrombotic tendency, the major clinical 
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features of classical PNH might be abrogated if this alternative CD59 construct was 
expressed on PNH stem cells. These cells would theoretically retain their selective 
growth advantage and avoid the AA that could ensue if PIG -A itself were corrected. 
The CD59 -TM construct was generated by replacing the GPI anchor signal of CD59 
with the carboxy terminus of membrane cofactor protein (MCP) amplified from 
HeLa cells. The amplified fragment contained a region known to comprise a 
transmembrane domain (TM). This CD59 -TM was then further subcloned into the 
retroviral vector pLXSN which is displayed schematically in figure 1.4. This vector 
was introduced into the amphotrophic packaging cell line PA317. Viral supernatant 
from this cell line has been used by these workers to achieve stable expression of 
CD59 in murine 3T3 cells and human PNH B- lymphoblastoid cell lines. They have 
shown that the presence of this novel molecule on these cells increases their in vitro 
resistance to complement when compared to untransduced controls (Rother et al 
1994). This work provides a rationale for attempts to transduce human PNH stem 
cells in an attempt to correct the clinical phenotype without inducing or worsening 
aplasia. 
Figure 1.4 
Diagram showing the basic structure of the LXSN retroviral construct. The virus 
name is an acronym: L =LTR (long terminal repeat), X= engineered DNA insert of 
choice, S =SV40 promoter sequence, N= Neomycin phosphotransferase resistance 
cassette. Transcription of the insert is driven from the 5'LTR while the SV40 
promoter drives the Neomycin gene. The virus was packaged in PA317 cells which 
supplied the gag/pol /env genes for particle assembly. In this case, the insert `X' is a 
form of CD59 which has been modified by excision of the GPI anchor signal and 
replacement by a transmembrane (TM) domain from MCP (membrane cofactor 
protein). This modification of CD59 allows it to attach to PNH cells which lack GPI 
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In -vivo PBSC purging in CML by a disease -specific mobilisation 
regimen 
2.1 Patients 
Eighteen patients with Ph +ve CIVIL were mobilised using a regimen of high dose 
hydroxyurea and G -CSF in an attempt to collect mainly Ph -ve PBSCs (Johnson et al 
1996a). To date, seven of these patients have been transplanted with cells harvested in 
this way (Johnson & Smith, 1997). Details of these patients including disease status and 
previous therapy are described in chapter 3. 
2.2 Mobilisation, collection and storage of PBSCs 
Newly diagnosed patients underwent a mononuclear cell collection on a single day as an 
autologous backup for future transplant procedures. Following this, their condition was 
initially stabilised with hydroxyurea. For mobilisation, patients initially received 6 
grams of hydroxyurea orally for 7 days but doses varied as experience was gained (see 
chapter 3). Overall, the average dose was 3.5 grams /m2 daily for 7 days rounded up to 
the nearest gram. It was given entirely as an outpatient in all cases. The day after 
hydroxyurea finished, G -CSF (Filgrastim, Amgen UK Ltd, Cambridge, UK) was 
commenced at a dose of 300µg/day subcutaneously. This was continued until the last 
day of harvesting. Prophylactic antibiotics were not given. In order to accurately define 
the first day of harvesting we combined two parameters: a rise in peripheral white cell 
count above at least 1x109/1. and the appearance in the peripheral blood of CD34 +ve 
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cells rising above our threshold of detection ( >0.05% of viable mononuclear cells). 
When these criteria were met, apheresis commenced using the mononuclear cell 
program on a Baxter CS3000+ (Baxter Healthcare Ltd., Berkshire, UK), 12 litres of 
blood being processed daily. Between 2 and 4 aphereses were required to achieve the 
target counts of >2x108/kg MNC and at least 1x106/kg (preferably 2x106/kg) CD34 +ve 
cells. Venous access was via bilateral antecubital vein cannulation or, in those with poor 
access, a double lumen femoral line. Those with an indwelling line were admitted while 
those with easy venous access were harvested on an outpatient basis. The product of 
each days apheresis was cryopreserved in 10% final concentration DMSO in a 
controlled rate freezer and then stored under liquid nitrogen. 
2.3 Assays performed on the harvest products 
Samples from the products were taken for assessment of harvest quality and detection of 
contaminating cells from the CML clone. Harvest quality was assessed by MNC counts 
(section 2.10), CFU -GM assay (section 2.16) and CD34 quantitation (section 2.10). 
Contaminating clonal cells were sought by cytogenetic analysis for the Ph chromosome, 
RT -PCR for the BCR -ABL transcript and FISH studies for the t(9;22) translocation. 
Cytogenetic and FISH analysis was performed by Helen Dickinson and Sue Ricketts in 
the cytogenetics department at St James's Hospital, Leeds, U.K. and RT -PCR by Paul 
Evans from the molecular pathology department at the General Infirmary, Leeds, UK. 
For cytogenetic analysis, samples from each leucapheresis were incubated in culture 
medium (RPMI +glutamine +FCS) for 48 hours, the last 17 hours of this in the presence 
of 0.2µg/ml colcemid. Cells were then washed, incubated with 0.075M KCL for 15mins 
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and fixed with a 3:1 methanol:acetic acid mixture. G- banding was performed on the 
cells prepared in this way and as many intact and assessable metaphases as were 
produced were examined microscopically for the presence of the Philadelphia 
chromosome. FISH Studies were carried out using the mBCR -ABL (minor breakpoint) 
translocation DNA probe (from Appligene -oncor Ltd., Watford, UK) following the 
manufacturers instructions with minor modifications. Slides were viewed with a triple 
bandpass filter which allows simultaneous viewing of the FITC (green), Rhodamine 
(red) signals and the DAPI (blue) counterstain. A combined red and green signal (often 
appearing yellow) indicates the translocation. Interphase nuclei and any metaphases seen 
were scored from each sample. A minimum of 50 cells were assessed for all the samples 
in this series. Overlapping or damaged nuclei were excluded as were any with high 
levels of background fluorescence. Marrow slides from CML patients at presentation 
were used as positive controls. Samples from normal marrows and patients with Ph -ve 
acute leukaemias were used as negative controls and produced a background false 
positive rate of 0 -4% resulting from random juxtaposition of the signals. The presence of 
a fusion transcript from the abnormal BCR -ABL gene was detected using a nested RT- 
PCR technique. A 0.5ml sample of the leucapheresis product from each days harvest 
was obtained. This contained a mean of 0.8x108 cells (range 0.45 -1.2x10$). RNA was 
then extracted from this using a commercial preparation based on the acid guanidinium 
phenol chloroform method (Trizol, Life Technologies ltd., Paisley, Scotland) to give a 
final volume of 6511. 2Oµ1 of this was reverse transcribed using random hexamers as 
primers and MoMLV reverse transcriptase giving a final volume of 40µl. These steps 
were controlled by a single round PCR for the ABL gene to demonstrate that adequate 
quality cDNA had been produced. Nested PCR was performed on 1µl of the cDNA 
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using p210 specific primers and the products were visualised on a 2% agarose gel by 
ethidium bromide staining. The B3A2 product yielded a 458 bp band and the B2A2 a 
383 bp band. Controls included 1 /100 dilutions of known positive B2A2 and B3A2 
cDNAs, two known negative cDNAs and RT and PCR blanks. The sensitivity of the test 
in our hands is of the order of 1 positive cell in 105 negatives. 
2.4 Transplant conditioning and reinfusion of PBSCs 
Transplant conditioning was either with busulphan alone (16mg/kg orally divided over 4 
days) or busulphan (same dose) and cyclophosphamide (120mg/kg intravenously divided 
over 2 days following the busulphan) depending on the centre involved. Appropriate 
hydration, MESNA, antiemetics and anticonvulsants were given concurrently according 
to regional transplant protocol. The cryopreserved PBSCs were thawed at the bedside 
directly from liquid nitrogen in a sterilised 37°C waterbath and each bag was infused 
within 15 minutes of thawing via a central line. 
2.5 Patient follow up 
All patients were commenced on a Interferon therapy as soon as peripheral blood counts 
allowed. They remained on this indefinitely if it was tolerated. Patients were regularly 
followed up and examined clinically and by laboratory methods for signs of disease and 
evidence of Ph +ve haemopoiesis. Bone marrow examination was performed at intervals 
to assess the %Ph +ve cells in the marrow. 
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Ex -vivo purging and stem cell purification in myeloma 
by CD34 selection 
2.6 Patients 
PBSCs from eight patients with multiple myeloma were CD34 selected, one of them 
undergoing two procedures. Six of these patients were autotransplanted with these 
selected cells, one of them twice (Johnson et al 1996b). Details of the patients' disease 
status, history and therapy are described in chapter 4. 
2.7 Mobilisation and collection of PBSCs 
PBSCs were mobilised with a combination of Cyclophosphamide and G -CSF 
(Filgrastim, Amgen UK Ltd., Cambridge, UK). Two schedules were used depending on 
the hospital the patients attended. Five patients (WW, BD, PC, JL, GL, in table 4.1) 
received Cyclophosphamide at a dose of 2 grams /m2 by 1 hour intravenous infusion 
followed by 300gg/day of G -CSF from day +1. The other three patients (KK, IB, PH, 
table 4.1) received 1.5 grains /m2 and 96011g/day G -CSF. Appropriate hydration, MESNA 
and antiemetics were given in all cases to minimise side effects from the 
cyclophosphamide. PBSCs were harvested at a mean of 8.5 days post cyclophosphamide 
when the absolute peripheral WBC was rising through 5x109/1. Patients were harvested 
on 3 successive days with the first 2 days products pooled for CD34 selection and the 
third days separately frozen as a backup. The cells were collected using the mononuclear 
cell program on a Baxter CS3000+ cell separator (Baxter Healthcare Ltd., Berkshire, 
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U.K.). Venous access was either via peripheral veins or (in most cases) a double lumen 
femoral catheter inserted for the purpose under local anaesthetic. Twelve litres of blood 
was processed daily. 
2.8 CD34 selection procedure 
This was performed using the Ceprate1V1 immunoaffinity system (Supplied by Cellpro 
Ltd, Wezembeek -Ottem, Belgium). The first days harvest was kept overnight at 4 °C and 
pooled with the second the following day. The cells are then washed, counted and 
incubated with a biotinylated anti CD34 antibody (from Cellpro). They are then washed 
again and passed through the CeprateTm avidin column which has been primed with 
saline and human albumin solution. This and subsequent steps are integrated and semi 
automated under computer control. The column is then flushed to remove unbound cells 
and this waste is collected and assayed (section 2.10). The CD34 +ve cells which have 
been retained in the column are released by gentle agitation using an integral magnetic 
stir bar and flushed into a collection bag in a final volume of around 100m1. 
2.9 Cryopreservation and storage of PBSCs 
The CD34 selected cells were volume reduced and frozen in a controlled rate freezer in 
10% (final concentration) DMSO and human albumin solution and stored under liquid 
nitrogen. The day 3 backup harvest was cryopreserved in the same manner but without 
any form of manipulation. 
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2.10 Assays performed on the harvest products 
These were performed on samples taken before and after processing on the column and 
from the column waste. Product quality was assessed by measurements of CD34 +ve 
cells, MNC counts, CFU -GM assays (section 2.16) and in some cases the P -delta assay 
(section 2.16). Tumour cell contamination was measured by IgH PCR. MNC counts 
were calculated from the total nucleated cell count on a Coulter automated blood cell 
counter with an adjustment by manual differential to exclude neutrophils and nucleated 
red cells. The CD34 quantitation was performed by Andy Rawstron using a modification 
of the Baxter method (provided by K. Unverzagt, Baxter Healthcare Ltd., Newbury, 
Berkshire, UK) on a Becton Dickinson FACScan (Becton Dickinson, Cowley, Oxford, 
UK). One million cells are labelled with CD34 -PE and CD45 -FITC then resuspended in 
FACSFIow with 501.1l of PI. Cells are then analysed on the FACScan using LYSIS II 
software. A live gate is set on viable leucocytes (CD45 +ve, PI -ve) and 50 -200 thousand 
events are collected. CD34 +ve events are defined by their CD34 Vs. CD45 and FSC Vs. 
SSC characteristics. CFU -GMs were assayed as described in section 2.16 and expressed 
as colonies of >50 cells at day 14 of growth x104/kg body weight. P -delta assays were 
performed on two patients according to the method described in section 2.16. 
IgH PCR was performed by Dr Roger Owen on all but one patient (PH) who did not 
amplify. DNA was prepared by proteinase K digestion, phenol -chloroform extraction 
and cold ethanol precipitation. The rearrangements were detected using CDR3 and 
CDRI fluorescent PCR techniques (Owen et al 1996). Both utilise a consensus JH 
primer which is labelled with a green fluorochrome. The CDR3 PCR utilises a second 
consensus primer from the framework 3 region of the gene. All samples were analysed 
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using this technique. If the result was polyclonal or amplification unsatisfactory the 
CDR1 PCR was used. This requires 6 reactions each using a family specific VH primer 
from the framework 1 region in addition to the fluorescently labelled JR primer. A 
schematic of the method is shown in figure 2.1. The PCR products were analysed using 
a DNA sequencer (Applied Biosystems 373A) whose computer software converts the 
fluorescent gel image for each sample into an 'electrophoretogram' which consists of a 
variable number of peaks whose height corresponds to the fluorescence intensity on the 
gel. A polyclonal pattern appears as a number of peaks arranged in a normal distribution 
while clonal rearrangements appear as distinct peaks either alone or within a polyclonal 
background (see figure 2.2). Size standards are loaded into each gel and this enables 
product sizing to within 1 base pair. By diluting clonal B cells into normal peripheral 
blood MNCs we have shown that the CDR3 PCR has a sensitivity of 10 -3 -104 and the 
CDR1 PCR a sensitivity of at least 10 -4. 
Figure 2.1 
Schematic of the IgH PCR. The heavy chain variable (VH), diversity (D) and joining 
(JH) regions are depicted, consisting of three complementarity determining regions 
(CDR 1 -3). Framework 1,2,3 and 4 (Fr 1 -4) are relatively constant areas of the 
sequence suitable for the design of PCR primers. All reactions utilise the same JH 
consensus primer (JH con), depicted by the arrow below Fr4. All samples were first 
tested using this primer and a Fr3 primer (the arrow below Fr3). If they failed to 
amplify with this, primers from the Frl region were used. This latter PCR needed 6 
primers for the 6 VH1 families. These are shown by the arrows below Frl. Around 













































Examples of electrophoretogram read -outs of the fluorescent IgH PCR on the applied 
biosystems gene scanner (see text, section 2.10). The x -axis shows the product size in 
base pairs and the y -axis is an expression of fluorescence intensity. 
A. Polyclonal fingerprint from normal B cells in the peripheral blood. There is a 
normal distribution of product sizes (peaks are 3 bp apart). 
B. A single 126 bp clonal band is demonstrated with suppression of all normal 
polyclonal B cell populations. This could be the picture in blood or marrow 
from a presentation ALL sample or myeloma with a large plasma cell burden. 
C. A 96 bp clonal band is clearly seen on a background of normal polyclonal B 
cells. This could represent molecular MRD in a remission sample in ALL or be 





2.11 Conditioning and reinfusion with CD34 selected cells 
All patients were conditioned for transplant with melphalan alone at a dose of 200mg/m2 
intravenously with appropriate hydration and monitoring. The cells were returned at 
least 24 hours following this. Patient IB had two autografts, the first with melphalan and 
the second with a combination of Busulphan 16mg/kg and Cyclophosphamide 
120mg/kg. Reinfusion of CD34 selected PBSCs was straightforward. Each vial of 
cryopreserved CD34 selected cells had a volume of around 9m1. Vials were rapidly 
thawed at 37 °C and diluted in 20m1 of sterile PBS before administration via an 
indwelling central venous catheter. 
2.12 Patient follow up and MRD monitoring 
Following discharge from the ward after engraflment, all patients were regularly 
assessed as outpatients for clinical and laboratory markers of disease. These included: 
bone pain, infection, FBC, renal function, calcium, urine or serum paraprotein 
estimations, 132M and examination of the peripheral blood and bone marrow. MRD was 
sought by the IgH PCR on serial bone marrow samples taken at approximately 3, 6 and 
12 months post transplant. 
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Cell culture methods 
2.13 Growth and maintenance of adherent cell lines 
Adherent cell lines were maintained in DMEM supplemented with 5% FCS both from 
Life Technologies Ltd., Paisley, Scotland. Media were supplemented with penicillin and 
streptomycin (pen/strep) from a 100x stock solution containing 1 gram of streptomycin 
and 1 Megaunit of Penicillin per 100m1. For routine use cells were grown to near 
confluence in vented 25cm2 tissue culture flasks covered with 5m1 of DMEM +5 %FCS 
at 37°C in a humidified incubator with 5% CO2. When approaching confluence, the 
medium was pipetted off and after washing with sterile 0.9% saline, 2m1 of Trypsin- 
EDTA (Life Technologies Ltd.) was added and the flask placed in the incubator for 5 
minutes. It was then agitated to achieve a single cell suspension and 0.1 -0.3ml 
(depending on the rate of cell growth) of the trypsin/cell suspension was added to 5m1 
fresh DMEM +5 %FCS in a new flask. The cell lines in use were split in this way every 3- 
4 days and rarely required interim feeding. There were four adherent cell lines used: 
i) NIH 3T3 murine fibroblasts. 
ii) GP +envAml2. This amphotrophic packaging cell line (Markowitz et al 
1988a) produced an MFG based retroviral construct (MFG -LacZ) which contains a 
nuclear localising beta- galactosidase gene allowing identification of successfully 
transduced cells by a colour enzyme reaction described in section 2.18. This cell line has 
no selectable marker and the viral titre (around 104 -105 cfu/ml on 111 3T3 cells) tends 
to fall with repeated passaging. Consequently it was frozen down and fresh aliquots used 
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approximately every 3 months following confirmation of viral titre (section 2.18). This 
cell line was kindly donated by Dr Paulám Patel of St James's Hospital, Leeds, UK. 
iii) VSN2 retrovirus in a fibroblast packaging cell line. This VSN2 producer 
line was selectable in Dulbecco's HAT medium (Life Technologies Ltd., Paisley, 
Scotland) on the basis of HGPRT activity. The Hypoxanthine and Thymidine in this 
selection medium supply pre -formed purines and pyrimidines for cell DNA synthesis by 
salvage pathways dependent on HGPRT. This rescues them from the toxicity of the 
Aminopterin in the medium which inhibits de novo nucleoside synthesis. The cells were 
grown to around 60% confluence in DMEM +5 %FCS. The medium was then removed 
and after washing, 5m1 HAT +5 %FCS was added and the cells returned to the incubator. 
The flask was fed with fresh HAT +5 %FCS every 4 days. After 14 days the cells were 
washed and the HAT replaced by DMEM +5 %FCS. When they were near confluent in 
this fresh medium they were split as described above. Cells were passaged twice in 
normal medium before harvesting viral supernatant (section 2.17). 
iv) PA317 amphotrophic packaging cells (murine fibroblast). Two producer 
lines based on these cells were used. Both had been created by transfection with the 
pLXSN retrovirus. LXSN consists of an LTR- driven (L) construct (X) and an SV40 
promoter -driven (S) neomycin resistance cassette (N) (Miller & Rosman, 1989). They 
thus have a marker (Neo) that can be PCRed or selected by exposure to the antibiotic 
6418 (see section 7.24). One producer line contained only the retrovirus with no 
additional DNA sequence and the other contained a novel CD59 (M1RL) molecule 
which had been modified by the addition of a transmembrane protein domain (CD59- 
TM) and was thus not reliant on GPJ linkage for cellular attachment (Rother er al 1994). 
82 
These lines were kindly donated by Dr Russell Rother of Alexion Pharmaceuticals, 
Newhaven , Connecticut, USA. 
2.14 Growth and maintenance of cells in liquid culture 
These lines were carried in RPMI 1640 medium supplemented with 10% FCS (Life 
Technologies Ltd., Paisley, Scotland). The cultures were held in 80cm2 vented tissue 
culture flasks in a 37°C, 5% CO2, humidified incubator. Cultures were fed with fresh 
medium by demi- depletion approximately every 3-4 days. The lines used were kindly 
donated by Dr Peter Hillmen. They were EBV transformed B lymphoblastoid cell lines 
derived from patients with PNH. PNH and normal B cell lines from several such patients 
were used. 
2.15 Cryopreservation of cell lines 
For storage purposes, cells were frozen and kept under liquid nitrogen. The adherent cell 
lines were frozen by taking one 25cm2 flask at around 75% confluence and trypsinising 
as described above (section 2.13). The single cell suspension achieved was washed in 
DMEM/FCS then resuspended in 2.75m1 DMEM with 50% FCS. An equal volume of 
20% DMSO diluted in DMEM was slowly added to this after both solutions had been 
cooled on ice to 4 °C giving a final concentration of 10% DMSO. Still on ice, this 5.5ml 
volume was aliquotted into 3x 1.8ml cryotubes which were transferred to a -90 °C 
freezer in a small polystyrene container and allowed to freeze before transfer to a liquid 
nitrogen store Lines in liquid culture were frozen one day after feeding. They were spun 
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down and resuspended and diluted in RPMI +50% FCS to a cell concentration of around 
5x10 /cells /ml. Equal volumes of 20% DMSO were added on ice at 4 °C as for the 
adherent lines described above and frozen in the same way. All cell lines were recovered 
from frozen in the same manner. A 1.8ml cryotube containing the cells of interest was 
removed from liquid nitrogen and thawed in a 37°C water bath. As soon as it defrosted 
it was transferred to a sterile hood and 10m1 of warm medium was slowly added over 3 
minutes. They were washed twice in the same medium and finally resuspended in 5m1 in 
a 25cm2 flask and transferred to an incubator. 
2.16 Semi -solid haemopoietic progenitor colony assays 
Assays were performed for: CFU -GM, BFU -E and the P -delta assay for more primitive 
progenitors (Gordon, 1994). The MNC plated out in these assays came from three 
sources: Density centrifugation of bone marrow obtained by needle aspiration, density 
centrifugation of peripheral blood obtained by venepuncture and apheresis samples 
obtained from a cell separator procedure. The latter was obtained using the mononuclear 
cell program on a Baxter CS3000+ apheresis machine (Baxter Healthcare Ltd, Newbury, 
Berkshire, U.K.). An aliquot of this MNC product was washed twice in MEMa medium 
(Life Technologies ltd.) supplemented with 15% FCS (MEMa +15 %FCS) and re- 
suspended in the same medium at 1x106 MNC /ml for use in the assays described below. 
Density centrifugation was performed by layering blood or marrow onto an equal 
volume of lymphopreplIvi (Nycomed Pharma, Oslo) and spinning at 1800rpm for 20- 
35mins depending on the sample volume. The turbid MNC layer produced was carefully 
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pipetted off and washed and diluted in the same manner as the apheresis product 
described above. CFU -GM and BFU -E assays were adapted to use methylcellulose 
rather than agar as a supporting matrix so that colonies could be more readily picked 
(aspirated) from the plates for analysis. All FCS used in the assays was batch tested and 
shown to support colony growth. Methylcellulose (2% solution 4000 centipoises, from 
Sigma -Aldrich company, Poole, Dorset, UK) was dissolved in MEMa to a concentration 
of 2.4% (1.8grams in 75m1) in an autoclaved conical flask containing a magnetic stir 
bar. This was agitated with the stirrer for 2-4 days in the dark at 4 °C. When a clear 
solution was achieved it was aliquotted and stored in light tight vessels at -20 °C. This 
can be thawed and re -frozen repeatedly. Growth factor supplementation for the CFU- 
GM assays was provided by 5637 (bladder carcinoma cell line) conditioned medium 
kindly donated by Debbie Clark, St James's Hospital, Leeds, UK. In the BFU -E assay, 
erythropoietin (EPO) came from Terry Fox labs, Vancouver, Canada and 35% bovine 
Serum albumin (BSA) from Sigma -Aldrich company, Poole, UK. 
CFU-GM: 
MEMa medium 0.75m1 
FCS 1.0m1 
5637 0.5ml 
MNC (106 /ml) 0.5ml 
methylcellulose 2.25m1 (0.9% final conc.) 
=5m1 in total 
8J 
BFU-E: 
MEMa medium 0.5ml 
FCS 1.5ml 
BSA (35 %) l30111 
EPO 10 units 
2- Mercaptoethanol 10µl (50mM) 
MNC (106/m1) 0.5ml 
Methylcellulose 2.25m1 (0.9% final conc.) 
=5m1 total 
In a sterile cabinet, the above reagents are added to a universal container and slowly 
mixed together using a syringe and 16 gauge needle. When the methylcellulose mixture 
is of an even consistency it is aliquotted out in 1mí amounts (105 MNC /dish) into four 
35mm covered petri dishes. These are gently rotated to spread the mixture evenly on the 
bottom and then placed in a humidified container within a 37 °C, 5 %CO2 incubator. 
Colony growth is scored at day 10 -14 by direct vision under an inverting microscope 
counting >50 cell aggregates as colonies for CFU -GMs and identifying clusters of 
erythroid bursts for the BFU -E assay. The result is expressed as the average number of 
colonies or bursts per 105 MNC plated (i. e. per dish). 
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P -Delta assay: (method courtesy of Debbie Clarke, St James's Hospital, Leeds, UK) 
Preparation of MP +a medium: 
MEMa medium is supplemented with 10% CFU -GM tested FCS, 10% Horse serum, 
methylprednisolone (MP, final nnr 7v1(1{41 anil ')mAQ T ic 
diluted from a 40mg vial (Pharmacia and Upjohn Ltd., Milton Keynes, UK) in lml 
water Add (1 25m1 of this to 1" 75ml medium and stare in 0.5ml aliquots at -2n °C Thic 
is finally diluted 1:1000 into the medium. 
This assay is thought to assess the presence of progenitor cells more primitive than CFU- 
GM or 11-FT T -E (Gordon et al 1996). 1(17 T\/IATC prepaared as described above are incubated . ( ordon J i. __ 1ß:.t. -. _.. -- 
for') hours in 10m1 1VPMw +15%Frs in a 25cm2 tissue culture flask at 17°c/5%rn2 to 
allow adherence of primitive cells to the plastic. The medium is then removed and the 
flask is washed three times with MEMa before replacing it with 9ml MP +a and lml 
5637 and placing back in the incubator for 7 days. The medium is then drawn off, spun 
for 4mins @1500rpm, washed and resuspend in MEMa +15 %FCS and this is plated in a 
standard CFI J-GM assay as described above: The result is expressed as the total number 
of CFT I -GM colonies derived from the original 107 cells adhered, 
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Using retroviral producer cell lines 
2.17 Production and collection of retroviral supernatant 
Adherent Producer cell lines were grown to near confluence in 80cm2 tissue culture 
flasks under the conditions described above. They were then washed and 16m1 of 
DMEM +5 %FCS was added to each flask. This was left for 24 hours after which time 
the medium was aspirated and passed through a 0.451,im filter to remove any cell debris. 
The filtered supernatant from all flasks was pooled and aliquots taken to assess the 
number of viral particles per ml. The supernatant was divided into volumes suitable for 
single use and stored at -90 °C. 
2.18 Assaying titre of retroviral supernatant. 
Supernatants containing retroviruses with the selectable neomycin resistance cassette 
(from VSN2 and LXSN -based lines) were used to transduce NIH 3T3 cells which were 
then subjected to Geneticin sulphate (G418, Life Technologies, Paisley, Scotland, UK) 
selection at a concentration of 40011.g/ml. Transduction was performed by plating 3T3s 
in 25cm2 tissue culture flasks containing a presumed number of viral particles based on a 
titre of 10' CFUs /ml suggested by the supplier. Three dilutions of virus were used giving 
an expected 10, 100 and 1000 CFUs /flask at that titre. The medium was supplemented 
with 61.1g/ml of polybrene to improve viral attachment. After 8 hours incubation, the 
viral supernatant was removed and G418 was added and replaced every 3 days. 
Surviving G418 resistant colonies were scored under an inverting microscope at 10 
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days. An alternative and more rapid way to assess the quality of batches of supernatant 
from the CD59 -TM producing virus and to cross check for contaminating producer cells 
is by flow cytometry. CD59 is not normally present on murine 3T3 cells which allows 
distinction of transduced from non -transduced cells by staining with this MAB. Cells 
were transduced as already described and then trypsinised, washed and resuspended in 
FACSFlow (Becton Dickinson, Cowley, Oxford,UK). They were transferred to a 96 
well microtitre plate and stained with 5µl of appropriately titred CD59 -PE conjugated 
MAB. After 15 minutes room temperature incubation, the cells were washed and 
analysed in a Becton Dickinson FACScann. The proportion of transduced cells can be 
rapidly displayed as the CD59 positive peak on histogram analysis using the machine's 
lysis II software. Non -transduced 3T3 cells and 3T3s transduced with the LXSN virus 
alone were assayed in parallel as controls (see chapter 5 and figure 5.2). 
MFG virus supernatant containing a beta -galactosidase gene was assayed using the 
same transduction method on 3T3s followed by staining of the transduced cells using X- 
GAL. Successfully transduced cells expressing the enzyme stain blue following exposure 
to X -GAL and can be read and counted in the same way as G418 resistant colonies 
under an inverting microscope (see figure 5.1). 
X -GAL is prepared as a stock solution of 40mg/m1 in dimethylformamide which can be 
frozen at -20 °C. 2.5ml of this is added to 100m1 of buffer giving a 1mg/m1 working 
solution which should be filtered (0.21..um pore) to remove crystal deposit prior to use. 
The solution is light sensitive and should be kept in the dark. The buffer is made up as 
follows: 
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Phosphate buffered saline 100m1 
Sodium deoxycholate 10mg 
NP40(detergent) 200µ1 (0.02 %) 
Magnesium Chloride 0.0406g 
Potassium Ferricyanide 0.1646g (0.05M) 
Potassium Ferrocyanide 01112g (0.05M) 
(All reagents from Sigma -Aldrich company, Poole, UK), Cells to be stained are fixed 
with 0.05% Glutaraldehyde for 20 mins then washed. X -GAL is then added for 2 -6 
hours. The cells are finally washed again and read under the microscope. 
Retroviral Gene Transfer 
219 Retroviral gene transfer into NIB 3T3 cells. 
This was done using supernatants containing VSN 2, MFG -LacZ, LXSN and CD59 -TM 
retroviruses. This allowed confirmation that the producer cell lines described in section 
2.13 were functioning and also allowed quantitation of viral titre as described in section 
2.18. integration and expression of the constructs in 3T3 cells were assessed in a 
number of ways: flow cytometry (CD59 -TM expression, section 2.25), PCR and G418 
selection for those with a neomycin resistance cassette (sections 2.21 and 2.18) and in 
situ staining with X -GAL for beta -galactosidase (section 2.18). The method of gene 
transfer has been briefly described in section 2.18 in relation to the techniques for 
assessing viral titre. 3T3 cells are plated at low density in 25cm2 tissue culture flasks 
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with 5m1 DMEM +5 %FCS and allowed to establish themselves overnight in an 
incubator. The medium is then removed and replaced with the viral supernatant of 
interest with polybrene at a concentration of 6.tg/ml. Fresh supernatant can be added 
repeatedly if desired to improve the MOI if required. Each time supernatant is added it 
is left on for 6 -8 hours. After this, the cells are washed and allowed to grow overnight. 
They can then be processed in a manner appropriate to the assays described above. Cells 
for FACS (section 2.18) or PCR (section 2.21) are trypsinised off and washed prior to 
assay while those for X -GAL staining or G418 selection (section 2.18) are washed and 
left in situ. 
2.20 Retroviral gene transfer into human PBSCs 
This was attempted with the supernatants containing VSN 2, MFG -LacZ, LXSN and 
CD59 -TM retroviruses. A number of improvements and alterations were made over time 
to optimise the transduction efficiency and these are described in the relevant results 
sections. The optimum method achieved was as follows: PBSCs were obtained either by 
venesection or by apheresis on a Baxter CS3000+ machine (Baxter Healthcare Ltd, 
Newbury, Berkshire, UK). PBSCs were separated from venesected whole blood by 
density centrifugation as described in section 2.16, while the apheresis samples required 
no further processing. Venesected cells came from patients with haematological 
malignancies, patients with PNI-I or normal volunteers while all apheresis samples were 
from haematology patients preparing for PBSCT. These latter patients had received 
chemotherapy and G -CSF (Filgrastim, Amgen UK) to mobilise stem cells into the 
peripheral blood. Cells were washed twice in saline before resuspension in 
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DMEM +5 %FCS. 6x106 MNC were placed in a 25cm2 flask with 8m1 of 
DMEM +5 %FCS supplemented with growth factors (SCF donated by Amgen UK Ltd., 
1L3 donated by Sandoz Pharmaceuticals, Camberley, Surrey, UK and 1L6 donated by 
Roz Banks, St James's Hospital, Leeds, UK, all at a concentration of 50ng/ml). 
The flask was incubated for 48hrs and then the cells and medium were transferred into 2 
universal containers and centrifuged. The medium was tipped off and the cells 
resuspended in 8m1 viral supernatant with 2m1 fresh DMEM +5 %FCS, the same growth 
factors as above and 61.1g/m1 of polybrene. This 10m1 volume was placed in a flask and 
after 6hrs incubation it was again centrifuged and the process repeated with fresh viral 
supernatant and supplements as above. The supernatants used had viral titres of around 
1 -5x105 cfu/ml which, with the 2 exposures described may achieve an MOI of 
approximately one. Pre -incubation with a cocktail of growth factors is intended to 
encourage cell division and therefore rates of transduction as retroviruses will only infect 
dividing cells. Following exposure to the virus, the cells are washed and set up in semi- 
solid colony assays as described in section 2.16. 
Assessing transduction efficiency 
2.21 PCR for the neomycin phosphotransferase gene. 
Single round PCR was shown to be insufficiently sensitive for most applications 
therefore a nested technique was used. The 2 sets of primers were synthesised in -house 




5' TCC ATC ATG GCT GAT GCA ATG CGG C 3' 




5' AAG CGA AAC ATC GCA TCG AG 3' 
5' ATA TTC GGC AAG CAG GCA TC 3' 
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Primers were stored at a concentration of 50pmol/µ1 in ammonia which was dried off in 
a vacuum centrifuge for 20- 30mins when required. lml of a master PCR mix sufficient 
for 40x 25µ1 tests for each round was made as follows and frozen at -20 °C: 
20111 of both primers (25pmol/test) 
5µl of dNTP's (200x) 
100111 of 10x Tac buffer 
10111 of 100mM MgCI 
Distilled H2O up to lml 
24111 of this mix was added to the target in each test microcentrifuge tube. Tac 
polymerase (Supertac, 5units /µl, from HT Biotech, Cambridge, UK) was added to the 
mix before it was aliquotted to the test tubes to give 1 unit of Tac per test. Finally, all 
tubes were covered with 2 drops of mineral oil. Positive (11.11 diluted VSN2 DNA) and 
negative controls and PCR blanks were set up at the same time. All tubes were 
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transferred to a pre -heated (95 °C) block on a programmable thermal controller (PTC- 
100 , Genetic Research Instrumentation Ltd., Dunmow, Essex, UK). The program 
used was: 30 cycles, Temperatures 55- 72 -95 °C with one minute at each stage and a 15 
minute final extension with a magnesium concentration of 1 mM. This produces a 420 
bp fragment from the positive control. For the second round, 11A of each first round 
product was transferred to a fresh tube and the process was repeated using exactly the 
same conditions with the internal primer mix. This yields a final 190 base pair fragment. 
The results are visualised and photographed under ultraviolet light after running on a 2% 
agarose gel. This gel is made by dissolving 2.4g agarose in 120m1 TAE buffer in a 
conical flask heated to boiling in a microwave. Ethidium bromide (15111 of 10mg/m1) is 
added when hand hot and the liquid poured into a carrier with well markers and allowed 
to set. 141 of the PCR products are placed into the wells after mixing with loading 
buffer and the gel is run along with standard 100bp ladders at 130 volts for 1 hour. 
2.22 Harvesting colonies from semi -solid medium. 
CFU -GMs or BFU -Es were carefully aspirated from the methylcellulose under direct 
vision using an inverting microscope. This is a fiddly and highly operator -dependent 
technique. The age and quality of the colony plates had a significant impact on the 
success of the procedure and it was best to pick colonies early at around 12 days. Older 
plates tend to dry and were difficult to aspirate. A fine plastic micro -pipette tip was fixed 
to a standard yellow tip on a 10111 pipette. This was carefully positioned under the 
microscope into the centre of a colony and the pipette released, drawing some or all of 
the cells into the tip. The micropipette tip was then detached and fixed to a standard 
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yellow tip on a 200µl pipette pre -loaded with PBS +1 %BSA and flushed out into a 
microcentrifuge tube. The cells were either processed for FACS analysis (section 2.27), 
or PCR (section 2.21). 
2.23 Assessing retroviral transduction of colonies using X -GAL 
X -GAL has been described in section 2.18. Colonies grown from cells transduced using 
MFG -LacZ supernatant were visualised after 12 days growth by the direct addition to the 
petri dishes of lml of X -GAL which was allowed to diffuse into the methylcellulose for 
6 hours before observing the colour change under the inverting microscope. 
2.24 Assessing retroviral transduction of colonies using G418 
Colonies grown from cells transduced with the retroviruses containing the neomycin 
resistance gene (VSN2, LXSN, CD59 -TM ) could be selected using G418 (section 2.18). 
Following transduction with retroviral supernatant the cells are split. One aliquot is kept 
in G418 containing medium (4001.tg/ml) for 24 hours then plated out for CFU -GMs or 
BFU -Es using methylcellulose (section 2.16) to which G418 has been added at the same 
concentration. The other aliquot is the control with no G418. The difference in growth 
between the two gives an approximate estimate of the proportion of cells successfully 
transduced. Parallel plates of non -transduced cells are set up with and without G418 to 
ensure the assay works and that G418 at these concentrations fully inhibits growth of 
normal cells. 
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2.25 Assessing retroviral transduction by Flow Cytometry 
The Flow Cytometric methods used are described in detail in the next sections (2.26- 
2.31). Two of these techniques were used for assessing transduction efficiency: Firstly, 
CD59 expression on 3T3 cells was used as a marker of successful transduction by the 
CD59 -TM vector as described in sections 2.18 and 2.19 (figure 5.2). Secondly, as CD59 - 
TM (unlike native CD59) is not cleaved by the enzyme PI -PLC, normal human cells 
were transduced with CD59 -TM supernatant and then treated with PI -PLC (section 2.31) 
before FACS analysis. Native CD59 (which is GPI linked) is entirely removed by this 
enzyme and the remaining fluorescence is due to the CD59 -TM and is a measure of the 
number of cells transduced. 
Flow Cytometry 
2.26 Basic Flow Cytometry methods. 
Stem cell quantitation was performed on a FACSor . All other assays were done on a 
FACScan (both manufactured by Becton Dickinson Ltd, Cowley, Oxford, UK). Two 
colour compensation settings were adjusted using the manufacturers CALIBritelm flow 
cytometer beads and the software appropriate to each machine (AUTOComp on the 
FACScan and FACSComp on the FACSort). Three colour work required additional 
settings which were done manually according to the manufacturers recommendations. 
Results were analysed using LYSYS II software on the FACScan and CELLQuest on 
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the FACSortTM. The MABs used were either commercially supplied or manufactured 
in- house. Table 2.1 shows a list of MABs, the clone from which they were derived and 
the source. All MABs used were pre -conjugated with FITC or PE. Cells for analysis 
were prepared by several methods depending on the source and the nature of the assay. 
Separation of MNCs from peripheral blood or bone marrow by density centrifugation 
has already been described in section 2.16. Whole blood lysis was performed by adding 
20m1 of 0.8% ammonium chloride (NI-14C1) to 2.4ml of peripheral blood in a universal 
container and incubating for 5 mins at 37°C with intermittent mixing. This was then 
spun down at 2000rpm for 5mins and the pellet resuspended in 25ml of FACSFlowTM 
and re -spun. Cells were washed twice in this way before being fmally resuspended in the 
same solution and counted on an automated blood analyser (Sysmex K 1000, from 
Sysmex Ltd., Milton -Keynes, UK). Adherent cell lines were trypsinised off tissue culture 
plastic (section 2.13), washed twice and resuspended and counted in the same way. 
Liquid cell cultures and apheresis samples were simply aspirated, spun down, washed 
and counted as above. When dealing with small numbers of cells, 1% BSA was added to 
the FACSF1owTM to minimise losses. Routine antibody staining was performed in round 
bottomed 96 well microtitre plates. The MABs used were titred such that 10 u of MAB 
would adequately stain up to a million cells. For staining, up to 106 cells were placed in a 
microtitre well and 10111 of each MAB was added. Plates were then agitated on a 
plateshaker to ensure adequate mixing and incubated at room temperature for 20 
minutes. Cells were then washed twice manually in FACSF1owTM and resuspended and 
transferred to Kahn tubes ready for analysis. Cells were not fixed but if not processed 






























































































































































































































































































































































































































2.27 FACS analysis of semi -solid colonies. 
This was done for whole plates (35mm petri dishes) of CFU- GM/BFU -E or for 
individual picked colonies. Whole plates (volume = lml of methylcellulose+reagents) 
were dissolved in 20m1 of FACSF1owTM +1 %BSA at around 12 days of growth. This 
solution was gently mixed for 30 mins. to allow the methylcellulose to fully dissolve and 
then centrifuged at 2000rpm for 5 mins. before tipping off the supernatant, resuspending 
the cell pellet and washing twice more in the same solution. Cells were then transferred 
to microtitre wells for staining as described in section 2.26. It was possible to harvest 
cells from individual colonies and analyse these by FACS after MAB staining. Colonies 
are grown and picked as described in sections 2.16 and 2.22. Once an individual colony 
has been transferred to a microcentrifuge tube, it is gently vortexed and then allowed to 
stand for 10 minutes to allow the methylcellulose to fully dissolve. The tube is then 
centrifuged for 2mins @2000rpm in a microcentrifuge. From this point on the tubes 
must be very gently handled to avoid loss of cells as there may only be a few hundred to 
a thousand present in each. The supernatant is carefully aspirated using an orange needle 
attached to a suction pump. A little liquid is left to avoid disturbing the cells. The cells 
are resuspended and 51.11 of each MAB of interest is added. This is mixed by pipetting 
and incubated at room temperature for 30 mins. The cells are then washed twice with 
200µl of FACSFIowTM +1 %BSA using the same careful technique for centrifuging and 
aspirating. After the second wash, 200111 FACSFIowTM is added and the cells mixed by 
pipetting and transferred to a Kahn tube. The microcentrifuge tube is washed out with a 
further 200µl FACSFIowTM and this is also transferred to the Kahn which can then be 
analysed on the FACScanTM. 
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2.28 Stem cell phenotyping. 
CD34 positivity was taken to define stem cells at all stages of development. CD34 
quantitation to assess the quality of PBSC harvests in relation to the stem cell 
mobilisation and selection procedures described in chapters 3 and 4 has already been 
discussed in section 2.10. Further CD34 subset analysis was undertaken in some cases, 
particularly in relation to the work on PNH stem cells described in chapter 7. This more 
extensive phenotyping work was performed by Andy Rawstron at the Leeds General 
Infirmary, Leeds, UK. 
Leucocytes were prepared either by whole blood lysis (section 2.26) or by density 
gradient centrifugation (section 2.16). For antibody staining, 2 -3 million cells were 
incubated in microtitre plates for 20 minutes at room temperature with 101.11 of each 
pre -titred antibody conjugate per million cells, then washed twice in FACSFlowTm. 
Cells were analysed on a Becton Dickinson FACSortim with CELLQuest software. 
The antibodies used were (see table 2.1): CD34 -PE, CD45 -FITC, CD38 -Cy5, IgG1 
control -PE /Cy5, IgG2a control- PE /Cy5, and CD59 -FITC. CD59 -FITC was supplied 
by Cymbus Biosciences U.K. Ltd. All other conjugates were prepared in -house by Dr 
Richard Jones. 
For CD34 quantitation, cells were incubated with CD34 -PE and CD45 -FITC, 
washed, and resuspended in 150µl FACSFlow with PI. A 50,000 event file was 
collected. Regions were set around the viable leucocytes (CD45 +ve,PI -ve) and 
progenitor cells (CD34 +ve,SSC1 °), the latter being a wide gate including some 
contaminating events. A further 200 - 500,000 events which satisfied both these 
regions were then acquired. A `tight' CD34 region was then set around the 
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progenitor cells using their CD34 Vs CD45 characteristics. FSC, SSC and PI of 
these gated cells were assessed to ensure that no apoptotic cells or debris had been 
included. CD34 +ve cells were calculated as a percentage of viable leucocytes. An 
equivalent number of leucocytes stained with IgG1 /2a control -PE, CD45 -FITC and 
PI were acquired, and the percentage of control events were deducted to give a final 
CD34 +ve percentage. The absolute numbers of circulating progenitors was then 
calculated from the total nucleated cell count. The main steps in this process are 
shown in Figure 2.3. 
For CD34 subset analysis, 50,000 events were acquired and a wide region was set 
around the progenitor cells (CD34 +ve,SSC1o). A 200 - 500,000 event file was then 
collected using this gate. In order to allow simultaneous analysis of CD38 and CD59 
expression by progenitor cells, only CD34 and light scatter characteristics were 
available for definition of progenitor cells. To analyse sufficient CD34 +ve cells, 
large numbers of leucocytes had to be acquired, resulting in increased contamination 
of the CD34 +ve region. To overcome this problem, regions were used from the 
CD34 quantitation assay to improve definition. In each case, the CD34 vs SSC and 
FSC vs SSC regions were assessed to determine whether they alone could identify 
progenitor cells with >95% accuracy, as defined by their combined CD34, CD45, PI, 
and light scatter characteristics. These regions were then applied to allow analysis of 
CD38 vs CD59, and controls. 
Figure 2.3 
FACS dot plots showing the main steps in CD34 quantitation as described in the text, 
section 2.28. The bottom left plot shows a 50,000 event file of CD45 vs PI. The R1 
gate excludes non -viable (PI +ve) cells. The top left plot shows gate R2 which 
contains events from Rl which are CD34 +ve and CD451ow. In the right hand plot, the 
forward and side scatter characteristics of the Rl and R2 gated cells are applied 











































































2.29 Phenotyping in PNH. 
Cell preparation and FACS methods are described in sections 2.16 and 2.26. The MABs 
used are shown in table 2.1. Examples of these analyses are described and shown in 
chapters 6 and 7. 
Neutrophils from PNH patients and normal controls were prepared for analysis by whole 
blood lysis (section 2.26). They were stained with pre -conjugated MABs reactive with 
GPI linked antigens present on normal neutrophils but absent on PNH cells (CD16, 
CD59 and/or CD55) and also a non -GPI linked MAB (CD15) present on all neutrophils 
as a control (section 2.26). The staining intensity for each MAB was analysed by FACS 
after gating on the neutrophil population by virtue of its FSC and SSC characteristics. 
Lymphocytes for analysis were separated from peripheral blood of normal controls and 
patients with PNH by density centrifugation as described in section 2.16, with final 
washing and suspension of the MNC layer in FACSFlowTM. Cells were stained with 
MABs against the GPI -linked antigens CD55 and CD59 along with antibodies against 
non -GPI linked B and T lymphocyte antigens (CD19 and CD3 respectively). 
Lymphocytes were identified by characteristic FSC and SSC profiles. 
PNH cell lines were also analysed. These EBV transformed B lymphoblastoid cell lines 
derived from PNH patients are described in section 2.14. Aliquots of cells from liquid 
culture were taken, washed, counted and suspended in FACSFlow. They were stained 
with the pan -B lymphocyte marker, CD19 (non -GPI linked) for identification and with 
CD55 and CD59 in the same way as described above for peripheral blood lymphocytes. 
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2.30 Assaying complement mediated cell lysis by FACS. 
The relative sensitivity of different cell populations to complement mediated lysis was 
assessed by FACS using the property of retention or loss of different fluorescent dyes 
after exposure to a sensitising antibody and fresh human serum (as a source of 
complement). This allowed concurrent MAB staining to identify cell subtypes. Assays 
were performed using two different fluorescent dyes, Calcein -AM ester (Molecular 
Probes Inc., Oregon, USA) and Propidium Iodide (PI). The PI was eventually preferred 
as it was possible to adjust the FACScanTm compensation settings so that this fluoresced 
in channel FL2 or FL3 allowing potential use of 2 other fluorochromes for cell 
identification. The Calcein -AM fluoresces in channel FL1 only prohibiting the use of 
FITC -conjugated MABs. 
The assay was initially developed to lyse peripheral blood lymphocytes and the EBV 
transformed B -cell lines described in section 2.14. For the Calcein -AM based assay, 
cells were prepared, washed and placed in microtitre wells at 1x106 cells /well (see 
sections 2.16 and 2.26). They were loaded with calcein and sensitised by incubating for 
15 minutes at room temperature with Sµ1 of appropriately titred Calcein -AM and 2411 of 
Anti HLA W6/32 (clone = W6 /32HL, source = ECACC, Porton Down, Wiltshire, UK). 
After washing, the cells were incubated with complement for 30 minutes at 37 °C. The 
source of complement was human serum which was collected and immediately frozen in 
aliquots at -90 °C. 50µ1 aliquots of an appropriate dilution of this serum was added to 
each test well. The optimum dilution of serum for the assay was defined as that at which 
there was the greatest disparity in lysis between normal and PNH cells both in peripheral 
blood lymphocytes and in the B -cell lines. This was determined by using serial dilutions 
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of serum (in FACSFIow) and proved to be 35% (see chapter 6). Controls using serum 
heat inactivated at 56 °C for 45 minutes (to remove complement), FACSFlowTm alone 
and without any sensitising HLA antibody were set up in parallel to confirm that no non- 
specific lysis occurred during the assay and that all test cells took up and retained 
Calcein -AM in the absence of complement. After further washing, the cells were finally 
stained with appropriate MABs (e.g. CD59 to distinguish normal from PNH cells) and 
analysed by FACS. It was important to add CD59 or CD55 after the lysis stage as these 
antibodies proved to be partly blocking and inhibited the inactivation of complement by 
these molecules on normal cells. Lymphocytes were identified by their FSC and SSC +/- 
additional MAB staining. Non -lysed cells retain the same intensity of fluorescence for 
Calcein -AM and the same FSC and SSC. Cells whose membranes have been 
compromised by complement have a lower staining intensity and reduced FSC and SSC 
allowing easy identification. Examples of this analysis are shown in chapter 6. 
The assay was subsequently modified to use PI allowing 3 colour analysis. This allowed 
simultaneous staining of a lineage specific antigen (e.g. CD19 on B -cell lines) and a GPI 
linked antigen (e.g.CD59) along with PI to assess the degree of lysis. The method was 
identical to that described above except Calcein is not used and the PI is added to the 
Kahn tubes after MAB staining and washing, 5mins. before analysis on the FACScan. 
In contrast to Calcein, PI is taken up by cells with damaged membranes therefore the 
lysed cells are identified by PI positivity and reduced FSC and SSC. 
Both the Calcein-AM and PI based assays were applicable to cells derived from semi- 
solid colony assays after recovery of these cells from methylcellulose culture as 
described in sections 2.16, 2.22 and 2.26. The assay conditions used were identical to 
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those described above for lymphocytes. MABs to glycophorin -A and CD13 +33 were 
used to discriminate BFU -Es and CFU -GMs respectively. 
2.31 Using PI -PLC. 
Recombinant PI -PLC from bacillus Thuringiensis (Oxford Glycosystems, Abingdon, 
UK) was used. This is an enzyme which cleaves the GPI anchor, effectively producing 
PNH cells by a chemical means. It was used to cleave GPI linked structures from intact 
cells. The CD59 -TM construct can be differentiated from native CD59 by virtue of its 
resistance to PI -PLC cleavage. For use, PI -PLC was diluted in FACSFlowTivi at a 
concentration of 1 unit/ml. Cells were treated with the enzyme in microtitre wells (up to 
1x106 per well). 100µl of PI -PLC (1 unit/ml) was added to each well and incubated at 
37 °C for 60 minutes along with appropriate controls. This procedure could be combined 
with antibody staining and/or a complement lysis assay in the same wells. 
Mobilisation of PNH patients with G -CSF 
2.32 PNH patients 
Four patients were investigated. All were under regular review with an established 
diagnosis of PNH. Informed consent for the procedure was obtained. The clinical details 
and baseline haematological parameters for these patients are described in detail in 
chapter 7. 
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2.33 Baseline investigations prior to G-CSF mobilisation. 
Before administration of G -CSF, written informed consent was obtained from all 
patients. Blood was taken for the following assessments: 
Haematology: FBC, differential WBC, blood film, reticulocyte count. 
NAP score: This was performed by Sheila O'Connor in our laboratory. NAP stock 
substrate was prepared by dissolving 30mg of napthol AS phosphate in 0.5m1 
dimethyl formamide and adding 100m1 0.2M tris buffer at pH 9.1. The NAP stain 
was prepared by adding 2mg fast blue BB to 10m1 of this stock substrate. Blood 
films from patients and controls were fixed in buffered cold formol acetate for 30 
seconds then rinsed. The slides are overlain with the NAP stain for 20 minutes, 
rinsed and counterstained with aqueous neutral red for 1 minute. NAP positivity is 
indicated by the presence of blue/black granulation in the neutrophil cytoplasm 
which is conventionally scored from 0 -4. The NAP score for a sample is the sum of 
the scores of 100 neutrophils assessed by light microscopy. The normal range in our 
laboratory is 40 -100. 
Biochemistry: A standard biochemical profile including urea, electrolytes, creatinine, 
liver function tests, calcium, protein and albumin estimations. 
FACS phenotyping: The patients neutrophils, red cells and lymphocytes were typed 
with appropriate MABs (table 2.1) to GPI linked antigens to assess the size of the PNH 
clone in each cell line according to the methods described in sections 2.26 and 2.29. The 
absolute numbers and proportions of stem cells in the peripheral blood of these patients 
was measured using the CD34 antigen and stein cell subsets were investigated as 
described in section 2.28. 
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Progenitor colony assays: CFU -GM, BFU -E and P -delta assays were set up from all 
patients peripheral blood as described in section 2.16. 
Complement sensitivity: A PI -based lysis assay was performed by FACS on all 
patients' separated peripheral blood lymphocytes as described in section 2.30. 
2.34 G-CSF mobilisation Regimen in PNFI. 
After the above baseline investigations had been performed, patients were given G -CSF 
(Filgrastim, Amgen U.K. Ltd.) in an attempt to mobilise PBSCs. G -CSF was given at a 
dose of 10p.g/Kg/day by subcutaneous injection for 4 consecutive days. This was 
administered as an outpatient with daily monitoring. Patients were assessed clinically by 
a haematology specialist nurse and a member of haematology medical staff each day. 
Phenotypic analysis of neutrophils and CD34 quantitations were carried out daily by 
FACS. CD34 subset analysis was performed on steady state blood and on day 5 (one day 
post G -CSF) as described in sections 2.28, 2.29 and 2.33. 
2,35 Collection and processing of mobilised peripheral blood. 
The day after G -CSF treatment was completed (day 5), 350m1 of peripheral blood was 
removed via an ante -cubital vein using a sterile venesection pack containing Acid citrate 
dextrose anticoagulant (Baxter healthcare Ltd., Berkshire, UK). Subsequent work was 
carried out in a sterile safety cabinet to avoid contamination of the cells prior to culture. 
The MNCs were separated from the blood by density centrifugation (section 2.16) in 
50m1 FalconTM centrifuge tubes with a spin of 35 minutes at 1800rpm. The MNCs were 
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pooled, washed and assayed. Excess MNCs were frozen in aliquots in l0 %DMSO at - 
90 °C and transferred to liquid nitrogen (see section 2.15). The same assays that were 
performed at baseline (section 2.33) were done on day 5. In addition, separated MNCs, 
hopefully enriched for CD34 +ve cells, were exposed to CD59 -TM retroviral supernatant 
as described in section 2.22 in order to assess the possibility of transduction of PNH 
stem cells with this construct. 
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Chapter 3. 
In -Vivo PBSC Purging in CML by a Disease -Specific 
Mobilisation Regimen 
3.1 Introduction 
3.2 Patient details 
3.3 Mobilisation of PBSCs in CML with Hydroxyurea 
3.4 Harvest quality 
3.5 Contaminating clonal cells in the harvest products 
3.6 Engraftment following reinfusion of PBSCs mobilised with Hydroxyurea 
3.7 Patient follow up 
3.8 Discussion 
3.1 Introduction 
CML is a clonal myeloproliferative disease which clinically progresses from 
an initial chronic phase through an accelerating phase and finally terminates in an 
inevitable blast transformation which results in the patients' death. The disease is 
characterised by the presence of a definitive molecular event resulting in the 
formation of a fusion gene (BCR -ABL) which codes for an abnormal tyrosine kinase 
which has an ill -defined transforming activity on myelopoiesis (Gordon & Goldman, 
1996). This abnormality is generally detected cytogenetically by the presence of the 
Philadelphia (Ph) chromosome but can also be assayed by FISH showing the t(9;22) 
translocation or by PCR for the BCR -ABL fusion inRNA (Cross et al 1993). At 
diagnosis, most patients have entirely Ph +ve metaphases in their marrow and blood. 
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Conventional drug therapy has been largely unable to alter this even in those whose 
disease is well controlled. This led to the view that haemopoiesis was entirely replaced 
by stem cells bearing the Ph abnormality in CML. This view has now been revised and it 
is appreciated that there is residual normal haemopoiesis in patients' marrows and that, 
as discussed below, certain laboratory and clinical manoeuvres can exploit this 
therapeutically (Gordon & Goldman, 1996; Goldman & O'Brien, 1993). 
Treatments considered to confer a survival advantage in CML are all associated with 
reduction, suppression or apparent elimination of Ph +ve cells (Giralt et al 1995). To 
date, the only widely accepted approaches which can achieve this are allogeneic marrow 
transplantation and IFN therapy (Allan et al 1995; Goldman et al 1988). Despite these 
promising approaches, much remains to be done in management as allografting is 
available to only a small minority of patients and IFN is not a cure. This has contributed 
to increasing interest in autologous marrow and stem cell transplantation in CML 
over recent years (Goldman, 1994). The use of ABMT in this disease grew from 
observations that some patients were rendered wholly or partially Ph -ve following 
accidental busulphan induced hypoplasia. Subsequently, similar findings were 
demonstrated after deliberate administration of AML -type chemotherapy regimens 
(Sharp et al 1979). This led to the use of ABMT initially for patients in blast crisis but 
increasingly in chronic phase ( OBrien & Goldman, 1994). Although there has been no 
large prospective randomised trial comparing survival between autografted and 
conventionally treated patients, over 200 transplants have now been reported in the 
literature (O'Brien & Goldman, 1994; McGlave et al 1994a). It seems clear that those 
transplanted in chrome phase do better than those in accelerated phase who in turn do 
better than those in blast crisis. Interestingly, at least half of those in chrome phase 
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achieve partial or complete cytogenetic responses. These cases generally relapse over 
time but may occasionally be durable. A recent analysis of the results shows a plateau in 
the survival curve following ABMT which has never been present in conventionally 
treated patients (McGlave et al 1994a). Retrospective comparisons must be viewed with 
caution but the suggestion is of a survival advantage for autografting with either marrow 
or peripheral blood stem cell support. 
If Ph negativity is a treatment goal and it is accepted as a possibility that clonal cells in 
harvest products can contribute to relapse in some malignancies (Brenner, 1996) then 
there may be a rationale for purging strategies in CML. Attention is now being directed 
to the manipulation and purging of such stem cell products in an attempt to reduce the 
number of Ph +ve cells reinfused (O'Brien & Goldman, 1995). If harvested CML 
marrow is placed in long term culture the Ph +ve cells tend to decline and an increase in 
the proportion of Ph -ve cells may be seen. Such cultures have been used as the source of 
stem cell support for CML autografts and despite some problems with engraftment a 
significant number of cases have been successfully transplanted with a reduction in Ph 
positivity, sometimes to zero (Barnett et al 1993). Other attempts to purge Ph +ve cells 
ex -vivo have included the use of in vitro IFN or chemotherapeutic agents and incubation 
with antisense oligonucleotides. There have been a number of small studies addressing 
the feasibility of combining one or more of these approaches to minimise the Ph +ve 
clone. Despite some encouraging preliminary results, it is impossible to say whether this 
will ultimately translate into clinical benefit. 
Since 1989, Carella et al in Genoa have been pioneering a technique for collecting 'in 
vivo purged' stem cells (Carella et al 1991). This relies on the differential recovery of 
Ph +ve and Ph -ve peripheral blood stem cells following myelosuppression. Variations of 
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this method have been used by a number of groups and it has been established that such 
cells can be collected in most CML patients and used for autografting (Johnson & 
Smith, 1997; Carella et al 1997). As with conventional autografting, there are patients 
many months out from such procedures whose bone marrows remain Ph -ve. The 
chemotherapy regimens used by most groups have proved toxic, with severe 
myelosuppression and a mortality of at least 5 %. In this chapter, I describe a technique 
for the mobilisation of predominantly Ph -ve PBSCs using a less toxic oral regimen of 
Hydroxyurea and G -CSF. We have mobilised PBSCs from 18 patients in this way 
and 7 of them have proceeded to PBSCT using only these cells (Johnson et al 1996a; 
Pratt et al 1998). The details of the patients, the mobilisation and harvest data, 
success of Ph -ve cell collection and outcome of transplantation are described and a 
comparison made with other regimens currently employed regarding toxicity and 
efficacy. 
3.2 Patient details 
Eighteen patients were studied. All had proven typical Ph +ve CML. Median age was 
48 years with a range of 29 -59. Median disease duration was 12 months (range 2 -48). 
One patient (ES) was in blast crisis at the time of mobilisation and one (GJ) was in 
second chronic phase. The remaining 16 were all in first chronic phase. The type and 
number of previous modalities of treatment varied. Nine of the patients had received 
only Hydroxyurea and 6 had received Hydroxyurea and a- interferon. Three had 
received other cytotoxic agents in addition. Patient details, disease status, duration 



















































































































































































































































































































































































































3.3 Mobilisation of PBSCs in CML with Hydroxyurea 
PBSCs were mobilised using a combination of high dose oral Hydroxyurea and G -CSF 
(Filgrastim). The procedure is summarised in chapter 2 section 2.2. 
Hydroxyurea dosage: The first case was a young female patient (GJ) whose 
transformation of CML had reverted to a 2nd chronic phase following intensive 
chemotherapy. Assuming her marrow reserve to be poor following this treatment, she 
was given a fairly low dose (3g daily for 7 days) of Hydroxyurea followed by G -CSF 
(300µg daily). The WBC nadir was 1.1x109/1. and she underwent 4 aphereses, 14 days 
post Hydroxyurea, commencing when the WBC rose to 1 x109/1. Despite this being a 
poor risk case, adequate cell numbers were obtained, all of which were Ph -ve. The doses 
that were used for each of the 18 patients are shown in table 3.2 along with the duration 
and depth of WBC nadir. 
Initially, patients were given 6g of Hydroxyurea daily for at least seven days with further 
doses beyond this if the WBC had not fallen below the normal range. However, the 
WBC continues to fall after the end of treatment so subsequently Hydroxyurea was 
given for a fixed period of seven days. Two of the patients received higher doses (8g for 
10 days (RK) and 6g for 10 days (AL)). They suffered no increased side effects and were 
successfully harvested. In 3 cases, the initial Hydroxyurea dose failed to achieve a 
satisfactory nadir (WBC remained 2.2- 3.6x10911.) and the procedure was abandoned 
before apheresis. Not surprisingly, these patients experienced no toxic effects. All 3 of 
these mobilisations were repeated using either the same or a slightly increased dose. 
They were all successfully harvested on the second occasion. The data suggests that 
Hydroxyurea produces a useful nadir in the majority of cases if given at a dose of 
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3.5ghn2 daily for 7 days. This probably errs on the side of caution and some patients may 
require more. In these cases, apheresis should not be attempted and repeat procedures 
are easily performed. This is preferable to using a higher initial dose which, for some 
patients, might produce unnecessary and unwanted side effects. 
Kinetics of Mobilisation: Most patients show a slow reduction in WBC starting after 4 
to 5 days of Hydroxyurea and continuing for 2 to 4 days beyond it. Nadir is reached 
around day +3. A significant number of patients show a transient rise in the WBC shortly 
after nadir is reached but this falls again within a day or two. This is presumably a 
response of residual neutrophils to G -CSF. At this time there are no detectable CD34 +ve 
cells in the peripheral blood which allows differentiation of this transient rise from true 
marrow recovery. Attempts to harvest 2 patients at this time were made initially but no 
stein cells were collected and successful harvests were subsequently achieved from 
them 9 to 11 days later. As shown in table 3.2, the duration of leucopenia following 
Hydroxyurea proved quite consistent (mean 13.8 days, range 6 -18) and the mean depth 
of WBC nadir was 0.8x109/1. Only one patient differed significantly from the rest of the 
group in their recovery time. This patient was in accelerated phase and recovered after 
only 6 days. The WBC tends to recover slowly over several days at the end of nadir. 
Because of this, the optimum time to commence apheresis can be difficult to judge. In 
our experience, the most useful guide is to combine the observation of a rising daily 
WBC with the detection of increasing numbers of CD34 +ve cells in the peripheral 
blood. Reliance on only an arbitrary rise in WBC may mean that apheresis is started too 
early and large numbers of fruitless daily procedures may be performed. 
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Toxicity: The side effect profile of the procedure can be considered in two parts: 
inevitable haematological toxicity and specific effects of high dose Hydroxyurea. The 
haematological toxicity is predictable from the nadir achieved. One third of cases were 
treated entirely as outpatients with no episode of neutropenic fever. The others were 
admitted with fever which responded to standard broad spectrum intravenous antibiotics 
in all but one case. This one patient went on to receive amphotericin B although fungal 
infection was not documented. All patients recovered fully from the mobilisation 
procedure and spent a median of 9 days in hospital. Twelve of the 18 patients required 
an average of 2 units of blood and 4 units of platelets, the remaining 6 needing no blood 
product support. Side effects directly related to Hydroxyurea were skin rash and mild 
oral mucositis affecting about half of the patients. Nausea or vomiting was not a feature 
in any of the patients. One patient reported some thinning of their hair but no significant 
alopecia was seen. 
3.4 Harvest quality 
Table 3.3 shows details of the measures of harvest quality for each patient. A mean of 
3.4 aphereses was required to achieve adequate cell numbers (range 1 -6). Mean values 
and ranges for harvested MNC, CD34 +ve cells and CFU -GMs were respectively: 
4.3x108/kg (range 1.2 -9.8), 3.0x106/kg (range 0.2 -6.7) and 64.4x104/kg (range 2.3 -170). 
Only three of the 18 patients (17 %) mobilised less than a million CD34 +ve cells per kg, 
which we would normally consider a relative contraindication to transplant. 
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GJ 3.6 1.6 80 
ES 1.9 2.0 113 
AL 2.6 6.6 67 
CM 5.9 1.4 74 
RK 3.6 6.7 ND 
CH 5.2 0.75 121 
SR 4.1 6.2 170 
AP 3.5 3.0 ND 
CB 3.0 0.3 71 
MD 2.8 5.4 38 
DJ 7.7 2.4 ND 
JG 8.1 2.0 ND 
JW 1.2 3.3 19.2 
PS 4.5 0.2 2.8 
RD 2.2 2.3 14.5 
EP 4.8 2.0 2.3 
BM 9.8 4.4 ND 
JT 2.7 3.4 ND 
MEAN 4.3 3.0 64.4 
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3.5 Contaminating clonal cells in the harvest products 
Assessment of clonal contamination by cytogenetics, FISH and PCR was made in all the 
apheresis products as described in chapter 2 section 2.3. Table 3.4 shows the results of 
these assays for each individual patient where the data is available. There is no available 
data on two of the patients as cytogenetics failed for technical reasons and the centre 
where the harvesting was carried out did not perform FISH. Fourteen patients are 
evaluable by conventional cytogenetics. All had 96 -100% Ph +ve metaphases in their 
marrow prior to mobilisation. Of these, 4 (28.5 %) had a complete response and a further 
4 (28.5 %) a major response (defined as >50% reduction in Ph +ve metaphases). One 
patient had a 46% response and the remaining 5 showed little or no response. FISH was 
a useful supplement to cytogenetics. It demonstrated that even in those harvests that 
were negative by cytogenetics there were 1 -19% contaminating clonal cells by FISH. In 
addition it gave information on two further patients both of whom appeared to have had 
major responses but in whom conventional cytogenetics failed for technical reasons. 
Overall, over half (56 %) of the patients showed a complete (28 %) or major (28 %) 
cytogenetic response to mobilisation with Hydroxyurea using this regimen. 
3.6 Engraftment Following Reinfusion of PBSCs Mobilised with 
Hydroxyurea 
Seven of the patients have been transplanted to date using only the PBSCs mobilised 
following Hydroxyurea/G -CSF. Two of the patients (ES and AL) were transplanted after 
transformation to blast crisis. The remaining 5 were in chronic phase. Conditioning 
chemotherapy and the techniques of reinfusion are described in chapter 2 section 2.4. 
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Engraftment of neutrophils to >0.5x109/1. occurred at a median of 17 days and platelets 
>20x109/1. at 21 days. One patient failed to make a clinical and haematological recovery 
from the procedure and died of veno- occlusive disease (VOD) and engraft lent failure 3 
months after return of PBSCs despite the infusion of additional backup huffy coat cells. 
The other 6 patients all left hospital within 33 days without any clinical problems 
beyond those that would be considered routine following a high dose procedure. 
Individual figures for engraftment are shown in table 3.5. 
3.7 Patient follow up 
Three of the seven transplanted patients have died. The causes of death were as follows: 
Patient AP died from transplant related toxicity (VOD) as described above. Patient AL 
relapsed with blastic disease. He had been transplanted in blast crisis, achieved a second 
chronic phase but relapsed again five months post PBSCT and was given a second 
autograft using huffy coat cells collected at diagnosis. He did not enter a second 
remission following this procedure and died from his disease eight months from the 
original procedure. Patient ES also died of disease relapse following transplantation in 
blast crisis but did achieve a 27 month second chronic phase with excellent quality of 
life which would be considered an impressive outcome in this setting. The remaining 
four patients are alive and well with follow up from 16 to 28 months. All are in chronic 
phase, three maintained deliberately on IF and one requiring Hydroxyurea to control 
their counts. Disease status has been monitored by cytogenetics. All patients had 100% 
Ph +ve bone marrows prior to transplant. The Ph status of the stem cells reinfused in 
each case is shown in tables 3.4 and 3.6. All patients were evaluated at 3 months 
121 
following the procedure by bone marrow cytogenetics. Two of them showed a major 
response (CM and MD) with 18% and 34% Ph +ve metaphases in their marrows 
respectively. Both are showing an increase in the Philadelphia clone with time. At 14 
months post autograft (the last assessment) the figures have risen to 86% and 50% 
positive respectively. Table 3.6 shows the follow up and outcome data along with 





























































































































































































































































































































































































































































































































































































































































































































































































































CML is an inevitably lethal malignancy curable only by allogeneic bone marrow 
transplantation. Pooled data from over 200 autografts in this disease (McGlave et al 
1994a) suggests that this procedure may extend life if performed in chronic phase, 
although few if any are likely to be cured. Gene marking experiments implicate 
contaminating tumour cells in autologous harvests in the relapse process in some 
diseases (Brenner, 1996). These observations allow us to hypothesise that purging the 
graft in CML before reinfusion might have clinical benefits. The differential recovery of 
normal and Ph +ve cells in the peripheral blood of these patients following 
myelosuppression has allowed collection of cytogenetically normal CD34 +ve cells for 
autografting (Carella et al 1991). This in vivo purging technique has been investigated 
using intensive chemotherapy priming but there has been substantial morbidity and some 
mortality associated with the procedure (Chalmers et al 1994; Carella et al 1997). In 
this chapter, I have described the collection of such cells using a less toxic regimen 
(Johnson & Smith, 1997). Eighteen patients with Ph +ve CML were mobilised using the 
Hydroxyurea/G -CSF regimen and 7 have been autografted. (Johnson et al 1996a; Pratt et 
al 1998). One patient in blast crisis (ES) achieved an adequate and entirely Ph -ve 
collection and remained well for 2 years post transplant. By contrast, some patients 
mobilise no negative cells even shortly after diagnosis. It is felt that the success of these 
procedures varies inversely with disease duration and prior treatment ( Carella et al 
1997) but this cohort is too small to draw conclusions for this particular regimen. 
The use of Hydroxyurea requires attention to dosage as the regimen is designed to 
produce a transient and short lived WBC nadir as opposed to intensive intravenous 
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regimens which accept profound myelotoxicity in all cases. The optimal starting dose 
from this data was 3.5g/m2 Hydroxyurea daily for seven days followed by G -CSF at 
3001.tg daily thereafter until the last day of harvesting. This produced a mean WBC 
nadir of 0.8x109/1 (range 0.2 -1.6). with a mean duration of 14 days. There were no 
prolonged cytopenias. This dose was inadequate for 3 out of the 18 patients who 
were not apheresed but re- mobilised after a short interval. The occasional need to 
repeat the schedule seems acceptable by contrast to the marked myelotoxicity of 
intravenous regimens. Hospital stay was a median of 9 days and one third of cases 
were treated as outpatients. Hospitalisation is almost universal for .:intravenous 
regimens with a median stay of 29 days and a 5% procedural death rate (Carella et 
al 1993; Chalmers et al 1994). 
Harvest quality from the Hydroxyurea regimen was adequate in most cases. A mean 
of 3.4 (range 1 -6) aphereses was required, giving mean values and ranges for harvested 
MNC, CD34 +ve cells and CFU -GMs o£ 4.3x108/kg (range 1.2 -9.8), 3.0x106/kg (range 
0.2 -6.7) and 64.4x104/kg (range 2.3 -170). Only 3 of the 18 patients (17 %) mobilised less 
than 106 CD34 +ve cells/kg, which we would normally consider a relative 
contraindication to transplant. 
The purging efficacy of this regimen appears very similar to that of other published data, 
although numbers are small and this should be viewed with caution. Overall there have 
been about 200 mobilisations reported using an Idarubicin and Cytarabine based 
regimen and around one third of the collections have been entirely Ph -ve with half 
demonstrating a major ( >50% Ph +ve reduction) response (Carella et al 1997). We found 
almost the same with 28% Ph -ve and 56% major response. 
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Results from the 7 transplanted patients are interesting. Engraftment and procedural 
toxicity appear comparable to standard autografting in CML with one death from VOD 
at 3 months and all other patients recovering normally. Two other patients have died, 
both from disease relapse, both having been transplanted in blast crisis. One of these 
(ES) survived over 2 years from PBSCT with a good quality of life. The remaining 4 
patients are alive in chronic phase. Two of these achieved major cytogenetic responses 
but these are slowly being lost over time. The transplant results from other more 
intensive regimens are similarly variable. Several authors have reported small cohorts of 
between 5 and 16 patients with small proportions of these cases becoming Ph -ve post 
procedure (Talpaz et al 1993; Chalmers et al 1994). Some patients have remained in 
cytogenetic remission approaching 3 years (Carella et al 1994) but long term follow up 
is needed. 
In summary, Ph -ve PBSCs can be collected and successfully reinfused in CML patients, 
particularly during the early stages of their disease. The optimum method remains to be 
determined but the severe toxicity of some of the more aggressive intravenous regimens 
may not be justified without proof of increased efficacy. Whether any form of 
autotransplantation will improve survival in CML is as yet unknown and whether any 
patients can be cured by such procedures remains doubtful at present. 
This form of in vivo stem cell purging has proved practical at a clinical level and could 
in theory be combined with other forms of purging ex vivo and become part of the 
management of CML for those without an allogeneic option. 
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Chapter 4. 
Ex-Vivo Purging and Stem Cell Purification in Myeloma 
by CD34 Selection 
4.1 Introduction 
4.2 Patient details 
4,3 CD34 selection on the Ceprate 
TM column 
4.4 Engraftment ifollo- wing CD34 selected PBSCT 
4.5 Patient follow up and monitoring of NMI-) 
4.6 Discussion 
4.1 Introduction 
Myeloma is a malignant haematological disease characterised by the 
progressive accumulation of clonal plasma cells in the marrow and sometimes at 
other sites (Roccadoro i'ileri, 1995). These cells usually produce a monoclonal 
immunoglohulin (paraprotein) detectable in serum and/or urine. in advanced disease, 
these findings are associated with a range of serious clinical manifestations including 
bone destruction, hypercalcaemia, marrow failure, infections and renal impairment. 
These complications cause considerable morbidity and the disease itself is generally 
fatal with a median survival from diagnosis of Around 30_36 months (Barlogie el al 
1989). 
Conventional chemotherapy for the disease has involved the use of alkylating agents 
and steroids, most commonly melphalan and prednisolone. Other drugs have been 
added including anthraryrlines And vinca alkaloids and a variety of regimens based 
on combinations of these agents has been investigated with varying results. There is 
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no international consensus on the interpretation of these trials, with some strongly 
favouring a particular combination and others unconvinced that there is any 
superiority to oral melphalan and prednisolone (Gregory et al 1992; Bergsagel, 
1995). This conventional chemotherapy achieves disease response in around 50% of 
cases but perhaps only 5% achieve CR (if this is strictly defined) and only 5% will be 
alive 10 years from diagnosis (Kyle, 1983). The introduction of infusional 
chemotherapy regimens and intensification of treatment with high doses of 
melphalan with or without stem cell support appears to have improved disease 
response with up to 50% CR rates in some series (Vesole et al 1996b). Importantly, 
there is now evidence that this more aggressive approach can extend survival (Attal 
et al 1996). In the light of this evidence, high dose therapy (HDT) supported by stem 
cell reinfusion is becoming more or less standard treatment for myeloma although 
many centres rightly restrict this to the context of large scale randomised trials. 
Despite the enthusiasm that this dose intensification has generated in the clinical 
community, the excellent responses that can be achieved appear not to be durable 
(Vesole et al 1996b; Harousseau et al 1995). Current HDT is therefore unlikely to 
cure the disease and for this reason, further modifications of the procedures are being 
evaluated. 
One such modification to autografting in myeloma is CD34 selection of stern cell 
products. Theoretical aspects of CD34 selection are discussed in chapter 1 and the 
methodology used for the work described here is outlined in chapter 2. The 
generation of small volume, highly purified stem cell products by this technology 
could have benefits in myeloma and other diseases either by acting as a starting point 
for therapeutic gene modification or through tumour purging. In myeloma, CD34 
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selection should result in a product greatly depleted of tumour cells, provided that 
they do not express the CD34 antigen. Conventional wisdom has assumed the clonal 
plasma cell, which is CD34 -ve, to be the cell of origin of myeloma (Rawstron et al 
1997a). In recent years however, there has been much debate regarding the identity 
of the proliferating cell pool in this disease and this is as yet unresolved. The plasma 
cells in myeloma can be shown by PCR techniques to be clonal by demonstrating 
patient specific rearrangements of the immunoglobulin heavy chain gene (IgH) 
(Owen et al 1996). It has been shown by ASO -PCR that B- lymphocytes with the 
same IgH rearrangement as the myeloma plasma cells circulate in small numbers in 
patient peripheral blood (Billadeau et al 1992). It has been suggested that these 
clonal B cells are the proliferating cells in myeloma (Pilarski & Belch, 1994). 
Further work has demonstrated, in the same patients, the presence of the myeloma- 
specific IgH rearrangement in association with different heavy chain constant genes 
(Billadeau et al 1993). This implies that the myeloma clone may arise from a pre - 
switch B cell but whether this is the `tumour stem cell' or a non -malignant stage of 
myeloma development requiring further tumorigenic events is unclear. It has 
therefore been suggested that there could be a primitive CD34 expressing pool of 
cells which are clonally relevant in myeloma although phenotypic work suggests this 
is not the case (Vescio et al 1994). 
In addition to the potential purging effects, CD34 selection in myeloma might lend 
itself to the investigation of gene therapy for the disease. As already discussed above, 
myeloma is chemosensitive and demonstrates a dose response to melphalan and 
other alkylating agents (Barlogie et al 1997). Drug resistance genes have been 
demonstrated to play a part in the ultimate failure of therapy (Sonneveld, 1995). The 
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effectiveness of chemotherapy might be enhanced by genetic modification of tumour 
cells to sensitise them or of normal stem cells to protect them and allow dose 
escalation. The genetic modification of normal CD34 cells in myeloma to secrete 
substances implicated in myeloma growth or development such as inhibitors to IL6 is 
also conceivable (Hata et al 1993) but as yet none of these approaches is viable 
without further advances in gene therapy techniques and clearer understanding of 
myeloma cell biology. The isolation of stem cells and their concentration in a small 
volume is advantageous to current strategies for gene therapy as it improves the MOI 
in viral transduction protocols as discussed in chapter 1 (Bregni et al 1992). CD34 
selection is one way of achieving this at clinical scale and it is thus important to 
investigate the clinical effects of such manipulation on engraftment post 
transplantation and to demonstrate its feasibility for a wide range of clinical 
applications. 
In this chapter, i describe eight patients with myeloma who underwent CD34 
selection using the Ceprate avidi.n-biotin immunoaffinity column. Six of these 
went on to have PBSCT with the selected cells. The intention was to establish how 
applicable the technique was to clinical scale transplantation. The cell products were 
investigated for their putative stem cell content at all stages of processing and for the 
presence of contaminating cells related to the myeloma clone. I wished to establish 
by laboratory and clinical monitoring whether this approach could yield adequate 
cells for PBSCT with acceptable short and long term engraftment capability and if 
there was a significant reduction in tumour cell contamination in the selected 
products (Johnson et al 1996b). 
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4.2 Patient Details 
Eight patients with myeloma were CD34 selected following mobilisation of PBSCs as 
described in section 2.7. One of them (PH) went through 2 procedures due to poor cell 
yields. The median patient age was 53 years (range 46 to 61). All but one of the patients 
(GL) were male. All patients received cytotoxic treatment until maximum response 
before undergoing mobilisation. Six of the eight patients had received only one modality 
of treatment (5 -8 courses of combination chemotherapy consisting of 
Cyclophosphamide, Vincristine, Adriamycin and Methylprednisolone -CVAMP as per 
the UK MRC Myeloma VII trial protocol) before harvesting, while the other two had 
been heavily pre -treated, one with ABCM (Adriamycin, BCNU (carmustine), 
Cyclophosphamide and Melphalan as per the UK MRC Myeloma VII trial protocol), a- 
interferon and CVAMP and the other with CVAMP followed by an unselected PBSCT. 
All patients had myeloma as defined by the UK MRC trial criteria. The median disease 
duration prior to transplant was 13 months with a range of 8 to 52. Table 4.1 shows the 
age, disease subtype, previous treatment and disease status at mobilisation for each of 
the 8 patients. We defined a partial remission (PR) according to the criteria used in the 
UK MRC Myeloma VII trial. This requires a 50% reduction in paraprotein (or 50% 
reduction in marrow plasma cell infiltrate in the case with light chain myeloma). We 
further defined a `good PR' as >75% reduction in paraprotein/plasma cell infiltrate with 
<15% plasma cells in the marrow. At the time of the procedure, as shown in Table 4.1, 
five patients were in a `good PR', two were in a PR and one was in relapse. None of the 
patients was in complete remission (CR). 
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4.3 CD34 selection on the CeprateTM column 
Nine CD34 selection procedures were performed on mobilised PBSCs from the eight 
patients (PH being processed on 2 separate occasions). The selection process on the 
Ceprate column is described in section 2.8. A mean of 45x109 (range 17 -122) MNC 
were processed on the column for each patient. The pre -column product contained a 
mean of 1.2% CD34 +ve cells (range 0.1 -2.3). The post column products contained a 
mean of 2.4x108 MNC an average of 49% of which were CD34 +ve (range 18.4 -98 %). 
Despite wide differences in the cell numbers processed and the percentage of these that 
were CD34 +ve the yield of CD34 +ve cells was relatively constant with a mean of 30.1% 
(range 24- 37.8). There was no correlation between yield and the percentage CD34 +ve 
cells in the harvest pre -processing. Figure 4.1 shows a photomicrograph of CD34 
selected cells, most of which resemble myeloblasts or small lymphocytes. Table 4.2 
shows a breakdown of the absolute numbers of cells processed for each patient at each 
stage of the processing and of the CD34 +ve proportions and yields before and after 
selection. On the left of the table, the first 3 columns show the absolute cell numbers 
put onto the column (top), retrieved from the column after CD34 selection (bottom) and 
lost in the column waste (waste). On the right of the table, the CD34 +ve percentages are 
shown at the top (pre -processing) and the bottom (final product post processing. The 
figures on the extreme right of the table show the %yields of CD34 +ve cells in the final 
selected product. 
Figure 4.1 
Photomicrograph of CD34 selected cells (post column/final product) stained with 
MGG. Most of the cells have the morphology of small lymphoid cells or larger blasts. 































































































































































































































































































































































































































































































































































































































































































CFU -GM assays were performed on 5 of the patients and showed an increase in numbers 
in the final, selected product with very few colonies in the waste (77.5x104/kg vs. 
10x104/kg). P -Delta assays, which may equate to the LTCIC (Gordon, 1994) were 
performed in two patients and showed a similar concentration of progenitors in the 
product. These results lend support to the assumption that selecting for CD34 +ve cells 
also selects the primitive precursors capable of long term marrow reconstitution. 
4.4 Engraftment following CD34 selected PBSCT 
Six patients were transplanted with a median of 2.0x106/kg CD34 +ve cells (range 1.5- 
9.4). Two patients were not transplanted, one due to rapid disease progression (BD) and 
the other because of an inadequate cell collection (PH). This latter patient had 
undergone a previous unelected PBSCT. In the 6 patients transplanted, engraftment of 
neutrophils to >0.5x109/1. took a mean of 16 days and platelets >20x109/1. took a mean 
of 17 days. This is similar to other reported experience with this selection method 
(Schiller et al 1995) and to our own experience in non -selected stem cell transplants in 
pre - treated myeloma patients. All six patients had unremarkable clinical courses and 
were discharged home well and self caring. One patient (IB) who had presented with 
predominantly tissue disease of IgD type relapsed within a month of the procedure with 
further skin lesions and underwent a second transplant with 1.6x106 CD34 +ve cells/kg 
(stored from the original selection procedure). This patient achieved rapid neutrophil 
recovery but never engrafted platelets and died two months later of massive relapse of 


































































































































































































4.5 Patient follow up and monitoring of 1VIRD 
Seven of the 8 patients had detectable IgH rearrangements in their marrows at 
presentation. The same rearrangement was present in two of these cases in the 
leucapheresis product. Both of these products were successfully purged by the column 
and all final products were PCR negative. In addition to this, the polyclonal PCR 
electrophoretogram pattern seen in the pre -column products was absent from all final 
products indicating a substantial reduction in normal B cells following CD34 selection. 
There were 2 early deaths in the 6 transplanted patients. Patient IB relapsed within one 
month and underwent a second selected PBSCT but died 2 months after the procedure 
with massive disease relapse. Patient KK died 4 months post transplant with progressive 
neurological signs and CT scan evidence suggesting progressive multifocal 
leucoencephalopathy. There was no evidence of disease progression at the time. PCR 
data post transplant is unavailable for these two cases. The remaining 4 patients were 
monitored for MRD by PCR and conventional methods. Post PBSCT, two achieved CR 
with PCR negativity (patients PC and WW), one was in conventional CR but PCR 
positive (JL) and one achieved only a PCR positive PR (GL). This latter patient 
remained stable for some time but eventually progressed and died two years post 
PBSCT. The three who achieved CR remain alive 4 years post transplant but only one is 
still in CR. This patient (PC) is well and persistently PCR negative. 
In summary, of 6 transplanted patients, 2 died early, 2 achieved CR and are alive but 
have needed further treatment, 1 achieved stable PR and died after 2 years and 1 
achieved CR, remains alive and well at 4 years without treatment and has no evidence 
of disease down to the molecular level. 
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4.6 Discussion 
This chapter describes the laboratory and clinical outcome of nine PBSCH CD34 
selection procedures in eight patients with myeloma, six of whom have been 
transplanted with a follow up to the present day of 4 years for those surviving. This 
cohort serves to demonstrate the clinical utility of the selection procedure. 
The absolute number of CD34 +ve cells harvested ranged from 1.9 to 28x106. This 
heterogeneity in mobilisation is common in our experience but we have not been able to 
relate it to any specific factor in this cohort. One surprising feature is the relatively 
constant yield of CD34 +ve cells (range 21- 37.8 %) despite wide variation in both the 
CD34 percentage and absolute numbers loaded onto the column. CD34 purity in the 
final product ranged from 18% to 90% (mean 49 %). The relationship of purity to 
tumour cell contamination may be important as a product of low CD34 purity may 
increase the likelihood of tumour cell contamination. Our PCR analysis does not show 
any increased detection of clonal cells in the products that were less pure but numbers 
are small and contamination below the level of detection by this assay may be relevant. 
Molecular analysis of IgH rearrangements in this study demonstrates that CD34 
selection can reduce the level of contaminating B cells to below that at which they can 
be detected by PCR. Despite this, the two patients whose harvests were PCR positive 
before selection remained positive post transplant in their marrows even though their 
reinfused stem cells had been apparently purged by the procedure. This highlights the 
point that eradication of disease in the body by adequate conditioning is an essential part 
of treatment. If the body burden of disease is incurable by intensive HDT then there is 
little point in manipulating the reinfusion product by CD34 selection in an attempt to 
141 
purge it of tumour. Myeloma may not currently be an ideal disease for CD34 selection if 
this is envisaged as a purely tumour purging strategy to improve survival. 
Short and long term engraftment after selected PBSCT appeared normal in this series 
with all the transplanted patients recovering and further problems being associated with 
disease relapse /progression rather than graft failure. CFU -GM's and p -delta cells were 
monitored as an indicator of engraftment potential and an increase in their numbers was 
seen in the final product. Although reassuring this can only be regarded as a very 
indirect indicator of stem cell numbers. The most important (and only direct) indicator 
of harvest quality is the ability to restore and maintain marrow function after reinfusion 
and this has been successfully achieved. Despite the difficulties of directly monitoring 
long term repopulating potential we feel that taken together this data supports the view 
that 'true' stem cells are contained within the CD34 fraction and are efficiently collected 
in a viable state by the Cellpro system and this finding has been consistent in other series 
(Schiller et al 1995). It is possible to conclude from this work and that of others that 
CD34 selection by this methodology is practical on a clinical scale and provides 
effective haemopoietic support for high dose therapy. 
While this chapter has described a cohort of patients with myeloma, this has been done 
mainly to demonstrate the applicability of the process and does not imply that this is the 
only or indeed a suitable area for this technology. As discussed in chapter 1, the ability 
to select CD34 cells can be regarded as an initial stage in the further purification and/or 
expansion of stem cells ex vivo (Alcorn & Holyoake, 1996). It can achieve a degree of 
tumour cell purging which may or may not ultimately improve survival in some diseases 
(Schiller et al 1995 Brugger et al 1994) and it may produce cell products which are well 
suited to gene therapy applications (Bregni et al 1992). 
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Chapter 5. 
Gene Transfer into Haemopoietic Stem Cells 
5.1 Introduction 
5.2 Assessing the potency of retroviral supernatants 
5.3 Assessing transduction efficiency 
5.4 Gene transfer into haemopoietic cells 
5.5 Discussion 
5.1 Introduction 
One of the therapeutic possibilities arising from an ability to collect and 
manipulate primitive stem cells is the introduction of novel DNA into these cells 
with the intention of reinfusing them into patients to alter a disease phenotype 
(Apperley & Williams, 1990b). Stem cells are unique in their ability to both 
proliferate and self renew (Gordon & Blackett, 1994) and these attributes offer the 
possibility of long term survival and expression of any new genetic material which 
they may have been used to deliver. This has made them an attractive target for the 
rapidly increasing number of gene therapy protocols (Dunbar, 1996a). 
There are many potential applications for stem cell modification by gene therapy, as 
has been discussed in chapter 1. Mechanisms of relapse in malignant disease are 
being clarified by gene marking experiments (Brenner et al 1995) and various 
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approaches to cancer treatment are under investigation including: tumour vaccine 
strategies, introduction of suicide genes and engineered expression of drug resistance 
cassettes in normal stem cells as chemoprotectants. Outside the field of malignancy 
there is great interest in the restoration of normal protein function in monogenetic 
disorders such as Cystic Fibrosis or the Haemophilias (Boucher et al 1994) and 
models for the treatment of diseases as diverse as AIDS and peripheral vascular 
disease are being developed. 
Chapter 1 describes a model system for therapeutic gene transfer into haemopoietic 
progenitors in PNH. This involves the use of a novel construct containing a form of 
CD59 modified to bind to cell membranes through a non -GPI linked mechanism 
(CD59 -TM). This would confer complement resistance to PNH cells (Rother et al 
1994). In order to further investigate the potential of this approach, experiments 
were undertaken to demonstrate efficient gene transfer to human haemopoietic 
progenitor cells using retroviral vectors including one containing CD59 -TM. This 
chapter describes the experimental approach and results of this gene transfer 
protocol using human stem cells derived from G -CSF mobilised and steady -state 
blood. 
5.2 Assessing the potency of retroviral supernatants 
In order to validate the supernatants from all the producer cell lines used in these 
experiments, assays were performed to assess the titre (expressed as colony forming 
units (cfu) per ml of supernatant) of infectious viral particles produced. Details of the 
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methods are described in chapter 2, section 2.18. Viral supernatant was collected, 
batched and frozen at -90 °C and the titre of each new batch was measured. 
Titre of the MFG -LacZ construct using X -GAL 
104 NIH -3T3 cells were plated in wells and allowed to grow for 24 hours. Serial 
dilutions of MFG -LacZ supernatant were added (from neat to 1 in 105) with 
polybrene (6p.ghnl) and incubated for 6 hours before being replaced with fresh 
medium and cultured for a further 24 hours. Plates were then stained with X -GAL as 
described in section 2.18. The lowest dilution of supernatant that still produced 
positive results was taken as the titre. The titre was assessed on two separate batches 
of supernatant and also using supernatant supplied frozen from the same source as 
the cell line (Dr Paulam Patel, St. James's Hospital, Leeds). The titre was no better 
than 104 cfuhnl on any batch despite X -GAL staining of the producer cell line 
showing that almost all cells expressed the construct (Figure 5.1). 
Titre of VSN 2 and LXSN -based supernatants using G418 
The VSN 2 and LXSN based retroviral constructs all contained a neomycin 
resistance cassette allowing survival of successfully transduced cells in the antibiotic 
G418. An estimate of titre was made by infecting 3T3 cells with serial 
concentrations of these supernatants and then placing the cells under G418 selection 
pressure. Surviving colonies of successfully transduced 3T3s were visible at around 
10 -12 days. The method is described in detail in section 2.18. VSN 2 and LXSN 
were assessed in this way. The LXSN -based CD59 -TM construct was initially also 
assayed by this method but thereafter it was validated by a more rapid FACS based 
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assay described in the next section. Results indicated that the VSN 2 had a titre of 
around 105 cfu/ml and this could be raised to nearly 106 after selection in HAT 
medium (see section 2.13). LXSN was shown to have a titre of between 105 and 
3.5x105 in different batches and the initial CD59 -TM titre was 2x10 cfu/ml. 
FACS - based assessment of CD59 -TM supernatant potency 
Since NIH 3T3 cells do not normally express the CD59 surface protein, successful 
transduction can be visualised by MAB staining for this antigen on a flow cytometer. 
The method is described in section 2.18. The first batch of CD59 -TM supernatant 
was assayed using G418 selection giving a titre of 2x105 cfu/ml. An aliquot of the 
same batch was used to infect 3T3s which were then analysed by FACS. This gave a 
%positivity for CD59 transduced cells in the 3T3s of 20.4% (see figure 5.2). 
Subsequent batches were assessed by this rapid method giving results between 18 
and 28% on frozen batches but up to 31% in fresh supernatant. 
Effects of storage on CD59 -TM supernatant 
The rapid FACS assay allowed investigation of the effects of storage and freezing on 
the potency of the CD59 -TM supernatant. Figure 5.3 is a series of representative 
results showing that batches retain about 65% of their potency after freezing. If 
thawed and re- frozen this falls to around 30% and if left for 24 hours at room 
temperature or at 4 °C almost all ability to successfully transduce 3T3s is lost. 
Wherever possible, fresh supernatant was used in these gene transfer experiments to 
maximise efficiency and it is clearly vital to avoid delays in using the supernatant 
after thawing. 
Figure 5.1 
Photomicrograph of the fibroblast producer cell line for the MFG -LacZ viral 
construct. The producer cells have been treated with X -GAL which stains cells blue 
if they contain the LacZ sequence, coding for a nuclear localised -beta- galactosidase. 
As shown, all the producer cells are stained positively indicating expression of the 
construct. See section 2.18 for methodology. 

Figure 5.2 
FACS histograms showing retroviral transduction of NTH -3T3 fibroblasts. The left 
hand plots are unstained cells after exposure to viral supernatant and the right hand 
plots are the same cells stained with a MAB to CD59 (FITC). The top plots were 
using LXSN vector with no CD59 construct, the middle plots are LXSN containing 
the wild -type CD59 -GPI linked molecule and the bottom plots are LXSN containing 
the modified transmembrane CD59, CD59 -TM. As shown, only the CD59 -TM leads 
to expression as the GPI -linked form is not bound to this mouse fibroblast line. This 
FACS technique was a rapid method of validating serial batches of the CD59 -TM 
supernatant and checking for contamination in the others. 
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Figure 5.3 
FACS histograms showing the effects of storage and freeze /thawing on the potency 
of the CD59 -TM supernatant based on its ability to transduce NIH -3T3 cells. The top 
plot shows that these cells are uniformly negative before exposure to supernatant. 
The remaining plots show the percentage transduction efficiency of different batches 
and the effects of freezing and being left to stand. While the supernatant tolerates 
one freeze thaw cycle fairly well (batch 1 frozen), further freezing or being left to 
stand overnight causes serious deterioration in efficacy. (RT = room temperature). 
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5.3 Assessing transduction efficiency 
Human stem cells were exposed to viral supernatants and then cultured in semi -solid 
medium. The resulting progenitor colonies were examined for evidence of successful 
transduction. Depending on the viral supernatant used, it was possible to assess 
transduction by G418 selection of colonies (section 2.24), X -GAL staining (section 
2.23) or picking individual colonies for PCR for the neomycin resistance gene 
(sections 2.21,2.22). All these possibilities were initially examined in order to arrive 
at the most reliable method from those available. 
Assessing transduction by MFr LacZ using X -GAL 
It was hoped that colonies (CFU -GM or BFU -E) grown from PBSCs after exposure 
to the MFG -LacZ virus could be stained in situ with X -GAL. In order to test this, the 
producer cell line was grown in semi -solid medium (methylcellulose) and then X- 
GAL was gently layered onto the petri dishes and allowed to diffuse in overnight. 
The producer cells were successfully stained in this way and an example is shown in 
figure 5.4. PBSCs were then exposed to the supernatant as described in section 2.20. 
CFU -GM and BFU -E were successfully grown from these cells on 3 occasions but I 
was unable to demonstrate positive X -GAL staining in any colonies. It is difficult to 
say whether this reflects failure of the supernatant to transduce the cells or failure of 
the staining procedure although the relatively low titre noted for the MFG -LacZ may 
suggest the former. As a consequence of this, future experiments employed other 
viral constructs. 
Figure 5.4 
Photomicrograph of the fibroblast producer cell line for the MFG -LacZ construct 
grown in semi -solid culture medium (methylcellulose). X -GAL has been gently 
layered onto the medium and allowed to diffuse in. The cells are successfully stained 




Assessing transduction by G418 selection 
Initially, normal colonies were grown in the presence of varying concentrations of 
G418 along with controls. Concentrations above 400µg/ml of G418 had significant 
effects on colony growth although the effects were highly variable. Concentrations at 
or above 800µg/ml generally abolished growth. Pre -incubation of the cells for 24 
hours in 400p.g/ml G418 containing medium before plating in the semi -solid assays 
proved more consistent at abolishing colony growth when the cells were 
subsequently plated with 400n/ m1 G418 in the methylcellulose. Following on from 
these dose finding experiments, PBSCs were exposed to viral supernatants 
containing a neomycin resistance gene. The intention was to use the difference in 
survival of transduced colonies with and without G418 selection as a quantitative 
measure of transduction efficiency. Appropriate controls were always set up in 
parallel. Unfortunately, the results of the selection and the intrinsic variation in 
colony growth between plates were never sufficiently reliable to be used in a 
quantitative manner for assessment and this technique was abandoned in favour of 
the more laborious but more accurate process of picking individual colonies to PCR 
for the neomycin gene as described in the next section. 
Assessing transduction by NEO PCR 
The most reliable method for demonstrating transduction of colonies was found to be 
PCR. The method is described in sections 2.21 and 2.22. After exposure to retroviral 
supernatant, cells were set up in semi solid assays and the resulting colonies were 
individually picked and transferred to a PCR tube. The PCR mix was added directly 
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to this target. Appropriate controls were run in parallel. These included non- 
transduced colonies, PCR blanks and VSN 2 DNA as a positive control. 
The initial attempts with a single round PCR showed no positive signals in any 
colonies despite a working positive control. Further experiments were set up where 
the colonies were split into two PCR tubes, one for NEO PCR and the other for a f3- 
globin PCR already working in the department (courtesy of Dr Paul Evans). As 
shown in figure 5.5, the f3-globin PCR worked for all colonies demonstrating that an 
adequate cell target had been picked and transferred to each tube. Viral producer 
cells were then PCRed (using around 500 cells /tube as a target- a similar quantity to 
a picked colony). Only occasional weak signals for NEO were obtained even in these 
cells, implying that the single round PCR was insufficiently sensitive. Internal 
primers were designed and synthesised for a nested PCR for NEO. Figure 5.6 shows 
results using this method compared to the single round PCR. The nested PCR gave 
reliable results for the detection of the NEO cassette. This nested technique was 
subsequently shown to work consistently on transduced colonies as described in the 
next section. 
PCRing a range of cell numbers from producer cell lines suggested that the NEO 
PCR worked best with a target of 50 to 800 cells under these conditions. Fewer than 
50 cells were unreliably detected and more than 500 -800 cells also began to produce 
negative signals. This range in fact corresponds well to the numbers of cells 
generally obtained from picking colonies as described above. Since the PCR could 
pick up 50 cells or less there could be a problem with small numbers of 
contaminating transduced cells in a culture plate which could be accidentally 
aspirated along with a negative colony. This problem would be greatest in plates 
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with large numbers of colonies where significant degrees of overlap were likely. 
Figure 5.7 shows an experiment where positive signals for NEO were generated from 
apparently cell free aspirates of methylcellulose (deliberately picked as controls) in a 
plate in which there were large numbers of colonies. These false positives proved 
only to be a problem in plates where there was heavy growth. 
5.4 Gene transfer into haemopoietic cells 
Details of the method for retroviral gene transfer are described in section 2.20. 
Experiments were done to assess transduction rates in CFU -GM and BFU -E derived 
from human PBSCHs and peripheral blood. All these samples were taken from 
patients with haematological malignancies in the PBSCT program in our department. 
The samples were taken after mobilisation with Cyclophosphamide and G -CSF. 
Initially some transductions were performed without pre- incubating the cells with the 
growth factor combination described in section 2.20. A few colonies were 
successfully transduced using these simple conditions but the rates shown in tables 
5.1 and 5.2 were only achievable with the protocol described. 
Tables 5.1 and 5.2 summarise the results from the gene transfer experiments 
performed. Table 5.1 relates to CFU -GM and BFU -E colonies grown from 6 
different patients' PBSCHs (samples 1 -6). The numbers of colonies individually 
assayed by PCR and the number and proportion of these which were positive for the 
NEO reporter gene are shown. Table 5.2 shows the same data for colonies grown 
from the peripheral blood of patients post G -CSF. 
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The median transduction rate of colonies with the LXSN virus was 36% (range 35- 
50) and with the CD59 -TM was also 36% (range 17- 63.5). The median rate for both 
PBSCHs and peripheral blood cells was the same at 36% (ranges: PBSCHs 25 -63.5, 
blood 17 -50). Median rate for CFU -GMs was 33% (range 17 -58) and for BFU -Es 
was 43% (range 33- 63.5). Overall then, both the CD59 -TM and LXSN supernatants 
produced useful and broadly similar rates of transduction. There is insufficient data 
to compare infection of CFU -GM and BFU -E but they are both transduced well using 
this protocol. Equally there appears in this limited data to be no difference between 
the ease of transduction of cells in harvest products or in the peripheral blood. 
Photographs of PCR gels showing examples of transduced CFU -GM and BFU -E are 
shown in figures 5.8 and 5.9. 
Figure 5.5 
Photograph of a PCR gel for the ß- globin gene. This single round PCR produces a 
350óp fragment if the target is present. The PCR tests have been performed on 
individual CFU -GM colonies picked from semi -solid medium. Lanes 1 to 9 are: 
1 100bp ladder 
2 positive control 
3 CFU -GM 
4 CFU -GM 
5 CFU -GM 
6 CFU -GM 
7 CFU -GM 
8 Blank 
9 100bp ladder 
As shown, the process of picking colonies always resulted in sufficient DNA target 
for this PCR. 
3 3 0 bp > 
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Figure 5.6 
Photograph of a PCR gel. This shows single -round and nested PCR for the neomycin 
resistance cassette on VSN2 retroviral producer cells. The lanes are labelled as 
follows: 
L 100bp ladder 
+ positive control (VSN2 DNA) 
B PCR blank 
1 VSN2 cells (nested PCR) 
2 VSN2 cells (nested PCR) 
3 VSN2 cells (nested PCR) 
4 VSN2 cells (nested PCR) 
5 VSN2 cells (single round PCR) 
6 VSN2 cells (single round PCR) 
7 VSN2 cells (single round PCR) 
8 VSN2 cells (single round PCR) 
The first 7 lanes (from left to right) are nested and the rest are single round. As 
shown, the controls are all correct with a 190bp fragment from the nested tests and a 
430óp fragment in the single round. None of the single round cell samples (5 -8) is 
positive while all 4 of the nested ones are, 1 and 2 being strongly positive and 3 and 
4 weakly so. 
+ + B 1 2 3 4++ B 5 6 7 8 L 
Figure 5.7 
Photograph of a PCR gel showing tests from samples taken from a 35mm petri dish 
containing CFU -GM colonies in semi -solid medium. All the samples are `blank' in 
otherwords there was no visible colony in the plate area the medium sample was 
harvested from. Three of the samples are positive (1,2,3) for the 190bp fragment 
amplified by the nested NEO PCR. This demonstrates the possibility of false 
positives arising from contaminating cells in the plate when there are large numbers 
of CFU -GM present. (L = 100bp ladder). 
1 2 3 L 
<- 190bp 
Figure 5.8 
Photographs of PCR gels for the NEO resistance gene which generates a 190bp 
fragment when positive. All samples tested are individual CFU -GMs, grown from a 
stem cell harvest and picked from the semi -solid medium (methylcellulose) using a 
fine pipette. The controls are colonies not exposed to any retroviral supernatant. 
None of these is positive for the NEO cassette. The top photo shows 10 samples from 
colonies grown from cells exposed to the LXSN retrovirus. 5 of these are positive 
indicating 50% successful transduction. The bottom photo shows the same 
experiment but using the retroviral construct containing the CD59 -TM insert. 3 of 
these are positive indicating 33% successful transduction. Results are shown in table 
5.1, sample 5. (L = 100bp ladder, B = PCR blank, + = positive control of VSN2 
DNA). 
L + 10 Controls 10 CFUs + LXSN 
L B 10 Controls 10 CFUs + CD59-TM 
Figure 5.9 
Photographs of PCR gels for the NEO resistance gene which generates a 190bp 
fragment when positive. All samples tested are individual colonies (CFU- GMBFU -E), 
grown from peripheral blood and picked from the semi -solid medium (methylcellulose) 
using a fine pipette. The controls (C) are colonies not exposed to any retroviral 
supernatant. None of these is positive for the NEO cassette. All other samples shown 
have been exposed to retroviral supernatant containing the CD59 -TM insert as well as 
the NEO cassette. The top half of the gel shows 12 BFU -Es so treated (table 5.2 sample 
1) with 6 (50 %) positive indicating successful transduction. The lower half of the gel 
shows 12 CFU -GMs treated in the same way with 2 (17.5 %) positive. (L = 100bp 
ladder, B = PCR blank, + = positive control of VSN2 DNA). 
L C C 12 BFU-Es + CD59-TM 























































































































































































































































































































































































































































One method by which stem cells may be manipulated for clinical use is by their 
genetic modification - gene therapy. In order to impact on disease phenotype, stable 
transduction of sufficient numbers of primitive cells would have to be achieved and 
this requires efficient methods for gene transfer. In order to establish a reliable 
protocol for the transduction of human peripheral blood stem cells, different 
retroviral vectors were investigated and attempts made to optimise the conditions for 
efficient transfer. The most appropriate assay technique for assessing transduction 
efficiency in human progenitor cells in this system was chosen. 
Conditions for viral producer cell culture and methods for the harvest of viral 
particles were employed which achieved titres of between 104 and 106 cfu/ml. The 
MOI required for the transfer protocol was considered too low at 10¢ and the MFG - 
LacZ construct which could not be concentrated beyond this, was not used in the 
final method. The LXSN based vectors including that containing the CD59 -TM 
sequence of potential interest in future studies in PNTJ was consistently produced at 
titres around 103 cfu/ml which was satisfactory. 
Assays for transduction efficiency were performed by histochemical staining, FACS- 
based MAB staining and PCR techniques. Using the CD59 -TM construct, it was 
convenient to use FACE analysis in experiments with non -human cells as they did 
not normally express this antigen. When working with human cells, PCR was used 
to detect the neomycin reporter gene in the LXSN -based vectors. It proved possible 
to reliably detect this gene in cell products and semi -solid human progenitor colonies 
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by adjusting the PCR conditions appropriately, allowing accurate assessment of 
transduction efficiency of progenitor cells. 
The most efficient gene transfer protocol involved multiple exposures to virus in the 
presence of growth factors (IL3, IL6, SCF) after a pre- incubation step with the same 
cytokines. When this was applied to mobilised and steady -state human peripheral 
blood cells, it proved possible to consistently transduce CFU -GM and BFU -E using 
the LXSN -based retroviral constructs. Rates of transduction were up to 63% of 
progenitors (median 36 %) with no clear differences between CFU-GM/BFU-E or 
between G -CSF mobilised or steady -state blood. This level of gene transfer and the 
consistency with which it was achieved in these relatively primitive cells would 
suggest that such approaches might be applicable to gene therapy research. The 
CD59 -TM vector was efficiently transferred to human progenitors making it possible 
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6.1 Introduction 
Complement sensitivity is a clinical and laboratory hallmark of PNH and is 
though to be mainly due to lack of the GPI -linked molecule, CD59 (Yamashina et al 
1990) (see Chapter 1, section 1.5). Abolishing this sensitivity could abrogate the 
resulting haemolysis and possibly the thrombotic risk in the disease (Rosse & Ware, 
1995). Restoration of CD59 activity in PNH cells could achieve this. In chapter 5, I 
have described a human gene transfer protocol and its potential applicability to stem 
cells derived from PNH patients. This would involve the transfer of a novel CD59 
construct anchored by a trans -membrane (TM) domain. It proved possible to 
transduce human progenitor cells with the novel CD59 -TM construct with 
integration indicated by PCR for a marker gene. Expression of the new molecule 
following transduction was demonstrated in murine fibroblasts by flow cytometry 
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(these cells do not normally display this antigen). Having achieved integration and 
expression, the next logical step would be to demonstrate function, i.e. show that 
PNH cells were protected from complement by the presence of CD59 -TM and to 
compare their complement sensitivity to that of normal cells and untransduced PNH 
cells. This required the development of an assay to measure the degree of functional 
correction following gene transfer in order to fully document the outcome of this 
gene therapy protocol. The conventional diagnostic test (Ham -Dacie) for PNH relies 
on complement sensitivity but is applicable only to erythrocytes, while the cells of 
interest for gene transfer in this setting would be mononuclear progenitors. It was 
therefore necessary to devise a means for assessing complement lysis which was 
applicable to the cell type of interest. 
This chapter describes the development of a flow cytometry method for this 
quantitation in different cell types as a means of investigating the degree of 
restoration of CD59 activity by the novel CD59 -TM construct proposed for use in 
PNH gene transfer experiments. 
6.2 Development of the FACS -based complement lysis assay 
Principle 
Cells whose membranes have been compromised by complement can be visualised 
by FACS using two simple properties. Firstly they shrink and show reduced FSC and 
SSC and secondly they become permeable to certain fluorescent dyes. Calcein -AM 
(section 2.30) fluoresces in the FL1 channel (FITC) and cells pre -loaded with this 
dye lose it progressively following exposure to increasing amounts of complement. 
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Cells which have been permeabilised by complement will also take up PI. This latter 
dye has the advantage that it can fluoresce in channels FL2 or FL3 on the 
FACScanl` "' allowing simultaneous staining with MABs conjugated to FITC or PE 
for more accurate cell identification. 
For the assay, cells are sensitised with anti -HLA W6/32 and then exposed to human 
complement along with appropriate controls (no serum and serum heat inactivated at 
56 °C for 30mins, to remove complement). Calcein is added along with the Iß,A 
W6/32 or PI is added shortly before processing on the FACScann. The detailed 
methodology is described in section 2.30. Several factors required investigation or 
optimising before the assay could be applied: 
Complement concentration in the assay 
The source of complement for these assays was human serum which was obtained by 
venepuncture, rapidly separated and frozen in suitable aliquots at -90 °C for repeated 
use, ensuring that a standard amount of complement from the same source was used 
in all experiments. A standard volume of varying concentrations of this serum was 
added to test cells in microtitre wells in order to establish the optimum amount of 
complement for the assay (see methods, section 2.30). Normal peripheral blood 
MNCs begin to lyse significantly at a concentration of 35% serum. The greatest 
differential in lysis between normal and complement- sensitive PNH cells (using cell 
lines from PNH patients) was also seen at this percentage. Stronger concentrations of 
serum caused lysis in a high proportion of normal and PNH cells which reduced the 
differential effect. 35% serum was therefore chosen as the optimum discriminating 
concentration in this system. Figures 6.1 and 6.2 illustrate typical examples. Figure 
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6.1 shows lysis in B- lymphoblastoid cell lines from PNH patient, demonstrating 
changes in FSC and SSC after exposure to complement. It also illustrates the 
differential complement sensitivity between these PNH and normal cells. Figure 6.2 
shows lymphocytes from 3 normal volunteer peripheral blood samples with lysis 
beginning consistently at a 35% serum concentration. 
Calcein or PI to indicate lysis? 
These proved to be equally effective at indicating the degree of lysis. There were 
several reasons why PI was ultimately preferred: It was quicker and easier to use, 
being added at the end of the procedure just before FACS analysis. PI is also cheaper 
and easier to store than calcein. In addition to these practical issues, PI will fluoresce 
in the FL3 channel of the FACScan after appropriate adjustment of the 
compensation settings and this allowed routine use of FITC and PE conjugated 
MABs along with PI. Calcein utilises the FITC channel. Use of PI thus allowed 
identification of cell types by one MAB (e.g. B lymphoblastoid cell lines using 
CD 19 -PE), discrimination between PNH and normal cells using CD59 -FITC and 
assessment of lysis in these cells using PI. Figure 6.3 shows a series of FACS 
histograms comparing calcein and PI as indicators of lysis in a normal (non -PNH) B 
lymphoblastoid cell line lysed as described above with increasing concentrations of 
serum. Both indicators show lysis beginning at 35% serum with no difference 
between the two. 
Blocking effects of CD59 /CD55 
In order to investigate whether the MABs (CD59 and/or CD55) used in these 
experiments interfered with the function of their antigens and reduced the ability of 
cells to handle complement, lysis assays were performed on cell lines pre and post 
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labelled with the antibodies. Normal (non -PNH) cells could theoretically be rendered 
PNH -like if these MABs were blocking and their resistance to complement would be 
reduced. Figure 6.4 shows an example of this with the normal cell line showing less 
resistance to complement if pre -labelled with CD59 and CD55. Since these 
antibodies did appear to be at least partly blocking, subsequent experiments were 
always carried out by staining with MABs after the lysis step. 
Quantifying lysis in PNH and normal cells 
Cells that are lysed in this system suffer two possible fates: either they are totally 
disrupted and appear in the low FSC /SSC debris in the bottom left quadrant of a 
FACS plot or they will be compromised and become PI +ve /calcein' °' with reduced 
FSC /SSC as described above. To quantify lysis in a mixture of PNH and normal 
cells, it was found preferable to express the result as the proportion of PNH cells 
remaining in the viable non -lysed PI -ve gate as this change in proportion takes into 
account those cells that are compromised and those that are disrupted. If only 
compromised, PI +ve cells are measured, the disrupted cells (many of which will be 
PNH) are excluded from the result. Figure 6.5 shows this method for a mixture of 
PNH and normal B lymphoblastoid cells. The cell population is gated loosely using 
FSC /SSC characteristics and a gate is then set round the PI -ve (viable) cells. This is 
then re -gated on FSC and SSC and this final population of cells with appropriate 
FSC and SSC which are viable (PI -ve) are separated using CD59 into normal and 
PNH. In this way the proportion of normal:PNH cells that remain viable after 
exposure to increasing concentrations of serum can be measured. The figure shows 
the proportion of PNH cells falling from 37% to 15% after lysis, indicating their 
increased susceptibility to complement. 
Figure 6.1 
FACS dot plots. The cell population analysed here is a mixture of normal and PNH 
phenotype B- lymphoblastoid cell lines derived from a patient with PNH (courtesy of 
Dr P Hillmen, Leeds Infirmary). 
In the left hand column, the top 2 plots show the change in the FSC /SSC 
characteristics of the cells on exposure to complement. The main population with 
high FSC seen in the upper plot is shifted to the left as the cells are permeabilised 
and shrink on exposure to 50% human serum (second plot down). The third plot 
down shows the use of PI to gate out dead cells in the mixture before exposure to 
complement. Only the gated area at the lower right of the plot is viable (PI -ve). The 
lower plot shows the differentiation of PNH from normal cells using CD59 
performed on the viable cells. The percentage of normal/PNH cells can be easily 
calculated from this. 
The remaining 8 sequential plots show these cells with their respective proportions 
after exposure to increasing amounts of complement. As demonstrated, the 
proportion of normal cells rises steeply as serum concentration increases and the 
sensitive PNH cells are lysed, with optimum discrimination at 35 %. At higher 
concentrations the lysis of all cells is considerable, reducing overall numbers for 
analysis and lowering the degree of discrimination (see text). 
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Figure 6.2 
FACS histograms showing lysis of normal peripheral blood lymphocytes by 
complement with PI as an indicator dye. Each of the 3 columns shows one sample. 
The increasing percentages of human serum added are indicated on the plots reading 
downwards. The percentage of lysed (Pi +ve) cells at each concentration is seen as a 
peak to the right of the histogram. This increases consistently at 35% serum in all 
cases. 
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Figure 6.3 
FACS histograms showing lysis of a normal (non -PNH) B cell line comparing the 
use of Calcein -AM and PI as dye indicators of cell lysis. 
The upper half of the figure shows 6 plots using calcein and increasing 
concentrations of serum. The right hand histogram peak gets progressively smaller 
and the left hand peak increases as cells are lysed, lose their calcein and shift left in 
their fluorescence. 
The lower half of the figure shows the same conditions exactly but with PI as the 
indicator. Here, lysed cells take up PI so that the right hand (PI +ve) peak increases 
with lysis. 
The two dyes are equally useful as indicators as they both show lysis beginning at 
35% serum concentration. 
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These FACS histograms show lysis of non -PNH, B -cell lines. The left hand column 
shows the experiment with pre -labelling by the MABs CD55 and CD59. The degree 
of lysis is higher than in the post labelled cells shown in the right hand column. The 
antibodies are functionally blocking these complement regulating molecules and 
converting normal cells to those with a `PNH' phenotype with regard to their 
complement sensitivity. 
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Figure 6.5 
FACS plots/histograms showing the differential lysis sensitivity of B cell lines of 
normal and PNH phenotype. The left hand column shows the gating method. The 
mixed cell population is loosely gated by FSC /SSC characteristics (top) then non- 
viable PI +ve cells are excluded (middle). Finally, a tighter gate is applied to these 
viable cells before histogram analysis. 
The right hand column shows the proportions of PNH:Normal cells remaining after 
exposure to two controls of no serum and heat inactivated serum (top and middle) and 
then 35% complement. As shown, the cell numbers fall with lysis after complement. 
The remaining cells are largely normal (right hand peak, CD59 +ve) as most PNH cells 
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6.3 Applying the assay to cell lines 
The cell lines used were produced by Dr Peter Hillmen and were kindly donated. 
These were EBV transformed human B- lymphoblastoid lines derived from the 
peripheral blood B- lymphocytes of patients with PNH. A number of such lines, 
some normal and some of PNH phenotype, were produced. Figure 6.6 shows an 
example of a normal and PNH line with FSC /SSC characteristics and CD59 staining. 
This antibody gives the clearest discrimination between normal and PNH cells. 
Using these lines, Rother et al have shown that the normal cells are less sensitive to 
complement than those with a PNH phenotype (Rother et al 1994). I have used the 
FACS based lysis assay described above to demonstrate this differential more 
clearly. Using these cell lines, the proportional changes in a mixture of viable PNH 
and normal cells before and after exposure to complement can be clearly seen (figure 
6.5). 
In order to show the importance of CD59 and perhaps other GPI -linked molecules in 
inactivating complement, further experiments were performed on the lines before 
and after treatment with the enzyme PI -PLC. This cleaves the GPI anchor, effectively 
creating PNH cells by a biochemical method. Figure 6.7 demonstrates the 
effectiveness of this enzyme and shows that CD55 and CD59 expression is abolished 
after PI -PLC with no change in the non GPI -linked CD 19 control. Figures 6.8 and 
6.9 show the results of a lysis assay using this principle. The normal line begins to 
lyse only at 40% serum before PI -PLC whereas the PNH line is largely lysed at 35% 
(figure 6.8). After PI -PLC, the normal line has changed dramatically and lyses at the 
same point and to a similar degree to the PNH line (figure 6.9). 
Figure 6.6 
TACS plots and histogram showing the CD59 staining characteristics of a normal 
and a PNH cell line. The red dots /peak show CD59 +ve normal cells and the green 
dots /peak show the CD59 deficient PNH cells. All cells are CD19+ve B cells as 
shown on the y -axis of the dot plots in the centre of the figure. The CD59 GPI- lirikéd 
antibody is particularly good at discriminating clearly between the populations in 
T1A TT T rive. 
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FACS histograms showing a normal B cell line stained for 3 MABs (CD59, CD55 
and CD 19) before and after treatment with PI -PLC. This enzyme cleaves the GPI 
anchor and thus removes CD59 and CD55 as shown in the top 2 plots. The non -GPI 
linked CD 19 B cell antigen is not affected by this enzyme and acts as a useful control 
as seen in the bottom plot. 
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FACS histograms showing a complement lysis assay in normal (top 4 plots) and 
PNH (bottom 4 plots) B -cell lines with no PI -PLC treatment. HI -serum is heat 
inactivated to remove complement and act as a control. The increasing amounts of 
serum shown lead to lysis as indicated by the increasing percentage of cells that take 
up PI (right hand histogram peak). As can be seen, the PNH cells are more sensitive 
and lyse at a lower serum concentration (35 %). The normal cells can be made 
complement sensitive by PI -PLC treatment as demonstrated in figure 6.9 (see text). 
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Figure 6.9 
FACS histograms showing a complement lysis assay in normal (top 4 plots) and PNH 
(bottom 4 plots) B -cell lines after PI -PLC treatment. HI -serum is heat inactivated to 
remove complement and act as a control. The increasing amounts of serum shown lead 
to lysis as indicated by the increasing percentage of cells that take up PI (right hand 
histogram peak). By contrast with non -PI -PLC treated cells (figure 6.8), the normal 
cell line is now as complement sensitive as the PNH line because it has lost all GPI - 
linked regulatory molecules (mainly CD59). Both lines begin to lyse significantly at 
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6.4 Applying the assay to peripheral blood 
Using cell lines, one can guarantee a pure source of large numbers of cells of clearly 
pre -determined phenotype. This means that there is no difficulty in achieving a 
mixture of known proportions of entirely normal and entirely PNH cells in a test. 
This would not be the expected situation in PNH peripheral blood, particularly in 
regard to the lymphocyte population which is often a great deal more heterogeneous 
with respect to PNH phenotype than the neutrophils and red cells. Patients with 
substantial PNH clones detected in the neutrophil population can have quite small 
numbers of affected lymphocytes. In order to see how sensitive the lysis assay was, I 
applied it to the peripheral blood lymphocytes of normal subjects and of four PNH 
patients. Figure 6.10 shows the results of an assay on lymphocytes from a PNH 
patient. Two peaks can be seen for CD59 staining indicating that around 41% of the 
lymphocytes are PNH. There is no change in the proportions of PNH:normal after 
treatment with heat inactivated control serum but the PNH cells are preferentially 
lost after fresh serum is added indicating that they are more complement sensitive. 
The assay was highly dependent on the population of PNH lymphocytes in each 
patient. Two of the four patients tested showed a positive result as displayed in 
figure 6.10 but the other two showed no detectable PNH cells by lysis although there 
were small clones of CD59 negative cells in these patients. It is therefore unlikely 
that this approach to demonstrating complement mediated lysis will be reliable if 
there are only small numbers of PNH cells present in the test sample. 
Figure 6.10 
These SAO S pots and histograms show the differential complement sensitivity of 
norms and PNH peripheral blood lymphocytes from one of our patients. The left 
hand coolumn shows the gating which is done in the same manner as described in 
figure X6.5. The right hand column shows 3 histograms: the top and middle ones are 
controls with no serum and heat -inactivated serum respectively, while the bottom 
one shows the effect of adding 35% fresh serum. As can be seen, the lymphocytes in 
this patient are about 40% PNH (CD59- ve,left hand peak) and 60% normal 
phenotype (CD59 +ve,right hand peak). The bottom plot shows how the PNH 
lymphocytes are preferentially lysed by complement leaving only 31% PNH cells 
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6.5 FACS analysis and lysis of semi -solid colonies 
Semi -solid colonies (CFU -GM and BFU -E) were grown from peripheral blood 
samples or PBSCHs as described in section 2.16. They could be individually 
harvested from a plate or the whole plate could be harvested by dissolving the 
methylcellulose in PBS (see section 2.22). FACS analysis was performed on these 
colonies by the methods described in section 2.27. 
The results of colony harvesting were inconsistent and a clear cut cell population 
was not visualised on the FACS for all samples. This was due to a combination of 
factors including the aspiration of the colony (a manual and very operator dependent 
technique), how dry the methylcellulose had become and the size and viability of the 
colonies themselves. Where there were only a few small colonies from a sample that 
had grown poorly, the cell populations on the FACS were often of poor quality and 
could be difficult to separate from debris. CFU -GM appear on the FACScanTm 
scatter plot as large cells of low to intermediate SSC. They are larger than BFU -E. 
Figures 6.11 and 6.12 show respectively scatter plots of 3 CFU -GM and 3 BFU -E 
single colonies. Gate R1 is placed around the populations which are quite discreet. 
The CFU -GM stain well for CD45 (leucocyte common antigen) and CD13 +33 (both 
myeloid cell markers) but negatively for the red cell marker GPA. The BFU -E show 
GPA (glycophorin) positivity, weak expression of CD34 and no expression of the 
monocytoid antigen CD14. Figure 6.13 shows a comparison between the expression 
of CD59 on normal and PNH cell lines with the expression on a single normal CFU - 
GM. As shown, CD59 is well expressed on these progenitor colonies. 
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Having established this method, I attempted to grow colonies from the peripheral 
blood of patients with PNH and analyse them on the FACS. These patients were 
mildly to moderately hypoplastic and as expected showed poor colony growth in 
culture making such experiments difficult. The size of the colonies that typically 
grew was less than ideal to visualise clearly on the FACS except in a few cases. 
Figure 6.14 shows the scatter plots for 6 single CFU -GM from one of these patients 
and below them it shows the CD59 expression of the colonies. Five of them are 
evaluable and of these, one appears to show a mixed population, one is negative and 
the other 3 are positive for CD59. The relatively small numbers of colonies that were 
successfully grown, picked and stained from PNH patient blood showed this pattern, 
with most of the colonies appearing to show a normal phenotype. Others have 
demonstrated the presence of dual populations of normal and PNH BFU -Es in such 
patients (Rotoli et al 1984) 
It proved impossible to apply the lysis assay to the cell samples harvested from 
single colonies for practical reasons. The assay requires too many washes and 
incubations to handle such small cell numbers. It was possible however to 
demonstrate that CFU -GM could be lysed under the same conditions as lymphocytes 
by pooling all the cells from a whole methylcellulose dish. Figure 6.15 shows an 
example of a dish of colonies harvested and stained for a variety of positive and 
control antibodies. Figure 6.16 shows a similar sample subjected to lysis on the 
FACScan. As the concentration of serum rises beyond 30 %, the cells lose their 
calcein as they are lysed in an almost identical pattern to that of lymphocytes. 
Figure 6.11 
FACS plots showing 3 individual CFU -GM colonies picked from methylcellulose. 
The left hand column shows the FSC /SSC characteristics of the cells in the colony 
and they are gated in region R1. The right hand column shows staining of the gated 
cells for: top plot= CD34 +ve,CD13 +33 +ve, middle plot =CD45 +ve,GPA(glycophorin 
A) -ve, bottom plot= non -stained control. These CFU -GM therefore stain as expected 
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FACS plots showing 3 individual BFU -E colonies picked from methylcellulose. The 
left hand column shows the F SC /SSC characteristics of the cells in the colony and 
they are gated in region Rl. The right hand column shows staining of the gated cells 
for: top plot = strong +ve Giycophorin(GPA), middle and lower plots = negative 
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Figure 6.13 
FACS histograms comparing the CD59 expression on PNI-1 and normal B -cell lines 
with the expression on a single CFU-GM harvested from methyïcellulose. The PNH 
line is negative and the normal line and the CFU -GM are positive for this antigen. 
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FACS plots and histograms showing CD59 staining on 6 individual CFU -GMs 
picked from methylcellulose. These colonies have been grown from the peripheral 
blood of a patient whose neutrophils are >90% PNH in phenotype. Of the 5 evaluable 
results shown, 4 are normal and one has a mixture of normal and PNH expression of 
CD59 (see text). 
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Figure 6.15 
FACS plot and histogram showing the scatter characteristics and MAB staining 
pattern of CFU -GM grown from a stem cell harvest product from an individual with 
myeloma All CFU -GMs in the dish have been pooled to obtain a larger cell sample 
for analysis. As shown, they stain for CD45,CD13 +33,CD59 and CD55 but are 
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Figure 6.16 
These plots show pooled CFU -GM from a normal individual exposed to increasing 
concentrations of complement. As shown, the percentage of calceini°W, CD13 +33 +ve 
cells (which are CFU -GM which have been permeabilised by complement) rises from 
14% to 40% as the serum concentration increases (see text). 
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6.6 Discussion 
In this chapter, I have described the results of a flow cytometry based assay for the 
demonstration of complement- mediated cell lysis. The assay is applicable to 
different cell types and because the degree of lysis is measured by fluorescence, it 
allows simultaneous cell identification using one or more labelled MABs. This 
approach allows the measurement of differential cell lysis in mixed cell populations 
defined by their surface antigen expression. 
Cells were sensitised with antibody and then exposed to concentrations of human 
complement. A combination of FSC /SSC changes and the gain or loss of an 
appropriate autofluorescent vital dye defined cells that had undergone 
permeabilisation by complement. PI was chosen as the most suitable indicator dye 
as it can be measured in channel 3 of the FACScan allowing cells to be labelled 
with 2 other MABs for identification. In the case of PNH cells for example this 
allows PNH and normal stem cells to be defined using CD59 and CD34 staining. 
The assay was applied to EBV transformed lymphoblastoid cell lines from PNH 
patients. The differential complement sensitivity of normal and PNH lines from 
these patients was easily demonstrated and could be measured in mixtures of these 
cells assayed simultaneously and separated by their CD59 staining characteristics. 
This principle has been used by Rother et al to demonstrate that retroviral 
transduction of these PNH lines with CD59 -TM restores CD59 expression and 
function as judged by an increase in their resistance to complement lysis. Although 
this increase is significant, it does not fully equate with the level of function in non- 
PNH cells (Rother et al 1994). As further evidence for the importance of CD59 
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activity (and perhaps other GPI -linked molecules) in inactivating complement, I have 
shown that biochemical removal of these GPI -linked structures using the enzyme PI- 
PLC renders normal cell lines as sensitive to complement lysis as their PNH 
counterparts. These experiments provide strong support for the central role of CD59 
in the pathogenesis of some of the clinical features in PNH. They suggest that there 
is a rationale for attempting CD59 -TM gene transfer into human PNH stem cells. 
The results with this assay on human peripheral blood lymphocytes, as opposed to 
lymphoblastoid cell lines, served to underline the requirement for a reasonable 
number of test cells in order to achieve a clear result. The proportion of lymphocytes 
that are affected in PNH patients is often very small even when the clone is large as 
judged by neutrophil and/or red cell phenotype. I found that the small numbers of 
PNH lymphocytes in some samples limited the assay in PNH peripheral blood and 
only 2 of the 4 patients tested could be shown to have a clearly positive complement 
sensitivity test by flow cytometry. Neutrophils were not sensitive to lysis in this 
system and red cells do not take up PI, so the assay is not suitable for routine 
diagnosis of PNH in the manner of a Ham's lysis test. 
In order to demonstrate functional correction of CD59 activity in PNH progenitors, it 
would be necessary to apply the assay to CFU -GM and BFU -E colonies. This was 
done by harvesting these cells from semi -solid growth medium (methylcellulose). It 
was demonstrated that these progenitor colonies are sensitive to lysis in this system. 
Two significant problems were encountered in attempting to grow colonies from 
PNH patient blood and assay them. Firstly there are technical problems as 
these 
hypoplastic patients have reduced blood progenitors and showed poor colony 
growth 
and secondly, the majority of progenitors appeared to be of normal phenotype unlike 
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the peripheral blood neutrophils. This phenomenon has been noted by others during 
immunophenotyping experiments on PNH blood and appears most marked in the 
most primitive precursors (Prince et al 1995; Musto et al 1997). This implies that 
collection of PNH stem cells from blood for gene transfer experiments would be 
difficult. I have proceeded to investigate the stem cell subsets in PNH patient blood 
before and after the administration of G -CSF in order to elucidate this unexpected 
observation (Johnson et al 1998) and to establish the practicality of attempting such 
a gene transfer experiment. The results are discussed in chapter 7. 
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Chapter 7. 
PBSC Mobilisation in PNH: 
a Prelude to Treatment by Autografting or Gene Transfer? 
7.1 Introduction 
7.2 Patient details and effects of mobilisation 
7.3 Changes in haematological parameters on G -CSF 
7.4 Phenotypic changes in peripheral blood neutrophils on G -CSF 
7.5 Progenitor mobilisation 
7.6 Stem cell subset analysis before and after G -CSF 
7.7 Discussion: prospects for autografting and gene therapy 
7.1 Introduction 
PNH is an acquired haemolytic anaemia resulting from a somatic mutation in a 
haemopoietic stem cell. The disorder is discussed in detail in chapter 1. The co- 
existence of normal and abnormal stem cell populations in these patients, the links with 
other stem cell disorders (AA/AML/MDS) and the ease with which PNH cells can be 
identified (using flow cytometry) has made this an attractive disease model for stem cell 
research. 
Two speculative approaches to the treatment of PNH are autografting and gene therapy. 
These would rely on a detailed understanding of the stem cell biology in this disease and 
require satisfactory means of collection, phenotypic assay and manipulation of PBSCs in 
these unusual patients. Important questions include: what are the effects of G -CSF in 
PNH? Are there differences in the behaviour of normal and PNH stem cells? Can 
normal and/or PNH stem cells be collected for clinical use and can methods of 
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mobilisation select for the normal cells thus effecting an in vivo purge as has been 
discussed in chapter 4 for CML? 
The effects of G -CSF on normal individuals and those with a variety of 
haematological disorders have been studied extensively (Stroncek et al 1996; To et 
al 1997). It has been used in both congenital and acquired marrow failure states and 
has an established track record in ameliorating neutropenia in these conditions both 
in short and long term studies (Dale et al 1993). In a manner analogous to this, G- 
CSF has been used in PNH patients suffering aplasia- related infective problems and 
the suggestion is that they may derive benefit (Ninomiya et al 1993). Interestingly, 
these workers reported that G -CSF induced phenotypic changes in PNH cells 
suggesting that this drug might alter the biology of the disease. Other groups have 
looked at stem cell phenotype in the peripheral blood of PNH patients (not on G- 
CSF) and found that the majority of the most primitive PBSCs appear to be of normal 
phenotype despite the opposite situation in the bone marrow (Prince et al 1995). This 
has led to tentative suggestions that normal PBSCs could be collected and used for 
autologous transplantation (Musto et al 1997; Prince et al 1995). Clearly these 
observations, which are contrary to expectations, require further investigation by 
combining the study of primitive and mature cell types in PNH patients intentionally 
mobilised using G -CSF. This chapter describes the first such clinical investigation 
(Johnson et al 1998). I sought through this work to clarify the existing contradictory data 
surrounding G -CSF in PNH, collect PNH stem cells for laboratory manipulation in a 
gene therapy protocol (see chapters 5 and 6) and investigate the practicality of PBSC 
collection for autologous transplantation in this disease. 
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The clinical consequences and changes in haematological parameters during G -CSF 
therapy in these patients are described, along with experiments designed to explain 
the apparent phenotypic changes in PNH neutrophils referred to above. Progenitor 
cell mobilisation was examined by assays of CD34 cells and CFU-GM/BFU-E and 
compared to that of normal individuals. Finally, the phenotype (PNH vs normal) of 
subsets of the CD34 fraction was studied in order to establish whether the most 
primitive progenitors are more or less affected and whether normal stem cells could 
be recruited into the peripheral blood. All experimental detail is described in chapter 
2 sections 2.28 to 2.35. 
7.2 Patient details and effects of mobilisation 
Four patients underwent stem cell mobilisation using G -CSF alone at a dose of 
lOp.g/Kg/day for four consecutive days. All patients had been previously diagnosed in 
our department and had classical haemolytic PNH. Diagnostic criteria included a 
positive Ham -Dacie acid lysis test and the demonstration on patient red cells and 
neutrophils of a population of CD59 /CD55 deficient cells by flow cytometry. One 
patient (DL) was on treatment for Aplastic Anaemia with Cyclosporin A (their original 
presenting diagnosis). All patients were prophylactically warfarinised to prevent 
thrombosis. Baseline clinical details and typical haematological values for the patients 
are shown in table 7.1 along with the size of their PNH clone, measured by flow 
cytometry on peripheral blood neutrophils (median 87% PNH, range 50 -97). All four 
patients completed the mobilisation regimen. A bone marrow aspirate was taken post 
G -CSF in one case (DT). One patient (ST) developed a chest infection after treatment 
195 
precipitating a haemolytic crisis. The others had no ill effects apart from mild bone pain 
related to the growth factor. 
7.3 Changes in haematological parameters on G -CSF 
Haematological monitoring included the F'BC, NAP score and reticulocyte count. The 
WBC rose in all patients on G -CSF from a baseline mean of 3.6x109/1. to a peak mean of 
15.3x109/1. (Figure 7.1). Although this is a definite rise it is substantially less than that 
seen in normal volunteers on G=CSF whose absolute neutrophils count alone reaches 
mean peak levels of around 28x109/1. on similar regimens (Stroncek et ai 1996). This 
presumably reflects the underlying hypoplasia in these patients. Interestingly, the 
NAP score (NAP being GPI -linked) rose in all patients during G -CSF treatment. Our 
normal range is 30 =120. The mean NAP score on day 1 was 41 while the mean on 
day 5 was 162. Three out of the four patients showed a steady increase which only 
began to fall again after discontinuing G -CSF while one patient's score rose initially 
but began to fall back towards baseline before G -CSF finished (Figure 7.2). Platelet 
counts did not change. Haemoglobin and reticulocyte counts for the four patients are 
shown respectively in figures 7.3 and 7.4. One patient (DL) was transfused at the end 
of G -CSF (day 5) but this had been planned as this patient was due their regular 
transfusion at this time in any case. As previously mentioned, one patient (ST) did 
have a haemolytic crisis that started 2 days post G =CSF. This patient normally suffers 























































































































































































































































Graph showing the changes in WBC in the peripheral blood of the 4 PNH patients 
over 8 consecutive days. The count on day 1 is pre -G -CSF (i.e. baseline) and this 
drug was administered daily from days 1 to 4 inclusive. The rise in WBC during 





Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
G- CSFgiven on days 1 -4 inclusive 
Day 8 
Figure 7.2 
Graph showing the NAP scores in the 4 PNH patients during treatment with G -CSF. 
The scores rise dramatically in all cases (normal range in our laboratory is 30 -120). 
While this phenomenon is well described in normal individuals on G -CSF, it has not 
been described in PNH where the NAP is classically low due to its GPI -linkage. See 
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Graph showing the changes in reticulocyte percentage in the 4 PNH patients during 
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7.4 Phenotypic changes in peripheral blood neutrophils on G-CSF 
It had been previously reported that PNH patients given G -CSF showed an increase 
in the expression of CD16 (a GPI -linked molecule) by FACS on neutrophils 
(Ninomiya et al 1993). Furthermore, this increased expression was said to be 
sensitive to treatment with PI -PLC implying that it was due to the presence of GPI 
linked CD16. It would be difficult to explain this phenomenon in terms of the 
molecular pathology of PNH. I looked at the neutrophil expression of three GPI - 
linked molecules (CD55,CD59 and CD16), a non -GPI linked molecule (CD15) and 
some irrelevant control antibodies (CD3, IgGl, IgG2). Expression was assessed 
before and after PI -PLC treatment. This more detailed study of the phenomenon 
allows for a different interpretation. We found an increase in MFI of negatively 
staining cells for all antibodies tested after G -CSF was administered. The size of the 
increase varied with the antibody. It was most marked with CD59. In many cases the 
increased expression of negatively staining cells took them well above the arbitrary 
positive /negative cut -off and if this were the only criterion analysed these cells 
would now be classed as positive. However, as shown in figure 7.5, this would be an 
inaccurate interpretation of the results. This figure shows that the CD 16 negative 
peak increases in MFI on day 4 of G -CSF but that there is still a clearly discernible 
`true' positive peak of similar size to baseline. Six days later, the MFI of both peaks 
has returned nearly to normal. Figure 7.6 shows the same cells before and after G- 
CSF but in addition they are shown treated and untreated with PI -PLC. As seen, the 
true positive peak remains sensitive to PI -PLC and is effectively abolished (from 5- 
10%+ve down to 0.5- 1 % +ve) after incubation with the enzyme. There is however no 
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effect of PI -PLC on the negative peak even after it has increased in MFI post G -CSF. 
Figure 7.7 shows essentially the same data for CD59. Here the increase in MFI of the 
negative peak is more dramatic and reaches the same levels as the positive peak 
which is swamped. PI -PLC does not reduce the MFI of the negative peak post G -CSF 
but cleaves the positive peak pre -G -CSF. Figure 7.8 shows the effects of G -CSF 
treatment on the same cells stained with irrelevant antibodies. Just as the CD 16 and 
CD59 negative peaks increase in MFI, so do the negative staining antibodies CD3, 
IgGI and IgG2. 
7.5 Progenitor mobilisation 
It was evident from the pre and post mobilisation progenitor cell numbers that all of 
the four patients under investigation had an element of marrow hypoplasia as is to be 
expected in most, if not all, PNH patients. Figure 7.9 shows the absolute CD34 
numbers in the cohort during administration of G -CSF. In normal subjects (n =6), we 
found steady state values for peripheral blood CD34 cells ranging from 0.9x106/1. to 
11.3x106 /1. with a median of 2.5x106 /l. In a larger series of normals who were given 
G -CSF, the mean baseline CD34 count was 8x106/1. and this rose to 55x106/1. after 
G -CSF (Stroncek et al 1996). In our PNH patients, the baseline figure was 0.5x106/1. 
(range 0.1 -0.8) and after G -CSF it rose to only 4.2x106/1. (range 1.3 -9). In both 
normal and PNH this represents a similar proportionate increase (7 -9 fold) despite 
the baseline CD34 count in the PNH patients being 5 -16 fold less than normal 
ranges. The kinetics of CD34 mobilisation appear to be similar in normal and PNH 
patients with the CD34 rise beginning around day 3 -5 of G -CSF and falling rapidly 
back to baseline a few days post G -CSF. This contrasts with the rise in WBC which 
occurs on day 2 and this may reflect the more complicated distribution of neutrophils 
in the body. 
CFU =GM and BFU =E numbers were also measured. These assays are at best only 
semi -quantitative and the figures vary dramatically between laboratories. For normal 
steady state peripheral blood (n =12), the method used here (see section 2.16) gave 
values of 8.2 CFU- GM/106 MNC plated (range 1.7 -33.3) and 27.7 BFU -E/106 MNC 
plated (range 15.3 =114.3). One of the PNH patients failed to grow any colonies, the 
other three did but the numbers were small. Pre G -CSF the CFU -GM numbers ranged 
from 1 to 4 with a median of 3/106 MNC plated and the BFU -E from 5 to 10 with a 
median of 6. After G -CSF there was no significant change detectable at these low 
levels (3 to 5 CFU- GM/106 MNC and 5 to 11 BFU -E). Again, this assay 
underlines 
the hypoplastic nature of the disease 
Figure 7.5 
This figure shows peripheral blood neutrophils from one of the PNH patients (ST) 
before, during and after administration of G -CSF. The cells have been stained for 
the GPI -linked molecule CD16 to differentiate normal from PNH. The increased 
MFI for CD16 on the negative cells is clearly demonstrated during G -CSF (middle 
plot) and returns to normal after the drug is discontinued (bottom plot). The small 
proportion of normal cells on the right of the plots remains largely unchanged (see 






6 DAYS POST G -CSF 
Figure 7.6 
This is a FACS plot showing the effect of the enzyme PI -PLC on CD16 staining on 
the neutrophils from PNH patient ST before and after G -CSF. This enzyme cleaves 
GPI anchors and if the increase in CD16 staining following G -CSF were due to a real 
increase in CD16 expression on the cell surface it should be abolished by PI -PLC 
treatment. The top 2 plots show that normal neutrophils (right hand peak, CD16 +ve) 
lose CD16 staining after PI -PLC but the PNH cells (left hand peak, CD16 -ve) are 
unaffected as they do not express this marker. In the bottom 2 plots, the same 
experiment is shown but G -CSF has increased the MFI for CD16 of the negative 
(PNH) cells in the left hand peak. As shown, this apparent increased expression is 
not PI -PLC sensitive indicating that it is not due to true CD16 expression. 
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NO PI-PLC 
L2-H\CD16 /26/ROD1305015\FL2-I1\CD16 
CD16 -PE 21 PRE G -CSF 
AFTER PI -PLC 
/26/ROD1405001\FL2-H\CD16 
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Figure 7.7 
This FACS plot is essentially the same as for figure 7.6 but shows the results with 
another GPI -linked molecule, CD59. In the upper plot, comparison of the red (pre- 
PI-PLC) and grey (post PI -PLC) traces shows the cleavage of the CD59 +ve peak by 
the enzyme and the lack of effect on the negative (PNH) peak. The lower plot 
shows the greatly increased MFI of the negative cells which now swamp the positive 
peak. These cells are not sensitive to PI -PLC cleavage however (grey trace) 
indicating that the MFI is not due to true increases in CD16 expression. 
CD59 NEG NO P I PLC 
CD59 NEO + P I PL_C 
ö aua y,, 
10° 
CD59 POS NO PIPLC 
CD59 POS + PIPLC 
PRE PIPLC. 
POST P I P'LC 
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Figure 7.8 
These FACS plots arc controls for the experiments s shown ll 111 ligures 7.5 to 'r using 
irrelevant MABs. Four antibodies are shown: a FITC and a PE conjugated CD3 and 
IgGI, none of which should be expressed on neutrophils. The cells are from the same 
PNH patient (ST). They all show the same pattern of increase in MFI after G -CSF 
which serves to underline the artefactual nature of the observation. 








Graph showing the increase in peripheral blood CD34 positive cells in the 4 PNH 
patients during the administration of G -CSF (given on days 1 to 4 inclusive). The 
kinetics of mobilisation is very similar to that in normal individuals with the rise 
beginning after 2 to 3 days of treatment. The absolute numbers are much lower than 
normal individuals due to the hypoplastic nature of the disease. See text for discussion. 
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7.6 Stem cell subset analysis before and after G -CSF 
PNI-1 arises in conditions of marrow hypoplasia and there is evidence for a growth 
advantage of the PNH clone over normal haemopoiesis in such states. The mechanism 
of this selection and the level of cell maturity at which it operates is unknown. I 
investigated the phenotype of CD34 subsets to see whether the distribution of PNH cells 
was uniform in primitive and mature cells and whether this distribution altered on G- 
CSF. Lack of CD59 expression was taken to define the PNH cells. The Combination of 
CD34 positivity with the level of expression of CD38 was used to identify stem cells of 
greater or lesser degrees of maturity. The CD34 +ve /CD38 -ve cell fraction is known to 
be enriched for progenitors that can differentiate into myeloid or lymphoid lineages and 
represents one of the earliest cell types identifiable by flow cytometry. These subsets 
were examined in our four PNH patients before and after administration of G -CSF. The 
changes in phenotype before and after administration of G -CSF was assessed on Mature 
neutrophils and early and late stem cells (defined as CD34 +ve /CD38 -ve and 
CD34 +ve /CD38 +ve respectively. The baseline neutrophil phenotype and the effects of 
G -CSF on this have been discussed in detail in section 7.4. There appears to be no 
significant change in the proportion of PNH:normal mature neutrophils following G -CSF 
(p >0.1). The situation for the more primitive subsets is however very different. One of 
the patients (ST) showed around 75% PNH cells in all subsets examined and this 
percentage did not change significantly after G -CSF administration. The other three 
patients showed considerable differences in the proportion of PNH cells in different cell 
compartments and a dramatic change following G -CSF. There was no obvious clinical 
distinction between patient ST and the others to explain this observation. In steady state 
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peripheral blood, these three patients were found to have almost no detectable PNH cells 
in the most primitive (CD34 +ve /CD38 -ve) subset (median 0 %, range 0 -7 %). The more 
mature CD34 +ve /CD38 +ve fraction had a proportion of PNH cells intermediate 
between the primitive CD34 +ve /CD38 -ve cells and the mature neutrophils (median 
47 %, range 29 -50). Following the administration of G -CSF, the pattern changed 
dramatically. Both the early and more mature stem cells became phenotypically `more 
PNH' (median 87 %, range 68 % -90% for the CD34 +ve /CD38 +ve cells and median 88 %, 
range 51 % -91% for the CD34 +ve /CD38 -ve cells). The changes in the CD38 -ve fraction 
were significant at p<0.05 but those for the CD38 +ve fraction were not (p<0.1). These 
changes reverted to steady state values within a few days of discontinuing G -CSF. Only 
one marrow sample was available in these patients (DT) and this was taken post G -CSF. 
The proportions of PNH to normal cells in the patient's marrow was very similar to their 
peripheral blood with the majority of cells being PNH in all subsets. Unfortunately there 
was no available marrow pre G -CSF but other studies have suggested that the numbers 
of CD34 +ve /CD38 -ve cells in the marrow of PNH patients in steady state are similar to 
























































































































































































































































































































7.7 Discussion: prospects for autografting and gene therapy 
The changes in haematological parameters and cell surface phenotype in 4 PNH 
patients before and after G -CSF are reported. The WBC rose in all patients to a peak 
mean of 15.3x109/1. This is less than that seen in normal volunteers on G -CSF whose 
absolute WBC reaches mean peak levels of around 28x109/1. on similar regimens 
(Stroncek et al 1996). These findings reflect the underlying hypoplasia in PNH. 
There is wide variation in the numbers of peripheral blood CD34 cells in normal 
individuals but all 4 PNH patients had baseline values that were 10 to 20 fold less 
than those generally reported. The mean baseline CD34 count in the peripheral blood 
was 0.5x106/1. for the PNH patients compared to 8x10 /l. in a series of normals. After 
G -CSF, the mean figures were 4.2x106/1. for the PNH patients and 55x106/1. for the 
normals. In both PNH and normal blood this represents a similar proportionate 
increase (7 -9 fold). 
The rise in NAP score in normal neutrophils on exposure to G -CSF is well 
documented and represents one of a range of stimulatory or priming effects of this 
cytokine (Avalos, 1996). It was interesting to observe this phenomenon in the PNH 
patients as this enzyme is known to be GPI -linked and consequently the NAP score 
in PNH is classically low. Since two of these patients had >95% PNH neutrophils 
circulating before and after G -CSF, I can be certain that the increase in NAP score 
occurred in both PNH and normal neutrophils as the NAP scoring by light 
microscopy confirmed that the majority of cells showed increased granulation. 
Increase in the NAP score in PNH patients post G -CSF has not been previously 
reported. 
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The relative proportions of normal and PNH cells occurring at different stages of cell 
maturity in steady state and G -CSF mobilised peripheral blood in these patients was 
studied. All four had substantial PNH clones as assessed by neutrophil phenotype which 
implies that the marrow precursors are also largely PNH. Previous studies of PNIH 
marrow have supported this view and shown a similar proportion of affected CD34 +ve 
cells to neutrophils (Terstappen et al 1993). Despite this it has been previously noted 
that the great majority of the most primitive peripheral blood stem cells are in fact of 
normal phenotype in sharp contrast to the marrow and the more mature cell types 
(Prince et al 1995; Musto et al 1997). My observations confirm this phenomenon in 
three out of the four patients. In addition I have shown a gradient of expression with the 
most primitive cells being normal, the more mature stem cells (CD34 +ve /CD38 +ve) 
having an intermediate proportion of PNH cells and the mature neutrophils being largely 
PNH. It is not clear why normal pluripotent cells should circulate selectively in the 
peripheral blood of these patients when they are only a small minority of the marrow 
precursors. Normal stem cells may be selectively released, perhaps due to a GPI -linkage 
deficiency involving adherence or homing, or they may have a survival advantage over 
PNH cells when in the peripheral blood which is not present in the marrow 
miroenvironment. This phenomenon is marked in the majority of patients and it is 
intriguing to consider that it may have some relevance to the pathogenesis of PNH. 
It has been suggested that these normal stem cells could be collected from the blood and 
used as a source of normal progenitors for autologous transplantation in PNH (Musto et 
al 1997; Prince et al 1995) but the absolute numbers of peripheral CD34 +ve cells in 
PNH patients is generally very small. A logical approach would be to mobilise stem cells 
from such patients with growth factors as is done in the management of other 
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haematological malignancies. However, my work shows that the number of stem cells 
mobilised by G -CSF in this condition is disappointing and the vast majority that are 
released are of PNH phenotype unlike those that naturally circulate. I found that after 
G-CSF the absolute number of CD34 +ve cells in the peripheral blood of these patients 
was a mean of 4.2x106/1. (range 1.3 -9.0) and in the important CD38 -ve fraction only a 
minority (median 12 %) remained of normal phenotype. Contrasting this with 
recommendations for harvesting in haematological malignancy where minimum post 
G -CSF levels of around 10- 20x106 CD34 +ve cells /1. of peripheral blood are preferred 
it suggests that it would be difficult to mobilise sufficient numbers of normal 
progenitors into the peripheral blood of PNH patients to support transplantation. 
In summary, conventional mobilisation techniques do not achieve adequate stern cell 
collections for autografting in this disease and far from the hoped for `in vivo purge' of 
PNH cells the reverse is true with a substantial increase in abnormal cells after G-CSF. 
Prospects for gene therapy are also poor due to the difficulties in obtaining adequate 
stem cells for transduction. For these approaches to be pursued, other technological 
advances might be required such as selection of normal stem cells in vitro, perhaps using 
high speed multi- parameter cell sorting and subsequent expansion of the poor stem cell 
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8.5 PNH: a disease model for the manipulation of stem cells 
8.1 Haemopoietic stem cells 
For many years, it has been accepted that there is a marrow pool of primitive 
cells defined by their ability both to self renew without differentiation and to 
differentiate to produce cells of any of the haemopoietic lineages (Gordon & 
Blackett, 1994; Leitman & Read, 1996). Despite an extensive literature on the 
subject and the introduction of therapies based on the use of these cells into routine 
clinical practice, our understanding of them is still limited. There is no one test that 
can precisely define them and, perhaps for this reason, their biology and behaviour 
remains controversial (Gordon & Blackett, 1994; Morrison et al 1995), 
The manipulation of haemopoietic stem cells for clinical use is of major interest in 
haematology but their elusive nature as targets for research has been a difficult 
hurdle which continues to delay the development of therapeutic strategies that have 
long held out promise but have yet to have a clearly defined place in patient 
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management. These include: the collection (mobilisation and harvesting), selection, 
expansion and modification of stem cells. These techniques are by no means 
exclusive. A complete understanding of stem cell biology might allow the controlled 
collection and selection of the precise cell population required for each clinical 
application. They could then be expanded and/or genetically modified and reinfused 
to achieve the desired therapeutic goal. 
Cell expansion ex vivo has already been achieved using both simple liquid culture 
and more complex stromal -based systems (Alcorn & Holyoake, 1996). Optimal 
conditions are not yet fully defined but suitable combinations of growth factors (e.g. 
IL3, IL6, SCF and erythropoietin) with or without stromal support have been 
consistently shown to yield large increases in post -culture cell numbers (Bodine et al 
1989; Ploemacher et al 1993; Haylock et al 1992a). Such products have been 
reinfused into patients with no observed toxicity (Silver et al 1993; Brugger et al 
1995a). Despite this, it remains unclear whether the true repopulating cells are 
expanded by these techniques (Srour et al 1993; Koller et al 1995) and early clinical 
trials have reported problems with engrafhnent (Holyoake et al 1995). 
Genetic modification of human blood cells can be achieved in the laboratory and in 
vivo (Dunbar, 1996b; Boucher et al 1994). Stem cells, with their capacity for 
renewal and differentiation have been popular targets for gene transfer protocols 
(Williams et al 1984b; Chatterjee et al 1995; Dunbar, 1996a) but there is still limited 
evidence that the currently available gene vectors can infect primitive, quiescent 
cells (Moore et al 1992; Dunbar et al 1995). The most studied vectors (based on 
retroviridae) can only integrate into host DNA at mitosis when the nuclear 
membrane is disrupted (Miller et al 1990). Other vectors are under development but 
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safe, stable integration over long time periods remains elusive and in vivo gene 
marking experiments have shown only limited expression in small proportions of 
cells after transplantation (Brenner, 1996). 
Despite the considerable technical difficulties in cell expansion and gene therapy, 
progress is continuing and it may become possible in the future to combine these 
techniques either to expand cell populations which have been genetically modified 
(Fraser et al 1990) or to expand the most appropriate subsets of primitive cells as a 
starting population for genetic modification. Such holistic marrow engineering is 
currently beyond our technology but clinical trials have been conducted in all these 
individual areas with encouraging preliminary results (Brenner, 1995; Brugger et al 
1994; Holyoake et al 1995). A greater understanding of the intrinsic kinetics of stem 
cells and their extrinsic interactions with the marrow microenvironment and soluble 
factors may lead to improvements in mobilisation, collection and culture expansion 
techniques. More precise assays for recognition of the pluripotent fraction are 
necessary for cell selection in systems which seek to purge grafts of contaminating 
tumour cells and considerable progress is needed in the field of gene therapy before 
effective introduction of engineered DNA into primitive cells with controlled long 
term expression in vivo is achieved. 
8.2 Stem cell mobilisation 
Despite a lack of understanding of the mechanisms involved in PBSC mobilisation, it 
has become a safe, effective and common clinical procedure in the last decade 
(Gratwohl et al 1996). In haematological malignancy and in solid tumours, high dose 
1 P 
chemo- radiotherapy is now routinely supported by reinfusion of mobilised PBSCs. The 
purpose of the mobilisation procedure has primarily been to harvest sufficient stem cells 
for safe engraftment. There are however other aspects. of these cell collections that are 
the focus of increasing interest. Harvest composition in terms of the proportions of cells 
at different stages of maturity is becoming better characterised and this knowledge may 
impact do our ability to predict the kinetics of short and long term haemopoietic 
reconstitution (Rawstron et al 1998). Most transplants are performed for malignant 
disease and contamination of the harvests by clonal cells can occur and may contribute 
to relapse in some patients (Brenner et al 1994). There are a number of factors which 
affect the success of cell collection and the degree of tumour contamination. These 
include: the timing of mobilisation in relation to the treatfent of the disease, the amount 
of pre- treatment the patient has undergone, the regimen used to mobilise cells and the 
timing of the harvest. 
In this thesis, I have described a mobilisation regimen in CML (Johnson et al 1996a). 
This is an example of a disease -specific approach which exploits.the timing of harvest to 
collect mainly non -clonal stem cells. This in vivo purging strategy relies on the 
differential mobilisation of Ph+ve/Ph -ve stem cells following myelosuppression and was 
evaluated in 18 patients. The Hydroxyurea/G -CSF regimen used was markedly less toxic 
than standard chemotherapy. 28% of the harvests were entirely Ph -ve and 56% showed a 
major. response. This compares favourably with other more intensive regimens (Johnson 
& Smith, 1997). Seven of the patients have been transplanted, two showing a major 
cytogenetic response post autograft (Pratt et al 1998).. 
There is as yet no clear consensus regarding the optimum mode of myelosuppression or 
the subsequent choice of growth.factor /cytokine for stem cell collection. Newer agents 
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are being investigated such as SCF, Flt3 ligand, M3 and MIP -la, all of which have been 
shown to have relevant activity. Combinations of these may prove more effective and 
less toxic but are only in early trial stages (Andrews et al 1994; Brasel et al 1995). With 
increasing experience, it may be possible in the future to mobilise stem cells in vivo in a 
more controlled manner using optimised regimens of cytotoxics and soluble factors and 
collect a better and more precisely characterised product for clinical use, with or without 
further ex vivo manipulations. 
8.3 Stem cell selection 
The cells harvested by traditional techniques from the marrow or the peripheral blood 
are of all lineages and all stages of maturation and function. The majority are of no 
therapeutic value in this setting. Procedures to select subsets of cells from a collection 
allow either the concentration of desired cell types (positive selection) or the elimination 
of unwanted cells from the product (negative selection). These processes are not 
mutually exclusive and combined positive and negative selection may provide the purest 
end result. 
In vitro selection of stem cells most commonly relies on the presence on their surface of 
the CD34 antigen (Krause et al 1996a). In haematological malignancy and solid 
tumours, CD34 selection is becoming widely used to purge clonal cells from harvests 
(providing they themselves do not express this antigen) ( Berenson et al 1991; Schiller et 
al 1995). Selected products may be further depleted of tumour by negative selection 
with antigens present on tumour cells but not on stem cells (e.g. CD19 in some B-cell 
malignancies) or they may be used as the starting point for further manipulations, 
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including cell expansion or genetic modification. Most culture expansion techniques 
use purified CD34 +ve cells as their initial cell source with the aim of maximising the 
number of primitive precursors which can undergo self renewal division and lead to a 
true increase in repopulation capacity in the final product (Alcorn & Holyoake, 1996; 
Haylock et al 1992a). Many gene therapy protocols are aimed at the primitive stem cell 
in an attempt to capitalise on its abilities to self renew and repopulate a marrow. The 
hope is that this will allow long term survival of the new DNA after reinfusion 
(Apperley & Williams, 1990b; Dunbar, 1996a). The titre in which gene vectors can be 
produced and their infection efficiency will combine to limit the proportion of target 
cells that are successfully transduced in any protocol. It is thus desirable to maximise 
the ratio of vector particles to stem cells (increase the multiplicity of infection). CD34 
selection achieves this by producing a concentrated stem cell source as a starting point 
for such protocols which should improve the targeting of vectors and ensure that 
adequate- numbers of the cell type of interest are transduced (Dunbar et al 1995). 
For these in vitro manipulations to be relevant, reinfusion of CD34 selected cells must 
be a clinical practicality and lead to effective short and long term haemopoietic 
reconstitution. I have investigated this question in patients with myeloma (chapter 4) 
(Johnson et al 1996b). PBSCHs were CD34 selected using an immunoaffinity column 
(Cepratem4). All but one of the patients achieved an adequate number of purified CD34s 
for reinfusion and the case that failed had been previously autografted and had poor 
marrow function. Engrafiillent in this cohort was similar to that seen in unelected 
transplants and long term follow up has shown no late haematological problems. I 
conclude that clinical scale CD34 selection is a safe and effective process. This allows 
the investigation of other additional manipulations of these cells. The question of 
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whether tumour purging by this means is clinically advantageous is currently being 
studied in many centres (Gribben et al 1991; Pico et al 1995; Williams et al 1996). 
8.4 Stem cell modification by gene therapy 
The unique ability of stem cells to both self renew and differentiate down any or all of 
the haemopoietic lineages makes them an ideal target for gene therapy (Gordon & 
Blackett, 1994; Dunbar, 1996a). Modification of the phenotype of such a cell would 
theoretically ensure persistence of the new gene. CD34 selection offers a pure cell 
source for transduction and appropriately altered cells could be expanded ex vivo to 
produce an adequate product for reinfusion. This deceptively simple notion draws on 
several separate techniques of stem cell manipulation, only some of which have reached 
the clinical arena. Selection technology is well advanced and I have shown it to be 
clinically safe and effective in the setting of myeloma (Johnson et al 1996b). Gene 
transfer into haemopoietic progenitors is achievable with high rates of efficiency and I 
have been able to do this in human peripheral blood and PBSCHs using PCR on CFU- 
GM and BFU -E colonies to assay the result. The median transduction rate I achieved 
in these progenitor colonies was around 36% depending on the vector used, with a 
range of 17 -63.5% in different experiments. The median rate for both PBSCHs and 
peripheral blood cells was the same at 36% (ranges: PBSCHs 25- 63.5 %, blood 17- 
50%). Despite this high transduction efficiency, there are serious problems in assessing 
whether the true pluripotent stem cells are effectively modified by these methods and 
experimental evidence suggests that retroviruses (by far the most studied vector) are 
unable to achieve this, despite some reports to the contrary (Miller et al 1990). Attempts 
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to `persuade' stem cells to cycle and allow infection to take place may abolish their self 
renewing properties and defeat the purpose. If stem cells can be modified, the 
conflicting theories regarding their in vivo behaviour (Gordon & Blackett, 1994; Kay, 
1965; Metcalf & Moore, 1971) cast some doubts on the predictability of the survival and 
expansion of the desired subset. This is to say nothing of the requirement to control 
expression of the new DNA in vivo. With these and other problems to overcome, it is 
not surprising that preliminary studies of clinical gene transfer have, in the main, shown 
only temporary low level expression of simple genes (Brenner, 1996; Dunbar, 1996b). 
For the future, better vectors and a more complete understanding of the biology of the 
stem cell are needed if indeed stem cells are to be a clinically useful target for 
therapeutic gene transfer. 
8.5 PNH: a disease model for the manipulation of stem cells 
PNH is an acquired stem cell disorder in which normal and abnormal cell populations 
co -exist in the marrow and blood. The molecular abnormality underlying the classical 
disease phenotype (intravascular haemolysis and a thrombotic tendency) is now well 
understood (Miyata et al 1993) although some aspects of aetiology and pathophysiology 
remain contentious (see chapters 1 and 7). Treatment for the more severely affected 
patients with PNH is unsatisfactory and mainly supportive. Some patients benefit from 
immunosuppression or allogeneic bone marrow transplantation (De Planque et al 1989; 
Kawahara et al 1992) but there is a clear need for safer and more effective approaches. 
The disease is interesting from the point of view of stem cell research for many reasons, 
including: its origin as an acquired somatic mutation in a haemopoietic stem cell, the 
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pressures that lead to the expansion of the resulting abnormal clone, the balance between 
normal and PNH stem cells and the link with aplasia and the development of AML/IVIBS 
(Young, 1992). The specific molecular lesion and the success of the few syngeneic 
transplants that have been performed in this disease indicate the potential for gene 
therapy and some authors have recently speculated that autografting may have a role 
because of the discovery that the most primitive PBSCs in PNH peripheral blood are 
normal (Musto et al 1997; Prince et al 1995). I have described clinical and laboratory 
findings that help to put the prospects for autografting and gene therapy in context 
(Johnson et al 1998). 
A novel retroviral construct of relevance to PNH was kindly provided by Russell Rother 
of Alexion Pharmaceuticals, Newhaven, Connecticut. This contained an engineered 
insert coding for a form of the complement regulatory protein, CD59 modified to bind to 
cells via a transmembrane domain (CD59 -TM) rather than by the natural GPI -linkage. 
Replacement of this gene protects PNH cells from complement, and thus has the 
potential to ameliorate the disease phenotype (Rother et al 1994). I have developed a 
FACS -based assay for complement sensitivity and have been able to demonstrate the 
relative resistance to complement of CD59 +ve cell lines by this method. The construct 
was used to successfully transduce haemopoietic progenitors from normal individuals 
and patients with haematological malignancy. The conditions for gene transfer were 
optimised using growth factors and multiple cycles of infection to give rates of 
transduction up to 63% (median 36 %) as assessed by single progenitor colony RT -PCR 
for the neomycin reporter gene. The gene was transferred to CFU -GMs and BFU -Es 
from peripheral blood and stem cell harvests with equal efficiency. 
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In an attempt to collect PNH stem cells for gene transfer and to investigate the potential 
of harvesting normal PBSCs for autografting in this disease, four patients were 
mobilised with G -CSF. The overall progenitor numbers were low, as expected in this 
hypoplastic condition and unsuitable for the gene transfer experiments described above. 
I was able to confirm in 3 out of 4 cases that the most primitive (CD34 +ve, CD38 -ve) 
PBSCs in the peripheral blood were indeed of normal phenotype but went on to show 
that following G -CSF, mainly PNH cells were released (Johnson et al 1998). I conclude 
that the prospects for gene therapy or autografting using conventional cell collection 
techniques are poor in PNH. Further manipulation of the small number of cells 
available is theoretically possible if they could be ex vivo expanded but the growth 
characteristics of PNH cells in culture are known to be poor and there would be 
considerable technical difficulties. 
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